Top

Luhua (Michael) Wang, MD

Department of Lymphoma - Myeloma, Division of Cancer Medicine

About Dr. Wang

I am a Professor in the department of Lymphoma & Myeloma at MD Anderson. I obtained my M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. I completed my clinical training as a resident at Norwalk Hospital, Norwalk, Conn., and as a Fellow in Oncology and in Hematology at MD Anderson.

I have published more than 150 peer-reviewed papers and have presented my work at meetings nationally and internationally. I am the current Director of Mantle Cell Lymphoma (MCL) Program of Excellence and Co-Director of Clinical Trials at MD Anderson.

During the past 15 years, I have focused on preclinical and clinical research and established a MCL-SCID-hu mouse model, which is the first human primary MCL animal model for the study of the biology and treatment of MCL. My clinical research of the Bruton’s tyrosine kinase inhibitor ibrutinib was published in the New Eng. J. Med. in 2013. I am currently acting as National PI of the multisite international phase 5 registration trial for ibrutinib in MCL. I am also the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.

Meet Michael Wang, M.D.

B-Cell Lymphoma Treatment & Research | MD Anderson Moon Shots Program

Pre-clinical study shows MD Anderson-developed drug effective for mantle cell lymphoma treatment

In the News

ASH: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax

Illustration of pink cancer cells float in in a purple backdrop

How BTK inhibitors treat mantle cell lymphoma

MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting

Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients

Mantle cell lymphoma specialist Michael Wang, M.D., talks to Onyeka Oriabure, an advanced practice registered nurse

What to know about mantle cell lymphoma

Majority of patients responded in CAR T-cell trial for mantle cell lymphoma

CAR T-cell therapy effective for relapsed mantle cell lymphoma patients

Novel combination provides more effective treatment option for mantle cell lymphoma

Present Title & Affiliation

Primary Appointment

Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Puddin Clarke Professorship in Multiple Myeloma Research, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX

Founding and Current Director, Mantle Cell Lymphoma Program of Excellence, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

1. Developed Bruton’s tyrosine kinase inhibitors to treat MCL. MCL is incurable and is typically treated using combinatorial chemotherapy. However, this strategy often causes severe toxicities, lethal infections, and secondary malignancies. Novel therapies have been used to treat MCL, including bortezomib and lenalidomide; however, these therapies have limited efficacy with a single agent response rate of less than 40%. To develop further treatments for MCL, I led an international phase II clinical trial with 18 centers to assess ibrutinib treatment in R/R MCL patients. The patients showed an unprecedented 68% overall response rate (ORR) in this trial. This clinical trial led to FDA approval of ibrutinib to treat MCL in 2013 via the “breakthrough” mechanism. In addition, the second-generation BTKi acalabrutinib was approved by the FDA in 2017 based on our multi-center trial showing an 80% ORR. The next-generation BTK inhibitor pirtobrutinib was also approved in 2023.

a. Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle cell lymphoma. N Engl J Med 369(6):507-16, 2013. PMC4513941

b. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 391(10121):659-667, 2017. PMC7864374

c. Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN: Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol 41:3988-3997, 2023. PMID 37192437

d. Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas J, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M: Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 386:2482-2494, 2022. PMID: 35657079

2. Developed lenalidomide and rituximab for B-cell lymphomas. Lenalidomide is an immunomodulatory agent used to treat myeloma. Through my long-term clinical observations, I hypothesized that agents active in treating myeloma would most likely be successful for treating MCL. To test this hypothesis, I evaluated the effects of lenalidomide and rituximab combinatorial treatment in a pre-clinical setting and observed synergistic efficacy against MCL. These pre-clinical findings led to a clinical trial. The clinical trial supported the pre-clinical findings, and treatment with these drugs showed a patient response rate of 57% and a median progression-free survival of 11.5 months. Subsequently, this treatment combination was used to treat B-cell lymphoma, both transformed and de novo, as well as newly diagnosed follicular lymphoma. Clinical outcomes of this chemo-free, non-toxic combination rivaled that of chemotherapy typically used to treat these lymphoma subtypes. I played a central role in developing this preclinical hypothesis and translating these findings to the clinic to treat B-cell lymphomas.

a. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M. Synergistic antitumor effects of lenalidomide and rituximab on MCL in vitro and in vivo. Am J Hematol 84(9):553-9, 2009. PMID 19565649

b. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia (9):1902-9, 2013. PMID 23545991

3. Developed patient-derived xenograft (PDX) mouse models of MCL. We have developed different approaches for generating PDX mouse models of MCL: (1) subrenal capsule xenograft where patient tumor tissues or cells are transplanted into renal capsules; (2) intraosseous transplantation where freshly isolated patients’ MCL cells are inoculated into the proximal mouse tibia; (3) intravenous/intraperitoneal engraftment where primary MCL cells are injected systemically via tail vein or peritoneal cavity into the NSG mice; and (4) subcutaneous xenograft where freshly isolated primary MCL cells are injected subcutaneously into NSG mice. These models have been successfully used by our group to evaluate novel therapies to treat both B-cell lymphomas and myeloma.

a. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW, Yi Q. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 14(7):2154-2160, 2008. PMID 18381957

b. Zhang L, Pham L, Newberry K, Qian J, Sun L, You Y, Yang J, Ou Z, Lin X, Ford R, Zhao X, Kwak L, Yi Q, Wang M. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther 12(11): 2494-2504, 2013. PMID: 23990113

4. Determined the mechanisms of ibrutinib resistance and identified novel therapies to overcome resistance. MCL accounts for 6-8% of all non-Hodgkin lymphoma cases and is a rare and incurable subtype of B-cell lymphoma. Constitutive activation of the B-cell receptor (BCR) pathway is a hallmark of B-cell lymphomas, including MCL. BTK is a critical component of the BCR pathway, and ibrutinib, a first-in-class, once-daily, oral covalent BTKi, was developed to impede BCR pathway activity. Ibrutinib led to remarkable anti-tumor efficacy both in the research laboratory and in the clinic. We reported several mechanisms for acquired BTKi resistance, including metabolic reprogramming towards oxidative phosphorylation, in Science Translational Medicine. By using single cell sequencing and clone tracking, we identified dynamic changes and clonal selection patterns of heterogenous MCL tumors collected from patients before, during, and after CAR T-cell treatment. These heterogenous changes corroborated with responses to therapy and clinical outcomes and were reported in Nature Communications, 2021.

a. Zhang L, Yao Y, Zhang S, Liu Y, Draetta G, Jones P, Futreal A, Nomie K, Wang L, and Wang M. Metabolic reprogramming towards oxidative phosphorylation as a novel therapeutic target for mantle cell lymphoma. Sci Transl Med 11(491):eaau1167, 2019. PMID: 31068440.

b. Zhang S, Jiang C, Han G, Hao, D, Lian J, Liu Y, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Dadillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, OK CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriquiez A, Thirumurthi S, Jain P, Wagner-Bartack N, Hill H, Nomie K, Flowers C, Futreal A, Wang L, and Wang M. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nature Commun 12(1):2877, 2021. PMC8128874

c. Jiang VC, Liu Y, Jordan A, McIntosh J, Li Y, Che Y, Jessen KA, Lannutti BJ, Wang M. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol 14:132, 2021. PMC8400406

d. Wang ML, Barrientos JC, Fruman RR, Mei M, Barr PM, Choi MY, Vos S, Kallam A, Patel K, Kipps TJ, Rule S, Flanders K, Jessen KA, Ren H, Riebling PC, Graham P, King L, Thursdon A, Sun M, Schmidt EM, Lannutii BJ, Johnson DM, Miller LL, Spurgeon SE. Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers. NEJM Evid 1(1):EVIDoa2100001, 2021. PMID: 38319241

5. Developed CAR T-cell therapy against lymphomas and multiple myeloma (MM). I participated in the CAR T-cell NCI trial that enrolled patients with chemotherapy-refractory diffuse large B-cell lymphoma, indolent lymphoma, and chronic lymphocytic leukemia. With CAR-T cell therapy, patients showed a >90% ORR. Furthermore, I helped design two active MCL CAR T-cell trials, ZUMA-1 and ZUMA-2, for which I serve as the overall PI. This trial prompted fast-track approval of brexu-cel CAR-T cell therapy by the FDA.

a. Wang M, Munoz J, Goy A, Locke FL, Jacobson FA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn I W, McSweeney PA, Miklos DB, Pagel JM, Kersten M-J, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382:1331-1342, 2020. PMC7731441

b. Jain P, Nastoupil L, Westin J, Lee HJ, Navsaria L, Steiner RE, Ahmed S, Moghrabi O, Oriabure O, Chen W, Badillo M, Flowers CR, Wang ML. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol 192:e38-e42, 2021. PMID: 33152104

c. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 Study. J Clin Oncol JCO2102370, 2022. PMID: 35658525

d. Jiang VC, Hao D, Jain P, Li Y, Cai Q, Yao Y, Nie L, Liu Y, Jin J, Wang W, Lee HH, Che Y, Dai E, Han G, Wang R, Rai K, Futreal A, Flowers C, Wang L, Wang M: TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer 21:185, 2022. PMID: 36163179

A complete list of the Published Work can be found in MyBibliography: https://pubmed.ncbi.nlm.nih.gov/?term=%28michael+wang%5BAuthor%5D%29+AND+%28anderson%5BAffiliation%5D%29&sort=

Clinical Interests

As a physician scientist, I am committed to advancing clinical and translational research to identify effective and safe treatments for patients with lymphoma and myeloma, concentrating on mantle cell lymphoma (MCL). MCL is a rare subtype of non-Hodgkin lymphoma. My principal focus is on improving the care of patients with MCL through the actions of my multidisciplinary team of basic, translational, and clinical research specialists. Together, we have worked on a host of preclinical studies and clinical trials devoted to patients with MCL. My lab is within the Lymphoma and Myeloma department and is well funded through multiple funding mechanisms, including two NIH R01s and an R21, two CPRIT grants, and two Leukemia and Lymphoma Society grants.

To promote continued research and improved treatment of MCL, I established the Mantle Cell Lymphoma Program of Excellence at MD Anderson Cancer Center as the world’s only program dedicated exclusively to MCL research and treatment. It is the largest institutional MCL group worldwide, with the greatest number of clinical trials aimed exclusively at MCL, the largest referral base and the most patients in the most clinical trials aimed specifically at MCL. Our clinical trials that resulted in the highest number of FDA approvals for MCL treatment: for the BTK inhibitors ibrutinib (Imbruvica), acalabrutinib (Calquence), and pirtobrutinib (Jaypirca) as well as the CAR T-cell therapy brexucabtagene autoleucel (Tecartus). I am also the founder and current Co-PI of the MD Anderson B-Cell Lymphoma Moon Shot® Program, whose goal is to use clinical, translational, and basic science approaches to double the cure rate of our B-cell lymphoma patients.

Education & Training

Degree-Granting Education

1988	Beijing Medical University, Beijing, CN, Physiology, M.S
1985	Shandong Medical University, Jinan, CN, Medicine, MD

Postgraduate Training

1999-2002	Medical Oncology/Hematology Fellow, Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
1998-1999	Attending Physician, Kelsey-Seybold Clinic, Houston, Texas
1997-1998	Chief Medical Resident, Medicine, Yale-Norwalk Hospital, Norwalk, Connecticut
1995-1997	Residency, Medicine, Yale-Norwalk Hospital, Norwalk, Connecticut
1994-1995	Internship, Internal Medicine, The University of Michigan Hospitals, Ann Arbor, Michigan
1991-1994	Visiting Associate, Molecular Biology, National Heart, Lung and Blood Institute, NIH, Bethesda, Maryland
1988-1991	Visiting Fellow (Recipient of Fogarty International Fellowship Award), Cell Biology, National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, Maryland

Licenses & Certifications

2023	Arizona State License
2022	Alabama State License
2022	Georgia State License
2022	Washington State License
2022	Louisiana State License
2022	Oklahoma State License
2022	Mississippi State License
2022	Tennessee State License
2021	DEA, Research
2021	Florida State License
2007	DEA, Controlled Substance
2004	American Board of Internal Medicine, Medical Oncology
1998	Texas State License
1998	American Board of Internal Medicine, Internal Medicine
1998	AHA Cardiac Life Support Certification

Experience & Service

Faculty Academic Appointments

Co-Principal Investigator, B-cell Lymphoma Moonshot Project, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2025

Program Chair, Lymphoma and Myeloma Grand Rounds, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2014

Associate Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2013

Founding Director, Myeloma Tissue Bank, Department of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2013

Assistant Professor, Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002 - 2009

Clinical Specialist, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2002

Instructor, Department of Dept. of Internal Medicine, University of Texas Medical School, Houston, TX, 1998 - 1999

Chief Medical Resident, Yale-Norwalk Hospital, Norwalk, CT, 1997 - 1998

Visiting Associate, National Heart, Lung and Blood Institute, NIH, Bethesda, MD, 1991 - 1994

Administrative Appointments/Responsibilities

Puddin Clarke Endowed Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present

Section Chief of Rare Lymphomas, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present

Co-Principal Investigator, B-Cell Lymphoma Moonshot Program, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - Present

Co-Director, Clinical Investigation and Translational Research, Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2017

Director, Mantle Cell Lymphoma Program of Excellence, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - Present

Director, Myeloma Tissue Bank, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2016

Other Professional Positions

Consultant, Schrodinger, 2024 - 2025

Consultant, Galapagos, 2024 - Present

Consultant, AstraZeneca, 2023 - Present

Consultant, Bristol Myers Squibb, Lugano, Switzerland, 2023 - Present

Course Director, Medscape, Houston, TX, 2022

Consultant, Be Biopharma, Houston, TX, 2022 - 2023

Consultant, Bristol Myers Squibb, Houston, TX, 2022 - 2024

Consultant, ADC Therapeutics America, Houston, TX, 2022 - 2023

Consultant, Amphista Therapeutics, Houston, TX, 2022 - 2023

Consultant, AbbVie, Houston, TX, 2022 - 2025

Consultant, Leukemia & Lymphoma Society, Rye Brooke, NY, 2022

Consultant, Deciphera, Houston, TX, 2022 - 2024

Consultant, BioInvent International, Houston, TX, 2022 - 2024

Advisory Board Member, VelosBio Inc / Merck, Houston, TX, 2022 - 2025

Consultant, Eli Lilly & Company, Houston, TX, 2022 - 2024

Consultant, PeproMene Bio, Houston, TX, 2022 - Present

Consultant, Upright Sciences, Houston, TX, 2021 - 2022

Consultant, Epizyme, Houston, TX, 2021 - 2022

Advisory Board Member, DTRM Biopharma (Cayman) Limited, Houston, TX, 2021 - 2022

Consultant, Bayer, Houston, TX, 2021 - 2022

Consultant, CStone, Houston, TX, 2020 - 2021

Consultant, Oncternal, Houston, TX, 2020 - 2023

Advisory Board Member, Genentech, Houston, TX, 2020 - 2023

Consultant, BeOne, Houston, TX, 2020 - Present

Consultant, InnoCare Pharma, Houston, TX, 2020 - Present

Consultant, Loxo Oncology / Eli Lilly, Houston, TX, 2019 - 2024

Consultant, Kite Pharma, Houston, TX, 2019 - Present

Consultant, Medscape, Houston, TX, 2018 - 2019

Consultant, Nano Pulse, San Francisco, CA, 2018 - 2018

Consultant, AxImmune, San Diego, CA, 2018

Consultant, MoreHealth, Houston, TX, 2017 - 2019

Advisory Board Member, Celgene, New York, NY, 2017

Consultant, Adienne Pharma & Biotech, Lugano, Switzerland, 2017

Consultant, Nordic Biotech, Lugano, Switzerland, 2017

Consultant, BioInvent International, Washington, D.C, 2017 - 2018

Consultant, Pharmacyclics LLC, Houston, TX, 2017 - 2018

Advisory Board Member, Asana Biosciences, San Diego, CA, 2016

Consultant, Acerta Pharma/AstraZeneca, Houston, TX, 2015 - Present

Consultant, Janssen, Houston, TX, 2013 - Present

Medical Liaison in Myeloma, The University of Texas MD Anderson Cancer Center - Orlando, Orlando, FL, 2002 - 2007

Attending Physician, Kelsey-Seybold Clinic, Houston, TX, 1998 - 1999

Attending Physician, St. Luke’s Episcopal Hospital, Houston, TX, 1998 - 1999

Intramural Institutional Committee Activities

IRG Reviewer, Institutional Research Grant Program, The University of Texas MD Anderson Cancer Center, 2018 - 2018

Member, Research Charges for Innovative New Trials (ReCINT) Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2018

Member, CCSG - The Hematologic Malignancies and the Stem Cell Transplantation Program, The University of Texas MD Anderson Cancer Center, 2014 - 2018

Member, China Steering Committee, Extramural Programs, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2005 - 2010

Member, Clinical Research Committee (CRC) MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2005 - 2007

Member, Clinical and Translational Research Steering Committee MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2005 - 2006

Member, NCI Sponsored Clinical Trial Faculty MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2002 - 2018

Member, Internal Advisory Committee to Complementary Integrative Medicine MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2002 - 2004

Extramural Institutional Committee Activities

Member, MCL Consortium Executive Committee, Lymphoma Research Foundation, 2021 - 2025

Editorial Activities

Reviewer, Clinical Care Options, 2020

Reviewer, Medscape, 2020

Reviewer, Lymphoma Research Foundation, 2020

Reviewer, University of Leeds, 2017

Reviewer, American Society of Hematology, 2015 - Present

Reviewer, 2014 Prix Galien, 2014

Honors & Awards

2020 - 2025	"Top Doctor", Top Doctor Awards
2017	Outstanding Service Award, Chinese American Hematologist Oncologist Network
2016	The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research, MD Anderson Cancer Center
2016	Certificate of Special Congressional Recognition, United States of America Congress
2015	Waun Ki Hong Award for Excellence in Team Science, MD Anderson Cancer Center
2014	The Irwin H. Krakoff Award for Excellence in Clinical Research, The University of Texas MD Anderson Cancer Center
2011	Best Doctor, U.S. News & World Report
2011 - 2012	"Top Doctor", Castle Cannolly Medical Ltd
2010	"America's Top Oncologist", Consumers' Research Council of America
2007	"America's Top Oncologist", Consumers' Research Council of America
1997 - 1998	Recognition Award for Outstanding Service as Chief Resident in Medicine, Norwalk Hospital, Norwalk, CT
1988 - 1990	Fogarty International Fellowship Award, National Institutes of Health, Bethesda, MD

Professional Memberships

AstraZeneca

2022

Janssen US IMBRUVICA MCL Advisory Board

2022 - 2022

Deciphera

2022 - 2024

AbbVie DLBCL & Follicular Lymphoma

2022 - 2023

AstraZeneca MCL Summit Steering Committee Meeting

2021 - 2022

AstraZeneca CAPITAL Study

2021 - 2023

Kite/PeerDirect Expert Insight Content Review

2021

AbbVie MCL Commercial Steering Committee

2021 - 2022

AstraZeneca MCL Summit Steering Committee Meeting

2020

New Bridge Pharmaceuticals Advisory Board Meeting

2020

Kite Pharma Investigator Meeting

2020

Genentech MCL Virtual Advisory Board

2020

Kite Blood Cancer Awareness Month Event

2020

Kite Pharma MCL Expert Focus Group

2020

PCYC MCL Virtual Commercial Steering Committee Meeting

2020

LOXO-305 Advisory Board Meeting

2020

AstraZeneca MCL Summit Steering Committee Meeting

2020

NHL OncoBoard

2020 - 2020

ACE-LY-308 Steering Committee Meeting

2020

Kite MCL Advisory Board

2020

AstraZeneca MCL Summit Steering Committee Meeting

2019

Kite Pharma MCL Advisory Board Meeting

2019

KTE-X19 Kite Pharma Advisory Board Meeting (MCL)

2019

Celgene CAR-T Cell Therapy Advisory Board Meeting

2017

AbbVie MCL National Advisory Board Member

2017

Clinical Faculty Review Committee (CFRC)

2017 - 2020

AstraZeneca External Experts Meeting

2017

Acerta Pharma Investigator Meeting

2017

Janssen

2017

The Leukemia & Lymphoma Society (LLS)

2017

BioInvent

2017

Pharmacyclics National Steering Committee

2016

Janssen Global Clinical MCL Advisory Board

2016

Celgene MCL Advisory Board

2016

Kite Pharma Investigator Meeting

2015

Lymphoma/Myeloma Hematology Grand Rounds

2011 - 2014

Texas Medical Association

2007 - Present

Lymphoma Research Foundation

2007 - 2008

Harris County Medical Society

2007 - Present

Chinese American Hematology Oncology Network

2006 - 2007

Chinese American Hematology Oncology Network

2005 - Present

Southwest Oncology Group (SWOG)

2005 - Present

American Society of Hematology (ASH)

2004 - Present

American Society of Cancer Research (AACR)

2004 - Present

American Society of Clinical Oncology (ASCO)

2003 - Present

Selected Presentations & Talks

Local Presentations

2026. Novel Therapies for Mantle Cell Lymphoma. Invited. Heme/Onc Grand Rounds. Houston, Texas, US.
2025. Ask the Expert. Invited. Ask the Expert Session. Houston, TX, US.
2025. Updates on Mantle Cell Lymphoma. Invited. Hamtpon Roads Oncology Updates 2024: Updates on Cancer Immunotherapy. Houston, Texas, US.
2025. Abstracts & Publications. Invited. Lymphoma/Myeloma Fellows Orientation Retreat 2025. Houston, Texas, US.
2025. Expert Perspectives in Mantle Cell Lymphoma. Invited. Houston, Texas, US.
2024. How do we use the TRIANGLE study in MCL -- autotransplant vs not. Panelist. Park City Lymphoma Myeloma Conference. Salt Lake City, Utah, US.
2024. Clinical Data in MCL: Current and Emerging Therapies. Invited. CancerNetwork Frontline Forum. Houston, Texas, US.
2024. Immunotherapy for Lymphoma. Invited. MCL Ask the Expert. Houston, Texas, US.
2024. Mantle Cell Lymphoma. Invited. The Lymphomas. Houston, Texas, US.
2024. Novel therapies for MCL. Invited. Houston, Texas, US.
2024. CAR T in B-cell lymphomas. Invited. Houston, Texas, US.
2024. CAR T in B-cell lymphomas. Invited. CAR T in B-cell Lymphomas CME Live Meeting Series: Faculty Presenter and In-Person Meeting Invitation. Houston, Texas, US.
2024. Integrating BTK Inhibitors Into the CLL/ SLL and MCL Treatment Paradigm. Invited. Community Oncology Connections: Integrating BTK Inhibitors Into the CLL/ SLL and MCL Treatment Paradigm: Considerations for Community Practitioners. Houston, Texas, US.
2024. Current Standard of Care and Clinical Evidence for BTK Inhibitors in MCL. Invited. Community Oncology Connections: Integrating BTK Inhibitors Into the CLL/ SLL and MCL Treatment Paradigm: Considerations for Community Practitioners. Houston, Texas, US.
2024. LBA-2 Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study. Invited. Rapid Readout Filming focusing on ASH 2023 Abstracts. Houston, Texas, US.
2023. Changing Treatment Landscape for MCL. Invited. Changing Treatment Landscape for MCL. Houston, TX, US.
2023. Current Standard of Care and Clinical Evidence for BTK Inhibitors in MCL. Invited. Current Standard of Care and Clinical Evidence for BTK Inhibitors in MCL. Houston, TX, US.
2023. Role of BTK Inhibitors in Patients with Mantle Cell Lymphoma. Invited. Role of BTK Inhibitors in Patients with Mantle Cell Lymphoma. Houston, TX, US.
2023. How I Treat MCL. Invited. How I Treat MCL. Houston, TX, US.
2023. How I Treat MCL. Invited. How I Treat MCL. Houston, TX, US.
2023. Mantle Cell Lymphoma - Treatment Considerations for Patients in Relapsed Setting. Invited. Mantle Cell Lymphoma - Treatment Considerations for Patients in Relapsed Setting. Houston, TX, US.
2023. Clinical Trial Advances in Mantle Cell Lymphoma. Invited. Clinical Trial Advances in Mantle Cell Lymphoma. Houston, TX, US.
2023. Chemo and Non-Chemotherapy Treatment of Mantle Cell Lymphoma. Invited. Chemo and Non-Chemotherapy Treatment of Mantle Cell Lymphoma. Houston, TX, US.
2023. CAR-T and Immunotherapy in Mantle Cell Lymphoma. Invited. CAR-T and Immunotherapy in Mantle Cell Lymphoma. Houston, TX, US.
2023. Management of newly diagnosed MCL: ASH Update. Invited. Management of newly diagnosed MCL: ASH Update. Houston, TX, US.
2022. New Directions in Targeted Therapeutic Approaches for Older Adults with Mantle Cell Lymphoma. Invited. New Directions in Targeted Therapeutic Approaches for Older Adults with Mantle Cell Lymphoma. Houston, TX, US.
2022. ROR1 and BTK: Translating Novel Targets into Clinical Practice. Invited. ROR1 and BTK: Translating Novel Targets into Clinical Practice. Houston, TX, US.
2022. Treatments for non-Hodgkin Lymphomas such as MCL and CLL Malignancies. Invited. Treatments for non-Hodgkin Lymphomas such as MCL and CLL Malignancies. Houston, TX, US.
2022. How I treat R/R Mantle Cell Lymphoma. Invited. How I treat R/R Mantle Cell Lymphoma. Houston, TX, US.
2022. ROR1 and BTK: Translating Novel Targets into Clinical Practice. Invited. ROR1 and BTK: Translating Novel Targets into Clinical Practice. Houston, TX, US.
2022. The Evolving role of BTKis in the treatment of Relapsed/Refractory MCL. Invited. The Evolving role of BTKis in the treatment of Relapsed/Refractory MCL. Houston, TX, US.
2022. Mantle Cell Lymphoma in 2022. Invited. Mantle Cell Lymphoma in 2022. Houston, TX, US.
2022. Emerging role of BTKi in R/R MCL. Invited. Emerging role of BTKi in R/R MCL. Houston, TX, US.
2022. Acalabrutinib and Other Novel Therapies in Mantle Cell Lymphoma. Invited. Acalabrutinib and Other Novel Therapies in Mantle Cell Lymphoma. Houston, TX, US.
2022. Novel Therapies for MCL. Invited. Novel Therapies for MCL. Houston, TX, US.
2021. Mantle Cell and Follicular Lymphoma: Managing the Disease in the BTKi Era. Invited. Mantle Cell and Follicular Lymphoma: Managing the Disease in the BTKi Era. Houston, TX, US.
2021. CAR T Cell Therapy for Multiple Myeloma. Invited. CAR T Cell Therapy for Multiple Myeloma. Houston, TX, US.
2021. Pirtobrutinib, A Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study. Invited. Pirtobrutinib, A Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study. Houston, TX, US.
2021. Acalabrutinib for Relapsed/Refractory MCL. Invited. Acalabrutinib for Relapsed/Refractory MCL. Houston, TX, US.
2021. Therapy of lymphoma from mantle zone cells, the place of BTK inhibitors: past, present and future strategies. Invited. Therapy of lymphoma from mantle zone cells, the place of BTK inhibitors: past, present and future strategies. Houston, TX, US.
2021. Novel Therapies for MCL. Invited. Novel Therapies for MCL. Houston, TX, US.
2021. Novel Therapy Options for Mantle Cell Lymphoma. Invited. Novel Therapy Options for Mantle Cell Lymphoma. Houston, TX, US.
2021. Standard Regimens and Novel Agents for Mantle Cell Lymphoma. Invited. Standard Regimens and Novel Agents for Mantle Cell Lymphoma. Houston, TX, US.
2021. Focus on Molecular Markers That Guide Treatment Options in Mantle Cell Lymphoma. Invited. Focus on Molecular Markers That Guide Treatment Options in Mantle Cell Lymphoma. Houston, TX, US.
2021. CAR-T Therapy, a hint of a cure. Invited. CAR-T Therapy, a hint of a cure. Houston, TX, US.
2021. MCL, a dream to cure. Invited. MCL, a dream to cure. Houston, TX, US.
2021. New progress on MCL treatment—perspective from US Physicians. Invited. New progress on MCL treatment—perspective from US Physicians. Houston, TX, US.
2021. 1st Lu Daopei Medical Cellular Immunotherapy Conference. Invited. 1st Lu Daopei Medical Cellular Immunotherapy Conference. Houston, TX, US.
2021. Mantle Cell Lymphoma: What is the best approach for patient in frontline NOT eligible for transplant?. Invited. Mantle Cell Lymphoma: What is the best approach for patient in frontline NOT eligible for transplant?. Houston, TX, US.
2021. KTE-X19, an Anti-CD19 CAR Therapy in Patients with relapsed/refractory MCL: Results of Phase 2 ZUMA-2 Study. Invited. KTE-X19, an Anti-CD19 CAR Therapy in Patients with relapsed/refractory MCL: Results of Phase 2 ZUMA-2 Study. Houston, TX, US.
2021. Acalabrutinib-Calquence launch event in R/R MCL in Saudi Arabia. Invited. Acalabrutinib-Calquence launch event in R/R MCL in Saudi Arabia. Houston, TX, US.
2021. Engineering the future of BTK Inhibition to show the evidence supporting Zanubrutinib & experience. Invited. Engineering the future of BTK Inhibition to show the evidence supporting Zanubrutinib & experience. Houston, TX, US.
2021. How I treat MCL. Invited. How I treat MCL. Houston, TX, US.
2021. BCM Expert Platform. Invited. BCM Expert Platform. Houston, TX, US.
2021. Virtual Clinical Hematology and Oncology Conference. Invited. Virtual Clinical Hematology and Oncology Conference. Houston, TX, US.
2020. Kite MCL Disease Education Speaker Meeting. Conference. Kite MCL Disease Education Speaker Meeting. Houston, TX, US.
2017. B-cell Lymphoma Moonshot: 6-month Scientific Update. Conference. B-cell Lymphoma Moonshot: 6-month Scientific Update. Houston, TX, US.
2009. Role of chemotherapy and stem cell transplant for multiple myeloma. Conference. Role of chemotherapy and stem cell transplant for multiple myeloma. Houston, TX, US.
2008. Update on the Management of Multiple Myeloma. Conference. Update on the Management of Multiple Myeloma. Houston, TX, US.
2008. The Role of Revlimid (lenalidomide) in Multiple Myeloma. Conference. The Role of Revlimid (lenalidomide) in Multiple Myeloma. Houston, TX, US.
2006. New Treatment Drugs for Myeloma. Conference. New Treatment Drugs for Myeloma. Houston, TX, US.
2006. Newer Approaches in the Treatment of Multiple Myeloma: do Emerging Therapies Offer an Advantage?. Conference. Newer Approaches in the Treatment of Multiple Myeloma: Do Emerging Therapies Offer an Advantage?. Houston, TX, US.
2006. Newer Approaches in the Treatment of Multiple Myeloma: Do Emerging Therapies Offer an Advantage?. Conference. Newer Approaches in the Treatment of Multiple Myeloma: Do Emerging Therapies Offer an Advantage?. Houston, TX, US.
2005. Advances in the Treatment of Multiple Myeloma. Conference. Advances in the Treatment of Multiple Myeloma. Houston, TX, US.
2005. Proteasome Inhibitors and Immunomodulators. Conference. Proteasome Inhibitors and Immunomodulators. Houston, TX, US.

Regional Presentations

2026. Non-Chemotherapy Approaches to Mantle Cell Lymphoma. Invited. Clinical Hematology & Oncology Conference 2026. San Diego, California, US.
2025. MCL Dream to Cure. Invited. 2025 Joint Conference of ANACP. Dallas, US.
2025. Mantle Cell Lymphoma: Key Studies From 18-ICML. Invited. Mayo Clinic Updates in Lymphoid Malignancies 2025: Best of Lugano. Truckee, California, US.
2025. CAR-T Cells in Mantle Cell Lymphoma. Invited. CAR-T Connect: MCL Medical Education Meeting with Royal Brisbane & Women's Meeting, US.
2025. My approaches to Managing the Controversies in the Treatment of Mantle Cell Lymphomas. Invited. 22ND Indy Hematology Review. Indianapolis, Indiana, US.
2024. How do we use the TRIANGLE study in MCL -- auto transplant vs not. Invited. Park City Lymphoma Myeloma Conference. Park City, US.
2023. ZUMA-2, Efficacy and Current Management Practices in R/R MCL and Discussion. Conference. ZUMA-2, Efficacy and Current Management Practices in R/R MCL and Discussion. San Diego, CA, US.
2023. Novel Agents and Regimens for Mantle Cell Lymphoma. Conference. Novel Agents and Regimens for Mantle Cell Lymphoma. New York, NY, US.
2023. Mantle Cell Lymphoma. Conference. Mantle Cell Lymphoma. New York, NY, US.
2023. Mantle Cell Lymphoma. Conference. Mantle Cell Lymphoma. Bologna, IT.
2023. ZUMA-2 and RWD. Conference. ZUMA-2 and RWD, US.
2023. How I Treat Mantle Cell Lymphoma. Conference. How I Treat Mantle Cell Lymphoma. Chicago, IL, US.
2023. How I Treat Mantle Cell Lymphoma in 2023. Conference. How I Treat Mantle Cell Lymphoma in 2023. Miami, FL, US.
2023. Perspective of the MCL disease space, unmet need and experience as a BRUIN study investigator. Conference. Perspective of the MCL disease space, unmet need and experience as a BRUIN study investigator. New Orleans, LA, US.
2022. Therapy Advances in MCL: with Message on Clinical Research for Junior Faculties. Conference. Therapy Advances in MCL: with Message on Clinical Research for Junior Faculties. New Orleans, LA, US.
2022. Increasing Therapeutic Options for Patients with Mantle Cell Lymphoma: Evidence From Clinical Trials. Conference. Increasing Therapeutic Options for Patients with Mantle Cell Lymphoma: Evidence From Clinical Trials, US.
2022. Novel Therapies for Mantle Cell Lymphoma. Conference. Novel Therapies for Mantle Cell Lymphoma. New York, NY, US.
2022. Zilovertamab Vedotin in Mantle Cell Lymphoma. Conference. Zilovertamab Vedotin in Mantle Cell Lymphoma. Bermuda, US.
2022. Approved and Emerging CAR-T cells in Mantle Cell Lymphoma. Conference. Approved and Emerging CAR-T cells in Mantle Cell Lymphoma. Bermuda, US.
2022. Novel Approaches for Relapsed Mantle Cell Lymphoma. Conference. Novel Approaches for Relapsed Mantle Cell Lymphoma, US.
2022. Novel Therapies for Mantle Cell Lymphoma. Conference. Novel Therapies for Mantle Cell Lymphoma, US.
2022. Novel Therapies in Mantle Cell Lymphoma. Conference. Novel Therapies in Mantle Cell Lymphoma, US.
2022. The role of ibrutinib in the actual and future therapeutic algorithm. Conference. The role of ibrutinib in the actual and future therapeutic algorithm, US.
2022. Novel Therapies for Mantle Cell Lymphoma. Conference. Novel Therapies for Mantle Cell Lymphoma, CA, US.
2022. Zilovertamab Vedotin in Mantle Cell Lymphoma. Conference. Zilovertamab Vedotin in Mantle Cell Lymphoma. Bologna, IT.
2022. Pirtobrutinib in Mantle Cell Lymphoma. Conference. Pirtobrutinib in Mantle Cell Lymphoma. Bologna, IT.
2022. Real-world data of TECARTUS in R/R MCL, Barriers and Challenges to Treatment with TECARTUS and Emerging Therapies for MCL. Conference. Real-world data of TECARTUS in R/R MCL, Barriers and Challenges to Treatment with TECARTUS and Emerging Therapies for MCL, TX, US.
2021. Moderating a panel focusing on B-Cell Lymphoma. Conference. Moderating a panel focusing on B-Cell Lymphoma. Atlanta, GA, US.
2021. Mantle Cell Lymphoma: Emerging Options and Evidence-Based Treatment Decision Making. Conference. Mantle Cell Lymphoma: Emerging Options and Evidence-Based Treatment Decision Making. Atlanta, GA, US.
2021. TECARTUS MCL KOL Session & TECARTUS MCL KOL Monograph Review. Conference. TECARTUS MCL KOL Session & TECARTUS MCL KOL Monograph Review. Dallas, TX, US.
2021. Oncology Town Hall: Primary Investigators Present Key Abstracts on CAR T Cell Therapy. Conference. Oncology Town Hall: Primary Investigators Present Key Abstracts on CAR T Cell Therapy, US.
2020. Current Treatment Landscape and Unmet Medical Need in Treating Patients with MCL - KOL Call on Cirmtuzumab. Conference. Current Treatment Landscape and Unmet Medical Need in Treating Patients with MCL - KOL Call on Cirmtuzumab, US.
2020. Virtual Investigator Perspectives filming. Conference. Virtual Investigator Perspectives filming, US.
2020. KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study. Conference. KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study. Orlando, FL, US.
2020. New options for refractory mantle cell lymphoma. Conference. New options for refractory mantle cell lymphoma. San Antonio, TX, US.
2020. ZUMA-2 presentation supporting education on KTE-X19 and its use in MCL. Conference. ZUMA-2 presentation supporting education on KTE-X19 and its use in MCL. Las Vegas, NV, US.
2019. Scientific Review. Conference. Scientific Review. Washington, DC, US.
2019. Targeted Oncology Dinner on Non-Hodgkin's Lymphoma. Conference. Targeted Oncology Dinner on Non-Hodgkin's Lymphoma. Dallas, TX, US.
2019. AZK Expert Session. Conference. AZK Expert Session. Gaithersburg, MD, US.
2019. Hematologic Malignancies. Conference. Hematologic Malignancies. Dallas, TX, US.
2019. Determining the value of maintenance ibrutinib therapy until progression in MCL. Conference. Determining the value of maintenance ibrutinib therapy until progression in MCL. New Orleans, LA, US.
2019. Mantle Cell Lymphoma and Future Treatment Paradigm. Conference. Mantle Cell Lymphoma and Future Treatment Paradigm. Sunnyvale, CA, US.
2018. Updated Treatment Strategies for MCL. Conference. Updated Treatment Strategies for MCL. Dallas, TX, US.
2017. Mantle Cell Lymphoma: A Dream to Cure!. Conference. Mantle Cell Lymphoma: A Dream to Cure!. Orlando, FL, US.
2015. New Drugs and Clinical Trials in Multiple Myeloma. Conference. New Drugs and Clinical Trials in Multiple Myeloma, US.
2010. Current Trends in Leukemia. Invited. Lymphoma and Myeloma: Progress in Multiple Myeloma. Dallas, TX, US.
2009. Scientific Discussant. Conference. Scientific Discussant. Orlando, FL, US.
2008. Practical Strategies for the Application of Novel Agents for the Frontline Treatment of Multiple Myeloma. Conference. Practical Strategies for the Application of Novel Agents for the Frontline Treatment of Multiple Myeloma. San Jose, CA, US.
2006. Newer Approaches in the Treatment of Multiple Myeloma. Conference. Newer Approaches in the Treatment of Multiple Myeloma. The Woodlands, TX, US.
2006. Front-line Multiple Myeloma Treatment Options. Conference. Front-line Multiple Myeloma Treatment Options. Sugar Land, TX, US.
2006. Updates from 2006 AACR and ASCO Meetings: Multiple Myeloma. Conference. Updates from 2006 AACR and ASCO Meetings: Multiple Myeloma. Indianapolis, IN, US.
2006. Updates from 2006 AACR and ASCO Meetings: Multiple Myeloma. Conference. Updates from 2006 AACR and ASCO Meetings: Multiple Myeloma. Nashville, TN, US.
2006. Updates from 2006 AACR and ASCO Meetings: Multiple Myeloma Update. Conference. Updates from 2006 AACR and ASCO Meetings: Multiple Myeloma Update. Kansas City, KS, US.
2006. Advances in Treatment Options for Multiple Myeloma. Conference. Advances in Treatment Options for Multiple Myeloma. El Paso, TX, US.
2006. Emerging Agents in Myeloma. Conference. Emerging Agents in Myeloma. Denver, CO, US.
2005. Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-Thalidomide-Dexamethasone Followed by Early Intensive Therapy. Conference. Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-Thalidomide-Dexamethasone Followed by Early Intensive Therapy. Boston, MA, US.
2005. New Therapies in Diffuse Large B-Cell Lymphomas. Conference. New Therapies in Diffuse Large B-Cell Lymphomas. Roanoke, VA, US.

National Presentations

2025. Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up. Conference. ASH 2025, Oral Presentation. Orlando, Florida, US.
2025. Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study. Conference. ASH 2025, Oral Presentation. Orlando, Florida, US.
2025. Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 study. Conference. ASH 2025, Oral Presentation. Orlando, Florida, US.
2025. The switch of TCA cycle mode determines the fate of pirtobrutinib-tolerant persister cells. Conference. ASH 2026, Oral Presentation. Orlando, Florida, US.
2025. Standard Therapies in Mantle Cell Lymphoma. Invited. Ottawa Grand Rounds, US.
2025. MCL Dream to Cure. Ottawa Hospital. Ottawa, Ontario, CA.
2025. Pirtobrutinib. Invited. iwNHL 2025. Cambridge, Massachusetts, US.
2025. Frontline therapy for MCL – which patient needs which initial regimen?. Invited. iwNHL 2025. Cambridge, Massachusetts, US.
2025. Fixed-Duration Outpatient Subcutaneous Mosunetuzumab + Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL). Conference. SOHO 2025, Oral Presentation. Houston, US.
2025. Fixed-Duration Outpatient Subcutaneous Mosunetuzumab + Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL). Poster. SOHO, Poster Presentation. Houston, US.
2025. A phase 1 trial of BTM-3566 in relapsed/refractory mature B cell lymphomas. Poster. ASCO 2025, Poster Presentation. Chicago, US.
2025. Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study. Conference. ASCO 2025, Oral Presentation. Chicago, IL, US.
2025. Chimeric Antigen Receptor (CAR) T-Cell Therapy Discussion. Invited. Lymphoma Research Foundation MCL Scientific Workshop. Chicago, IL, US.
2025. Chimeric Antigen Receptor (CAR) T-Cell Therapy Discussion. Invited. Mantle Cell Lymphoma Scientific Workshop. Chicago, IL, US.
2024. Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2. Poster. ASH 2024, US.
2024. A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL). Poster. ASH 2024, US.
2024. Next Questions: Mantle Cell Lymphoma. Conference. SOHO 2024. Houston, TX, US.
2024. Advanced Stage MCL Bruton’s Tyrosine Kinase inhibitors + Chemo-Based. Conference. PPLC 2024. Omaha, Nebraska, US.
2024. ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE 3, DOUBLE-BLIND, PLACEBOCONTROLLED ECHO TRIAL. Conference. EHA 2024. Madrid, ES.
2024. A MULTI-CENTER, OPEN-LABEL, PHASE 1/2 STUDY OF ONCT-808, A ROR1-TARGETING CAR-T CELL THERAPY, IN ADULTS WITH RELAPSED/REFRACTORY (R/R) AGGRESSIVE B CELL LYMPHOMAS (BCL). Conference. EHA 2024. Madrid, ES.
2024. Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study. Conference. ASCO 2024, US.
2023. Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study. Conference. Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study. San Diego, CA, US.
2023. Trial-in-Progress: A Phase 1/2 Multi-Center Study of Onct-808, a ROR1-Specific CAR T, in Adult Patients with Relapsed/Refractory Aggressive B Cell Lymphoma. Conference. Trial-in-Progress: A Phase 1/2 Multi-Center Study of Onct-808, a ROR1-Specific CAR T, in Adult Patients with Relapsed/Refractory Aggressive B Cell Lymphoma. San Deigo, CA, US.
2023. Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study. Conference. Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study. San Diego, CA, US.
2023. Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL. Conference. Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL. San Diego, CA, US.
2023. Discussion of BTKi in MCL. Conference. Discussion of BTKi in MCL. San Diego, CA, US.
2023. CAR-T Cell. Conference. CAR-T Cell. Houston, TX, US.
2023. Mantle Cell Lymphoma. Conference. Mantle Cell Lymphoma. Houston, TX, US.
2023. Unmet Need in Relapsed/refractory (RR) Mantle Cell Lymphoma (MCL) Post-Bruton Tyrosine Kinase Inhibitor (BTKi): Systematic Literature Review and Meta-Analysis). Conference. Unmet Need in Relapsed/refractory (RR) Mantle Cell Lymphoma (MCL) Post-Bruton Tyrosine Kinase Inhibitor (BTKi): Systematic Literature Review and Meta-Analysis). Houston, TX, US.
2023. Lisocabtagene maraleucel in R/R MCL: primary analysis results from the MCL cohort of the single-arm, multicenter, phase 1 seamless design TRANSCEND NHL 001 study. Conference. Lisocabtagene maraleucel in R/R MCL: primary analysis results from the MCL cohort of the single-arm, multicenter, phase 1 seamless design TRANSCEND NHL 001 study. Houston, TX, US.
2023. Mantle Cell Lymphoma - Treatment Considerations for Patients in Relapsed Setting. Conference. Mantle Cell Lymphoma - Treatment Considerations for Patients in Relapsed Setting. Houston, TX, US.
2023. Third line MCL: ZUMA-2 and RWD. Conference. Third line MCL: ZUMA-2 and RWD. Bologna, US.
2022. Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Conference. Loxo / Eli Lilly. New Orleans, LA, US.
2022. Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve MCL: 2-Year Safety and Efficacy Analysis. Conference. AstraZeneca. New Orleans, LA, US.
2022. Preclinical data in MCL. Conference. Preclinical data in MCL. Boston, MA, US.
2022. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. Conference. Kite. New Orleans, LA, US.
2022. Trial in progress: A phase II, open-label, multicenter study of capivasertib, a potent, oral pan-AKT inhibitor in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CAPITAL). Conference. AstraZeneca. New Orleans, LA, US.
2021. Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma – Phase-II Window-2 Clinical Trial. Conference. Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma – Phase-II Window-2 Clinical Trial. Atlanta, GA, US.
2021. Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL). Conference. Openhealth. Atlanta, GA, US.
2021. Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study. Conference. Lilly. Atlanta, GA, US.
2021. Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma. Conference. ApotheCom. Atlanta, GA, US.
2021. CAR T-Cell Therapy in Mantle Cell Lymphoma. Conference. CAR T-Cell Therapy in Mantle Cell Lymphoma. Houston, TX, US.
2021. Best Management of TP53 Mutated Mantle Cell Lymphoma. Conference. Best Management of TP53 Mutated Mantle Cell Lymphoma. Kailua-Kona, HI, US.
2021. Outcomes with KTE-X19 in patients with (R/R) Relapsed/Refractory Mantle Cell Lymphoma in ZUMA-2 who had progression of disease within 24 months of diagnosis. Conference. Outcomes with KTE-X19 in patients with (R/R) Relapsed/Refractory Mantle Cell Lymphoma in ZUMA-2 who had progression of disease within 24 months of diagnosis. Houston, TX, US.
2021. Novel Therapeutic Options. Conference. Novel Therapeutic Options. Houston, TX, US.
2021. Outcomes with KTE-X19 in patients with (R/R) Relapsed/Refractory Mantle Cell Lymphoma in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24). Conference. Outcomes with KTE-X19 in patients with (R/R) Relapsed/Refractory Mantle Cell Lymphoma in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24). Virtual, US.
2021. Advancement in MCL at ASH 2020. Conference. Advancement in MCL at ASH 2020. Houston, TX, US.
2020. Ibrutinib with rituximab (IR) and short course R-HyperCVAD/MTX is very efficacious in previously untreated young patients with mantle cell lymphoma (MCL) – WINDOW-1 Study. Conference. Pharmacyclics LLC, US.
2020. Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results From a Phase 2 Study. Conference. Acerta Pharma, US.
2020. VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma. Conference. VelosBio, US.
2020. LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study. Conference. Loxo Oncology, US.
2020. One-Year Follow-Up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma. Conference. Kite Pharma, US.
2020. Pharmacological Profile and Clinical Outcomes of KTE-X19 by Prior Bruton Tyrosine Kinase Inhibitor Exposure or Mantle Cell Lymphoma Morphology in Patients With Relapsed/Refractory Mantle Cell Lymphoma in the ZUMA-2 Trial. Conference. Kite Pharma, US.
2020. KTE-X19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results from Phase 2 of ZUMA-2. Conference. Kite Pharma, US.
2020. New Development of Mantle Cell Lymphoma. Conference. Hebei Clinical Oncology Society, US.
2020. New approaches to MCL: Beyond Chemotherapy. Conference. DAVA Oncology, US.
2020. First-Line Ibrutinib Plus Venetoclax in MCL for Older Patients or Those With a TP53 Mutation: Ongoing Open-Label Arm of the PCYC-1143 Phase 3 SYMPATICO Study. Conference. Pharmacyclics LLC. Houston, TX, US.
2020. KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results from Phase 2 of ZUMA-2. Conference. Kite Pharma, US.
2020. New Approaches to MCL: Beyond Chemotherapy. Conference. DAVA Oncology, US.
2020. KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results from Phase 2 of ZUMA-2. Conference. Kite Pharma, US.
2019. Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) – Results of Phase-II Window-1 Clinical Trial. Conference. ASH Annual Meeting, Poster Presentation. Orlando, FL, US.
2019. KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. Conference. ASH Annual Meeting, Oral Presentation. Orlando, FL, US.
2019. Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy. Conference. ASH Annual Meeting, Oral Presentation. Orlando, FL, US.
2019. Long-Term Follow-Up of Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Mantle Cell Lymphoma. Conference. Long-Term Follow-Up of Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Mantle Cell Lymphoma. Houston, TX, US.
2019. Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). Conference. Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). Houston, TX, US.
2018. Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Conference. AstraZeneca. San Diego, CA, US.
2018. ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma. Conference. Kite Pharma. Chicago, IL, US.
2017. Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study. Conference. Acerta Pharma. Atlanta, GA, US.
2017. Debate Topic: Chemotherapy for MCL - Pro. Conference. Debate Topic: Chemotherapy for MCL - Pro. Houston, TX, US.
2017. The Future of Clinical Trials - Randomized International-Focused Studies with Pharma. Conference. MDACC. Houston, TX, US.
2017. Maintenance Therapy Approaches in the Post-Transplant and Non-Transplant Settings Based on Patient- and Disease Related Factors Including Cytogenetic Profile. Conference. Maintenance Therapy Approaches in the Post-Transplant and Non-Transplant Settings Based on Patient- and Disease Related Factors Including Cytogenetic Profile. Houston, TX, US.
2016. Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial. Conference. Pharmacyclics. San Diego, CA, US.
2015. Novel Agents for B-cell lymphoma. Conference. Novel Agents for B-cell lymphoma. Flushing, NY, US.
2015. Novel Agents in Multiple Myeloma. Conference. Novel Agents in Multiple Myeloma. Houston, TX, US.
2015. Approach to Relapsed Multiple Myeloma. Conference. Approach to Relapsed Multiple Myeloma. Houston, TX, US.
2014. Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial. Conference. ASH Annual Meeting, Oral presentation. San Francisco, CA, US.
2012. Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up. Conference. ASH Annual Meeting, Oral Presentation. Atlanta, GA, US.
2011. The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. Conference. ASH Annual Meeting, Oral presentation. San Diego, CA, US.
2010. Carfilzomib, an irreversible proteasome inhibitor, induces caspase-dependent apoptosis and inhibits the growth of mantle cell lymphoma in vitro and in tumor-bearing SCID mice. Conference. Onyx Pharmaceuticals Inc. Washington D.C, DC, US.
2010. Long-term storage in TRIzol has little effect on microarray-based gene expression profiling in primary myeloma or acute myeloid leukemia cells. Conference. Long-term storage in TRIzol has little effect on microarray-based gene expression profiling in primary myeloma or acute myeloid leukemia cells. Washington, DC, US.
2010. Clinical Debates in Multiple Myeloma: The Evolving Role of Transplant. Conference. Clinical Debates in Multiple Myeloma: The Evolving Role of Transplant. Newport Beach, CA, US.
2010. Clinical Debates in Multiple Myeloma: the Evolving role of Transplant. Conference. Clinical Debates in Multiple Myeloma: the Evolving role of Transplant. Chicago, IL, US.
2010. Clinical Debates in Multiple Myeloma: The Evolving Role of Transplant. Invited. Chicago, Illinois, US.
2009. A Phase I/II study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma. Conference. ASH Annual Meeting, Oral Presentation. New Orleans, LA, US.
2008. Cyclin D1 as a Universally-Expressed mantle Cell Lymphoma-Associated Tumor Antigen for Immunotherapy. Conference. 50th American Hematology Society, ASH Oral Presentation. San Francisco, CA, US.
2006. Complete Remission Represents the Major Surrogate Marker of Long Survival in Multiple Myeloma. Conference. ASH Annual Meeting, Oral Presentation. Orlando, FL, US.
2006. Lenalidomide in Combination with Dexamethasone is More Effective than Dexamethasone in Patients who Have Received Prior Thalidomide in Relapsed or Refractory Multiple Myeloma. Conference. ASCO, Oral Presentation. Atlanta, GA, US.
2005. Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-Thalidomide-Dexamethasone Followed by Early Intensive Therapy. Conference. ASH Annual Meeting, Oral Presentation. Atlanta, GA, US.
2005. A Phase I, Multi-center Dose Escalation Study of Atiprimod in Patients with Refractory or Relapsed Multiple Myeloma. Conference. ASH Annual Meeting, Oral Presentation. Atlanta, GA, US.
2005. Treatment of Multiple Myeloma: Past, Present, and Future. Conference. Chinese Academy of Medical Sciences and Peking Union Medical College Cancer Institute/Hospital Multidisciplinary Management of Lymphoproliferative Disorders. Beijing, US.

International Presentations

2026. Clinical results CAR-T for mantle cell lymphoma: what’s next?. Invited. 4th Meeting on Innovative Immunotherapies for Lymphoid Malignancies. Milano Marittima, IT.
2026. Recent Progress in Mantle Cell lymphoma - small molecules, biologics, and cell therapy. Invited. SOHO Asia 2026 Meeting. Houston, US.
2025. How I Treat R/R Mantle Cell Lymphoma. Invited. Houston, US.
2025. Updates on Mantle Cell Lymphoma. Invited. Lymphomas in Brazil. Houston, US.
2025. Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study. Conference. ICML 2025, Oral Presentation. Lugano, CH.
2025. Customizing therapy for MCL – Current therapies for MCL and their combinations. Invited. ICML Lymphoma Hub Symposium. Lugano, CH.
2025. Customizing therapy for MCL – Sequencing therapies and practical management of adverse events in MCL”. Invited. ICML Lymphoma Hub Symposium. Lugano, CH.
2025. MINIMAL RESIDUAL DISEASE WITH BENDAMUSTINE-RITUXIMAB WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ECHO TRIAL. Poster. EHA 2025, Poster Presentation. Milan, IT.
2025. Evolving treatment paradigm MCL. Invited. Hematology Oncology Conference in Israel, US.
2025. The role of CAR-T: current and future vision. Invited. 9th Postgraduate Lymphoma Conference. Prague, CZ.
2025. How I Treat Mantle Cell Lymphoma. Invited. Czech Lymphoma Study Group. Prague, CZ.
2025. Mantle Cell Lymphoma. Invited. Inaugural Pan-Hematology Clinical Meeting 2026. Puerto Rico, US.
2024. AZ Heme Masterclass-Place of BTKi in 1L MCL. Invited. Canada Masterclass. Vancouver, CA.
2024. BTK Degraders. Invited. iwNHL 2024. Nice, FR.
2024. BCL-2 inhibitors:. Invited. iwNHL 2024. Nice, FR.
2024. Should frontline treatment for MCL be ‘chemo-free’ – where do cellular therapies fit in?. Invited. iwNHL 2024. Nice, FR.
2024. Emerging novel agents. Invited. 8th Postgraduate Lymphoma Conference. Naples, IT.
2024. Emerging novel agents. Invited. 8th Postgraduate Lymphoma Conference. Naples, IT.
2024. CAR-T cells. Invited. 8th Postgraduate Lymphoma Conference. Naples, IT.
2024. CAR-T cells. Invited. 8th Postgraduate Lymphoma Conference. Naples, IT.
2023. The Role of Cell Therapies in Mantle Cell Lymphoma. Conference. The Role of Cell Therapies in Mantle Cell Lymphoma. Krakow, PL.
2023. CAR-T cell. Conference. CAR-T cell. Houston, US.
2023. Mantle Cell Lymphoma. Conference. Mantle Cell Lymphoma. Cape Town, ZA.
2023. Lisocabtagene maraleucel in R/R MCL: primary analysis results from the MCL cohort of the single-arm, multicenter, phase 1 seamless design TRANSCEND NHL 001 study. Conference. Lisocabtagene maraleucel in R/R MCL: primary analysis results from the MCL cohort of the single-arm, multicenter, phase 1 seamless design TRANSCEND NHL 001 study. Lugano, CH.
2023. The Big Debate: Best therapy in aggressive MCL: Time for frontline chemotherapy-free regimens?. Conference. The Big Debate: Best therapy in aggressive MCL: Time for frontline chemotherapy-free regimens?. Lugano, CH.
2023. ICML Rapid Readout Filming. Conference. ICML Rapid Readout Filming. Lugano, SZ.
2023. Zilovertamab vedotin (MK-2140) in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): 14-month follow-up of the phase 1 waveLINE-001 study. Conference. Zilovertamab vedotin (MK-2140) in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): 14-month follow-up of the phase 1 waveLINE-001 study. Lugano, CH.
2023. Ibrutinib-rituximab and venetoclax (IRV) followed by risk-stratified R-HyperCVAD/MTX in young patients with untreated mantle cell lymphoma – phase-II WINDOW-2 trial. Conference. Ibrutinib-rituximab and venetoclax (IRV) followed by risk-stratified R-HyperCVAD/MTX in young patients with untreated mantle cell lymphoma – phase-II WINDOW-2 trial. Lugano, CH.
2023. ROR1 Modalities in NHL. Conference. ROR1 Modalities in NHL. Lugano, CH.
2023. ROR1 Therapeutic Modalities in Non-Hodgkin's Lymphoma. Conference. Merck. Lugano, CH.
2023. BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma. Conference. BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma. Chicago, US.
2023. Zilovertamab Vedotin. Conference. Zilovertamab Vedotin. Bologna, IT.
2023. Update in MCL (Clinical Trials and RWD). Conference. Update in MCL (Clinical Trials and RWD). Houston, US.
2022. CAR-T cells in Mantle Cell Lymphoma. Conference. CAR-T cells in Mantle Cell Lymphoma. Houston, US.
2022. The Role of Ibrutinib in the Actual and Future Algorithm for Mantle Cell Lymphoma. Conference. The Role of Ibrutinib in the Actual and Future Algorithm for Mantle Cell Lymphoma. Houston, US.
2022. Mantle Cell Lymphoma. Conference. Mantle Cell Lymphoma. Houston, US.
2022. Primary Results From the Double-Blind, Placebo-Controlled, Phase III SHINE Study of Ibrutinib in Combination With Bendamustine-Rituximab and Rituximab Maintenance as a First-Line Treatment for Older Patients With Mantle Cell Lymphoma. Conference. Janssen. Vienna, AT.
2022. Three-Year Follow-Up of Outcomes With KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma in ZUMA-2. Conference. Kite. Vienna, AT.
2022. Zilovertamab vedotin (MK-2140) for the treatment of non-Hodgkin lymphoma: The phase 1 dose escalation and cohort expansion WAVELINE-001 study of an anti-ROR1 antibody-drug conjugate. Conference. Merck. Vienna, AT.
2022. Primary Results From the Double-Blind, Placebo-Controlled, Phase III SHINE Study of Ibrutinib in Combination With Bendamustine-Rituximab and Rituximab Maintenance as a First-Line Treatment for Older Patients With Mantle Cell Lymphoma. Conference. Janssen. New Orleans, US.
2021. Role of MR after first-line Bendamustine + Rituximab or r-chop in pts with MCL from a large us real-world cohort. Conference. Role of MR after first-line Bendamustine + Rituximab or r-chop in pts with MCL from a large us real-world cohort. Houston, US.
2021. Role of Maintenance Rituximab (MR) After First-Line 1(L) Bendamustine + Rituximab (BR) or R-CHOP in Patients (Pts) With Mantle Cell Lymphoma (MCL) From a Large US Real-World (RW) Cohort. Conference. Role of Maintenance Rituximab (MR) After First-Line 1(L) Bendamustine + Rituximab (BR) or R-CHOP in Patients (Pts) With Mantle Cell Lymphoma (MCL) From a Large US Real-World (RW) Cohort. Houston, US.
2021. Hematologic Malignancies--Lymphoma and Chronic Lymphocytic Leukemia Abstract: Outcomes with KTE-X19 in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24). Conference. Hematologic Malignancies--Lymphoma and Chronic Lymphocytic Leukemia Abstract: Outcomes with KTE-X19 in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24), US.
2020. Improve Treatment Outcomes in MCL with Novel Agents. Conference. Janssen, CN.
2020. BeiGene Lymphoma MKT. Invited. The 3rd Tianjin International Lymphoma Summit (TILS), CN.
2020. Therapeutic Advances in Mantle Cell Lymphoma: Highlights of my MD Anderson Career. Conference. Virtual Edition of the 5th International Forum on Leukemia and Lymphoma, CN.
2020. Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial. Conference. Kite Pharma, US.
2019. Mantle Cell Lymphoma - Efficacy and Safety Data of ACE-LY 004 Clinical Trial. Conference. AstraZeneca Pharmaceuticals. Porto Alegre, Sao Paulo, Rio de Janeiro, BR.
2019. Results From the Safety Run-In Period of the SYMPATICO Study Evaluating Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma. Conference. 15-ICML, Poster Presentation. Lugano, CH.
2019. Ibrutinib with rituximab (IR) and short course R-HyperCVAD/MTX is very efficacious in previously untreated young pts with mantle cell lymphoma (MCL). Conference. 15-ICML, Oral Presentation. Lugano, CH.
2019. Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in TRANSCEND NHL 001. Conference. 15-ICML, Poster Presentation. Lugano, CH.
2019. Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001. Conference. 2019 ASCO Annual Meeting, ASCO Poster Presentation. Chicago, US.
2019. Update on Mantle Cell Lymphoma. Conference. Update on Mantle Cell Lymphoma. Calgary, CA.
2019. Haimatus Latin American Summit 2019. Conference. Janssen. Sao Paulo, BR.
2018. Combination Strategies for the Treatment of MCL. Conference. Oncology Meeting Innovations. Whistler, CA.
2018. What will it take to improve outcome in MCL in 2018. Conference. Oncology Meeting Innovations. Whistler, CA.
2018. Optimizing the Management of Patients with MCL in the Era of Biological Agents. Conference. Physicians' Education Resource, LLC. Hollywood, US.
2017. New Perspective in MCL. Conference. New Perspective in MCL. Rome, IT.
2017. Ibrutinib-Rituximab Followed by Reduced Chemo-immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: a Window of Opportunity to Reduce Chemo. Conference. Ibrutinib-Rituximab Followed by Reduced Chemo-immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: a Window of Opportunity to Reduce Chemo. Lugano, CH.
2017. The Future of Clinical Trials - Randomized International-Focused Studies with Pharma. Conference. The Future of Clinical Trials - Randomized International-Focused Studies with Pharma. Houston, US.
2016. Mantle Cell Lymphoma. Conference. Mantle Cell Lymphoma. Berlin, DE.
2016. Emerging Treatment Approaches in Relapsed/Refractory MCL - Targeting BTK. Conference. Emerging Treatment Approaches in Relapsed/Refractory MCL - Targeting BTK. Taipei, TW.
2016. MCL Treatment Experience at MDACC. Conference. MCL Treatment Experience at MDACC. Taipei, TW.
2015. Road to Cure: B-cell Lymphoma. Conference. Road to Cure: B-cell Lymphoma. Tianjin, CN.
2015. Novel Therapies in B-cell lymphoma: so many stars. Conference. Novel Therapies in B-cell lymphoma: so many stars. Xiamen, CN.
2015. Rapid Progress in the Therapy of B Cell Lymphoma. Conference. Chinese Medical Association. Harbin, CN.
2015. Ibrutinib in combination with rituximab for relapsed mantle cell lymphoma: An update from a Phase II clinical trial. Conference. 13th ICML. Lugano, CH.
2015. Lenalidomide in combination with rituximab for relapsed or refractory mantel cell lymphoma: Updated analysis of a phase 2 trial. Conference. Lenalidomide in combination with rituximab for relapsed or refractory mantel cell lymphoma: Updated analysis of a phase 2 trial. Chicago, US.
2015. Ibrutinib: Targeted Therapy in Lymphoma. Conference. Ibrutinib: Targeted Therapy in Lymphoma. Bangkok, TH.
2013. Final results from the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma. Conference. Final results from the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma. Chicago, US.
2013. A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL). Conference. A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL). Chicago, US.
2013. The Medal Group. Invited. Hematologic Malignancy Conference, Hong Kong, China, CN.
2011. Oral Lenalidomide Plus 4 Doses of Rituximab Induced Prolonged Remissions in Relapsed/Refractory Mantle Cell Lymphoma: A Completed Phase I/II Clinical Trial. Conference. Oral Lenalidomide Plus 4 Doses of Rituximab Induced Prolonged Remissions in Relapsed/Refractory Mantle Cell Lymphoma: A Completed Phase I/II Clinical Trial. Lugano, CH.
2010. Berubicin, a topoisomerase II poison with high CNS uptake, inhibits cell growth and induces apoptosis in diffuse large B-cell lymphomas. Conference. EORTC, NCI, & AARC. Berlin, DE.
2010. Berubicin, a novel mechanistically altered anthracycline potently inhibits cell growth and induces apoptosis in mantle cell lymphoma. Conference. EORTC, NCI, & AARC. Berlin, DE.
2010. PX-171-006, A Phase IB Dose-Escalation Study of Carfilzomib and Lenalidomide and Low Dose Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. Conference. PX-171-006, A Phase IB Dose-Escalation Study of Carfilzomib and Lenalidomide and Low Dose Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. Barcelona, ES.
2010. Results of an ongoing open-label, phase study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM). Conference. Results of an ongoing open-label, phase study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM). Chicago, US.
2010. High Complete Response Rates with Lenalidomide Plus Rituximab for Untreated Indolent B-cell non-Hodgkin’s Lymphoma. Conference. High Complete Response Rates with Lenalidomide Plus Rituximab for Untreated Indolent B-cell non-Hodgkin’s Lymphoma. Chicago, US.
2010. Clinical Case: Lenalidomide post Thalidomide. Conference. Celgene, PT.
2010. Non-Hodgkin's Lymphoma I: Mantle Cell Lymphoma, Oral presentation. Conference. The Medal Group, SG.
2010. Diagnosis and Treatment of Newly Diagnosed Multiple Myeloma, Oral Presentation. Conference. The Medal Group. Singapore, SG.
2009. PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM) -- Preliminary results. Conference. Proteolix. Berlin, DE.
2009. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Conference. 2009 ASCO Annual Meeting, ASCO Oral Presentation. Orlando, US.
2009. Predictive Features for Long Survival in Multiple Myeloma. Conference. Predictive Features for Long Survival in Multiple Myeloma. Washington, US.
2008. Complete remission and survival in multiple myeloma. Conference. 2008 ASCO Annual Meeting Proceedings, ASCO Oral Presentation. Chicago, US.
2007. Recent Data on Multiple Myeloma. Conference. Chinese Conference on Medical Oncology. Beijing, CN.
2007. Targeted Therapies in Mantle Cell Lymphoma: An MD Anderson Experience. Conference. Chinese Conference on Medical Oncology. Beijing, CN.
2007. Important New Agents and Combinations for Future Myeloma Treatment. Conference. Sino-American Lymphoma Symposium. Shanghai, CN.
2007. What New Agents are Most Important in Future Myeloma Treatments?. Conference. 3rd Malignant Lymphoma Academy. Tokyo, JP.
2007. Waldenstrom's Macroglobulinemia. Conference. 3rd Malignant Lymphoma Academy. Tokyo, JP.
2007. Overview of the Current Management of Multiple Myeloma. Conference. 3rd Malignant Lymphoma Academy. Tokyo, JP.
2006. Lenalidomide in Combination with Dexamethasone is More Effective Than Dexamethasone alone in Patients with Relapsed or Refractory Multiple Myeloma Regardless of Prior Thalidomide Exposure. Conference. Joint meeting of the 7th International Conference of the Asian Clinical Oncology Society and the 9th Annual Meeting of Chinese Society of Clinical Oncology. Beijing, CN.
2005. Multidisciplinary Management of Lymphoproliferative Disorders; Treatment of Multiple Myeloma: Past, Present and Future. Invited, CN.

Formal Peers

2023. Clinical Trial Advances in Mantle Cell Lymphoma. Visiting. Houston, TX, US.
2022. The similarities and differences between MCL and CLL: How to move the fields forward in partnership. Invited. Houston, TX, US.
2021. Mantle Cell Lymphoma, Dream to Cure. Invited. Houston, TX, US.
2021. Cancer Is A Disease Not A Death Sentence: Mantle Cell Lymphoma Relapsed/Refractory. Invited. Houston, TX, US.
2021. Experience in Clinical Research of Lymphoma and Myeloma. Invited. Houston, TX, US.
2021. My Experience in Lymphoma and Myeloma at MD Anderson. Invited. Houston, TX, US.
2021. Targeting BTK: Covalent vs non-covalent inhibitors. Visiting. Houston, TX, US.
2021. Post-ASH QILU Hematology Forum. Visiting. Houston, TX, US.
2020. Mantle Cell Lymphoma - An update on management. Invited, IN.
2020. Clinical management update in Mantle Cell Lymphoma and Long-term BTKi practice. Visiting, US.
2020. Update on MCL: long term ibrutinib therapy for MCL, and differentiation for BTKi inhibitors. Visiting, US.
2020. AstraZeneca’s Focus on B-Cell Malignancy Posters. Visiting, US.
2020. New Development of mantle cell lymphoma. Invited, CN.
2020. New Development of mantel cell lymphoma. Visiting, US.
2020. Advances in CAR-T Therapy for Mantle Cell Lymphoma. Visiting, US.
2020. New Development of Mantle Cell Lymphoma. Visiting, US.
2020. CAR-T Therapy for Mantle Cell Lymphoma. Visiting, US.
2020. Preclinical and clinical investigations in mantle cell lymphoma: a MD Anderson Journey. Invited, CN.
2020. The new development of MCL. Visiting, CN.
2020. Progress in the treatment of relapsed and refractory mantle cell lymphoma. Visiting, US.
2020. The new development of mantle cell lymphoma. Visiting, CN.
2019. The Role of Ibrutinib in the Actual and Future Therapeutic Algorithm. Visiting. Rome, IT.
2019. Hematology Visiting Professor Series. Visiting, CA.
2019. Role of BTKi in Management of MCL. Visiting. Riyadh, Jeddah, Kuwait and UAE, SA.
2019. MD Anderson Cancer Center Successes and Research. Invited. El Paso, TX, US.
2019. How I treat MCL?. Invited. Moscow, RU.
2019. Treatment Approaches in B-Cell Lymphomas. Visiting. Moscow, RU.
2018. Novel Therapies in B-cell Lymphoma. Invited. Tampa, FL, US.
2017. Science Advisory Board for anti-FcgRIIB. Visiting. Washington, DC, US.
2017. ECHO Investigator Meeting for ACE-LY-308. Visiting. Chicago, IL, US.
2017. Mantle Cell Lymphoma: Past, Present & Future. Visiting. Phoenix, AZ, US.
2017. GPCRs in Oncology Roundtable. Visiting. Washington, DC, US.
2017. Mantle Cell Lymphoma: Applying Emerging Evidence in Practice. Visiting. Atlanta, GA, US.
2015. Mantle Cell Lymphoma. Invited. Houston, TX, US.
2015. A Strategy to Cure B-Cell Lymphoma. Invited. Duarte, CA, US.
2015. The Progress on the Treatment of Mantle Cell Lymphoma (MCL). Invited. Dalian, CN.
2015. B-cell Lymphoma: A Strategy to Cure. Invited. Beijing, CN.
2015. EPIC NHL, CLL, and WM in 2015 and Beyond: Expert Roundtable. Visiting. Las Vegas, NV, US.
2015. Translational Research in B-Cell Lymphoma. Invited. Tampa, FL, US.
2015. Translational Research on B-Cell Lymphoma at MDACC. Invited. Omaha, NE, US.
2014. 2nd Ludaopei Hematology Forum. Invited. Beijing, CN.
2012. The George Assimos Lectureship. Visiting, US.
2010. The current therapy for Multiple Myeloma. Visiting, US.
2009. Myeloma Symposium. Visiting. Puerto Morelos, Quintana Roo, MX.
2006. Update on the Treatment of Multiple Myeloma. Visiting. San Antonio, TX, US.
2006. Clinical Controversies in Multiple Myeloma. Visiting. Houston, TX, US.
2006. Advances in the Treatment of Multiple Myeloma. Invited. St. Louis, MO, US.
2005. Exploring Myeloma. Visiting. Houston, TX, US.
2005. Advances in the Treatment of Multiple Myeloma. Invited. Valhalla, NY, US.

Less

Grant & Contract Support

Date:	2023 - 2026
Title:	Development of novel BTK-MALT1 dual inhibitors to treat MCL
Funding Source:	Leukemia and Lymphoma Society
Role:	PI
ID:	MCL7003-24

Date:	2023 - 2027
Title:	Targeting HSP90 to enhance CAR-T immunotherapy in patients with MCL
Funding Source:	Leukemia and Lymphoma Society
Role:	PI
ID:	MCL7004-24

Date:	2023 - 2027
Title:	Understanding resistance mechanisms to enhance CAR-T immunotherapy for MCL
Funding Source:	LLS (Sub: UVA)
Role:	PI
ID:	MCL7004-24

Date:	2023 - 2026
Title:	Development of novel BTK-MALT1 dual inhibitors to treat MCL
Funding Source:	Sub-K: UTMB - Galveston
Role:	PI
ID:	MCL7003-24

Date:	2022 - 2024
Title:	A Pre-Clinical Study of BTM-3566 in Mantle Cell Lymphoma
Funding Source:	Bantam Pharmaceutical, LLC
Role:	PI
ID:	LAB11-0342

Date:	2022 - 2024
Title:	A Preclinical Study of AZD4573 (CDK9i) as a Potential Therapy in B-cell Lymphoma
Funding Source:	AstraZeneca
Role:	PI
ID:	LAB11-0342

Date:	2022 - 2024
Title:	Anti-Tumor Activity of Tafasitamab in Mantle Cell Lymphoma
Funding Source:	Inctye
Role:	PI
ID:	LAB11-0342

Date:	2021 - 2025
Title:	Preclinical Study of Anti-ROR1 CAR-T Cell Therapy in Mantle Cell Lymphoma
Funding Source:	Oncternal Therapeutics
Role:	PI
ID:	LAB11-0342

Date:	2021 - 2024
Title:	Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP210062 (FT 57)

Date:	2020 - 2025
Title:	Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies
Funding Source:	NIH/NCI
Role:	PI
ID:	R01CA250503

Date:	2020 - 2025
Title:	Targeting SOX11 in Mantle Cell Lymphoma
Funding Source:	NIH/NCI
Role:	PI
ID:	R01CA252222

Date:	2020 - Present
Title:	Shaw Wagener MCL Research
Funding Source:	MD Anderson Cancer Center
Role:	PI

Date:	2019 - 2022
Title:	Targeting the Unique Paracaspase MALT1 to Overcome Ibrutinib Resistance in Relapsed/Refractory Mantle Cell Lymphoma Patients
Funding Source:	NIH/NCI
Role:	PI
ID:	R21CA237969

Date:	2019 - 2026
Title:	Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents
Funding Source:	AstraZeneca
Role:	PI
ID:	PA18-0942

Date:	2019 - Present
Title:	Maky & Shaun Zanganeh MCL Research Fund
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2018 - 2021
Title:	FoxM1 as a Novel Therapeutic Target to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Funding Source:	NIH/NCI
Role:	PI
ID:	R21CA234851

Date:	2018 - Present
Title:	Stock Grill Challenge for B-Cell Moonshot
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2017 - Present
Title:	Agilent Bravo Automated Liquid Handling Platform
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2017 - 2019
Title:	"The Identification of the Genetic Mechanisms Underlying MCL Progression and Therapeutic Resistance"
Funding Source:	Sister Institution Network Fund Grants (SINF)
Role:	PI

Date:	2017 - 2022
Title:	BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01-CA210250

Date:	2017 - Present
Title:	Personal Therapy B-Cell Lymphoma, Cullen Foundation Award
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2016 - 2017
Title:	A Pre-Clinical Study of Cirmtuzumab (anti-ROR1 Monoclonal Antibody) Alone and in Combination with Ibrutinib in MCL/DLBCL
Funding Source:	Oncternal Therapeutics
Role:	PI

Date:	2016 - 2018
Title:	Overcoming Primary Ibrutinib Resistance in mantle Cell Lymphoma Using Patient-Derived Models and Molecular Profiling
Funding Source:	NIH/NCI
Role:	PI
ID:	R21CA202104

Date:	2016 - 2024
Title:	An Adaptive Personalized Clinical Trial using a Patient-Derived Xenograft Strategy to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP160019

Date:	2016 - 2018
Title:	Strategic Alliance-in Vitro and in Vivo Pre-Clinical Evaluation of the P13K P110B/a Inhibitor KA2237 or the HDAC6 Inhibitor Alone and in Combination with the BTK Inhibitor Ibrutinib in Aggressive B-Cell Lymphomas
Funding Source:	Karus
Role:	PI

Date:	2016 - 2018
Title:	T. Gary Rogers MCL Program of Excellence
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2015 - Present
Title:	Garfield Mantle Cell Lymphoma Research
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2014 - 2019
Title:	B-Cell Lymphoma Moonshot Program
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2014 - 2017
Title:	Mechanisms of Ibrutinib Resistance and Strategies to Improve Ibrutinib Efficacy
Funding Source:	PHARMACYCLICS INC
Role:	PI
ID:	LAB11-0342

Date:	2014 - 2016
Title:	Reverse Phase Protein Array Profiling of Samples from Patients with Relapsed/Refractory Multiple Myeloma Treated with Carfilzomib, Bendamustine, and Dexamethasone in a Phase I/II Clinical Trial
Funding Source:	Onyx
Role:	PI

Date:	2013 - Present
Title:	Mantle Cell Lymphoma Program of Excellence, Kinder Foundation
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2012 - 2013
Title:	The effect of BTK inhibitor PCI-32765 plus carfilzomib on tumor survival, propagation, metastasis, and microenvironment in patient-derived MCL-bearing SCID-hu mice
Funding Source:	The University of Texas MD Anderson Cancer Center Lymphoma SPORE DRP award (Developmental Research Program)
Role:	PI

Date:	2012 - 2014
Title:	A Phase II, Multicenter, International Study of Lenalidomide and Rituximab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Non-Hodgkin Lymphoma
Funding Source:	Sister Institution Network Fund (SINF)
Role:	PI

Date:	2012 - 2013
Title:	Carfilzomib, a novel proteasome inhibitor, induces growth inhibition and apoptosis of mantle cell lymphoma in patient-derived MCL-bearing SCID-hu mice
Funding Source:	Onyx fund
Role:	PI

Date:	2011 - Present
Title:	Mantle Cell Program of Excellence
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2011 - Present
Title:	William Burchenal Memorial Fund
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2011 - Present
Title:	Hunter Lynn Research and Education Fund
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2011 - Present
Title:	Steven and Nancy Fox Cancer Research
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2011 - 2014
Title:	A study of the action of a novel potent topoisomerase II inhibitor berubicin on mantle cell lymphoma in MCL-bearing SCID-hu mouse model
Funding Source:	Institutional Research Grant (IRG)
Role:	PI
ID:	3-0065055

Date:	2010 - 2015
Title:	SPORE in Multiple Myeloma Tissue Core
Funding Source:	The University of Texas MD Anderson Cancer Center Multiple Myeloma SPORE
Role:	Core Leader

Date:	2010 - 2015
Title:	Project: Targeting Multiple Myeloma by Combining CDK Inhibitors and Bcl-2 Antagonists
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	Co-Project Leader

Date:	2008 - Present
Title:	Kimmel Research
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2008 - Present
Title:	Edward Crutchfield Research Fund
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2005 - 2008
Title:	Minimal Residual Disease Detection in Mantle Cell Lymphoma Using High-Sensitivity Molecular Cloning
Funding Source:	Institutional Research Grant
Role:	PI
ID:	43721274

Selected Publications

Peer-Reviewed Articles

Wang Y, Larson MC, Hwang SR, Villa D, Kugathasan L, Kumar A, Joseph A, Brooks TR, Hill BT, Bond DA, Maddocks KJ, Nizamuddin IA, Kahl BS, Danilov A, Argao C, Ruan J, Ryan CE, Merryman RW, Grover NS, Khan NB, Ouchveridze E, Tun AM, Ayyappan S, Mou E, Pongas GN, Lossos IS, Harris ZI, Munoz JL, Young P, Portell CA, Baidoun F, Alhaj Moustafa M, Reagan PM, Banaszak LG, Pophali PA, Velayati A, Greenwell IB, Gerber D, Jain P, Wang ML, Narkhede MS, Mehta A, Stack AC, Messmer MR, Bhansali RS, Barta SK, Moyo TK, Ghosh N, Kamdar MK, Anna J, Stanisic AV, Karmali R, Maurer MJ, Cerhan JR, Cohen JB, Martin P. Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma. Blood Adv 10(4):1372-1380, 2026. e-Pub 2026. PMID: 41380101.
Dutta, RP, Lee, H, Leshchenko, VV, Shukla, RP, Yan, F, Liu, Y, Kaniskan, HÜ, Qiu, X, Jin, J, Alinari, L, Wang, L, Parekh, S. SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma. Blood Advances 9(24):6267-6278, 2025. e-Pub 2025. PMID: 40845256.
Hodson DJ, Shouse G, Shin HJ, Salar A, Bobillo S, Ribrag V, Macpherson NA, Cordoba R, Kim JS, Guidez S, Herrera AF, Morschhauser F, Colton D, Izuzquiza M, Sambamurthy N, Munugalavadla V, Vicente S, Gorgun G, Chen R, Younes A, Wang ML. Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL). Clin Cancer Res, 2025. e-Pub 2025. PMID: 41427952.
Shah, N, Zinzani, PL, Wang, L, Nasta, S, Lech-Maranda, E, Ogawa, Y, Fakhri, B, Kuss, B, Miyashita, K, Patel, K, Coombs, CC, Ma, S, Patel, MR, Barve, M, Tessoulin, B, Stathis, A, Ennishi, D, Hashimoto, D, Kojima, K, Zelenetz, AD, Cohen, JB, Vose, JM, Maddocks, K, Munir, T, Sun, F, Bian, Y, Balbas, M, Tsai, D, Abada, PB, Cheah, CY. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma. Blood Advances 9(23):5954-5964, 2025. e-Pub 2025. PMID: 40845254.
Liu, Y, Hill, H, Li, Y, McIntosh, J, Jiang, VC, Yan, F, Yao, Y, Fei, Y, Zhang, J, Qu, L, Yao, J, Jain, P, Chen, K, Wang, L. Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 41272086.
Wang, W, Cai, Q, Liu, Y, Nie, L, Lee, H, Yan, F, Fei, Y, Yao, Y, Li, Y, Tan, L, Lorenzi, PL, Wang, Y, Yao, J, Chen, Z, McIntosh, J, Yu, CT, Jain, P, Jiang, VC, Vargas, J, Li, X, Zhang, T, Li, S, Santos, DA, Thirumurthi, S, Seeley, E, Simon, LM, Flowers, CR, Ok, CY, Wang, L. TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma. Blood 146(21):2544-2560, 2025. e-Pub 2025. PMID: 40700581.
Li, Y, McIntosh, J, Jiang, C, Yan, F, Vargas, J, Che, Y, Wang, W, Li, CF, Fei, Y, Lee, C, Nie, L, Yao, Y, Wang, L, Lee, H, Liu, Y. BCL-2/BCL-XL dual inhibition triggers Gasdermin D-mediated pyroptosis in mantle cell lymphoma. Cancer Letters 632, 2025. e-Pub 2025. PMID: 40754138.
Li, Y, McIntosh, J, Jiang, C, Yan, F, Vargas, J, Che, Y, Wang, W, Li, CF, Fei, Y, Lee, C, Nie, L, Yao, Y, Wang, L, Lee, H, Liu, Y. BCL-2/BCL-XL dual inhibition triggers Gasdermin D-mediated pyroptosis in mantle cell lymphoma. Cancer Letters 632, 2025. e-Pub 2025. PMID: 40754138.
Li, Y, McIntosh, J, Jiang, C, Yan, F, Vargas, J, Che, Y, Wang, W, Li, CF, Fei, Y, Lee, C, Nie, L, Yao, Y, Wang, L, Lee, H, Liu, Y. BCL-2/BCL-XL dual inhibition triggers Gasdermin D-mediated pyroptosis in mantle cell lymphoma. Cancer Letters 632, 2025. e-Pub 2025. PMID: 40754138.
van Meerten T, Kersten MJ, Iacoboni G, Hess GR, Mutsaers PGNJ, Martin Garcia-Sancho AM, Goy A, Gine E, Hill BT, Weng WK, Reagan PM, Patel K, Galal A, Herbaux C, Sanderson R, Forcade E, Topp MS, Houot R, Zheng D, Zhang W, Kanska J, Shen RR, Damico Khalid R, Kloos I, Dreyling M, Wang ML. Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3. Blood, 2025. e-Pub 2025. PMID: 41160777.
Ahmed, N, Kambhampati, S, Hamadani, M, Hu, ZH, Grover, NS, Shadman, M, Locke, FL, Gerson, JN, Frank, MJ, Budde, LE, Wang, L, Kim, S, Bye, M, Kharfan-Dabaja, MA, Sauter, C, Hematti, P, Turtle, CJ, Ahmed, S, Moskop, A, Logan, BR, Nunes, A, Dalton, D, Kloos, I, Lee, D, Xu, H, Pasquini, MC, Herrera, AF. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma. Blood Advances 9(20):5382-5396, 2025. e-Pub 2025. PMID: 40706035.
Jiang, C, Xue, Y, Kim, H, Cai, Q, Zhang, T, Nie, L, McIntosh, J, Liu, Y, Chen, H, Zhou, J, Wang, L. YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma. Blood Advances 9(19):4963-4976, 2025. e-Pub 2025. PMID: 40690748.
Akkad, N, Feng, L, Westin, JR, Hagemeister, FB, Lee, HJ, Fayad, LE, Ahmed, S, Nair, R, Rodriguez, MA, Strati, P, Chihara, D, Flowers, CR, Claret, LC, Ibanez, K, Wang, L, Fowler, N, Henderson, J, Davis, RE, Neelapu, SS, Green, M, Nastoupil, L. A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma. Blood Advances 9(17):4396-4404, 2025. e-Pub 2025. PMID: 40517417.
Wang, L, Salek, D, Belada, D, Song, YQ, Jurczak, W, Kahl, BS, Paludo, J, Chu, MP, Kryachok, I, Fogliatto, L, Cheah, CY, Morawska, M, Sancho, JM, Li, Y, Patti, C, Forsyth, C, Zhang, J, Lesley, R, Ramadan, S, Rule, S, Dreyling, M. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. Journal of Clinical Oncology 43(20):2276-2284, 2025. e-Pub 2025. PMID: 40311141.
Freeman, C, Srinivasan, S, Hodkinson, BP, Deshpande, S, Henninger, T, Boyle, M, Wang, L, Dreyling, M, Scott, DW. Prognostic biomarkers in MCL. Blood 145(25):3052-3056, 2025. e-Pub 2025. PMID: 40101138.
Phillips, T, Wang, L, Robak, T, Gallinson, D, Stevens, DA, Patel, K, Ramadan, S, Wun, CC, Jurczak, W, Smith, SD. Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma. Haematologica 110(3):715-724, 2025. e-Pub 2025. PMID: 39234862.
Roeker, LE, Coombs, CC, Shah, N, Jurczak, W, Woyach, JA, Cheah, CY, Patel, K, Maddocks, K, Wang, Y, Zinzani, PL, Munir, T, Koh, Y, Thompson, M, Muehlenbein, CE, Wang, C, Sizelove, R, Abhyankar, S, Hasanabba, S, Tsai, D, Eyre, TA, Wang, L. Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta haematologica 148(2):180-197, 2025. e-Pub 2025. PMID: 38824917.
Wang, L, Jurczak, W, Trneny, M, Belada, D, Wróbel, T, Ghosh, N, Keating, MM, Van Meerten, T, Alvarez, RF, von Keudell, GR, Thiéblemont, C, Peyrade, F, André, M, Hoffmann, MS, Szafer-Glusman, E, Lin, J, Dean, JP, Neuenburg, JK, Tam, CS. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO). The lancet oncology 26(2):200-213, 2025. e-Pub 2025. PMID: 39914418.
Manzar, G, Pinnix, CC, Dudzinski, SO, Marqueen, KE, Cha, E, Nasr, L, Yoder, A, Rooney, MK, Strati, P, Ahmed, S, Nze, CC, Nair, R, Fayad, LE, Wang, L, Nastoupil, L, Westin, JR, Flowers, CR, Neelapu, SS, Gunther, J, Dabaja, BS, Wu, SY, Fang, PQ. Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas. Frontiers in immunology 16, 2025. e-Pub 2025. PMID: 39958356.
Wang, Y, Flowers, CR, Wang, L, Huang, X, Li, Z. CASi: A framework for cross-timepoint analysis of single-cell RNA sequencing data. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 38724550.
Pinnix, CC, Dabaja, BS, Gunther, J, Fang, PQ, Wu, SY, Nastoupil, L, Strati, P, Nair, R, Ahmed, S, Steiner, RE, Westin, JR, Neelapu, SS, Rodriguez, MA, Lee, HJ, Wang, L, Flowers, CR, Feng, L, Esmaeli, B. Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma. JAMA Oncology 10(9):1195-1203, 2024. e-Pub 2024. PMID: 38990564.
Wang, L, Robak, T, Maddocks, K, Phillips, T, Smith, SD, Gallinson, D, Calvo, R, Wun, CC, Munugalavadla, V, Jurczak, W. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma. Blood Advances 8(17):4539-4548, 2024. e-Pub 2024. PMID: 38781315.
Nze C, Andersen C, Ayers A, Westin JR, Wang ML, Iyer SP, Ahmed S, Pinnix CC, Vega F, Nguyen L, McNeill L, Nastoupil LJ, Zhang K, Bauer C, Flowers CR. Impact of Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation in Non-Hodgkin Lymphoma. Blood Adv 8(14):3825-3837, 2024. e-Pub 2024. PMID: 38607394.
Guruprasad, P, Carturan, A, Zhang, Y, Cho, JH, Kumashie, KG, Patel, RP, Kim, KH, Lee, JS, Lee, Y, Kim, JH, Chung, J, Joshi, A, Cohen, IJ, Shestov, M, Ghilardi, G, Harris, J, Pajarillo, R, Angelos, M, Lee, YG, Liu, S, Rodriguez, J, Wang, L, Ballard, HJ, Gupta, A, Ugwuanyi, O, Hong, SA, Bochi-Layec, AC, Sauter, CT, Chen, L, Paruzzo, L, Kammerman, S, Shestova, O, Liu, D, Vella, LA, Schuster, SJ, Svoboda, J, Porazzi, P, Ruella, M. The BTLA–HVEM axis restricts CAR T cell efficacy in cancer. Nature Immunology 25(6):1020-1032, 2024. e-Pub 2024. PMID: 38831106.
Lionel AC, Gurumurthi A, Fetooh A, Eldaya R, Ahmed S, Iyer SP, Nastoupil LJ, Westin J, Nair R, Fayad L, Malpica L, Tummala S, Flowers C, Neelapu SS, Wang ML, Jain P. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leuk Lymphoma 65(5):669-673, 2024. e-Pub 2024. PMID: 38248629.
Bijou, I, Liu, Y, Lu, D, Chen, J, Sloan, S, Alinari, L, Lonard, DM, O’Malley, BW, Wang, L, Wang, J. Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. PloS one 19(4 April), 2024. e-Pub 2024. PMID: 38683834.
Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, Abramson JS, Arnason J, Ghosh N, Mehta A, Andreadis C, Solomon SR, Kostic A, Dehner C, Espinola R, Peng L, Ogasawara K, Chattin A, Eliason L, Palomba ML. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. J Clin Oncol 42(10):1146-1157, 2024. e-Pub 2024. PMID: 38072625.
Kim DH, Siddiqui S, Jain P, Wang M, Thakral B, Li S, Miranda R, Vega F, Medeiros LJ, Ok CY. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present. Hum Pathol 146:1-7, 2024. e-Pub 2024. PMID: 38460798.
Yan F, Jiang V, Jordan A, Che Y, Liu Y, Cai Q, Xue Y, Li Y, McIntosh J, Chen Z, Vargas J, Nie L, Yao Y, Lee HH, Wang W, Bigcal JR, Badillo M, Meena J, Flowers C, Zhou J, Zhao Z, Simon LM, Wang M. The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma. Exp Hematol Oncol 13(1):14, 2024. e-Pub 2024. PMID: 38326887.
Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Dehner C, Kim Y, Ogasawara K, Kostic A, Siddiqi T. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood 143(5):404-416, 2024. e-Pub 2024. PMID: 37890149.
Li S, Tang G, Jain P, Lin P, Xu J, Miranda RN, Cheng J, Yin CC, You MJ, Wang ML, Medeiros LJ. SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma?. Mod Pathol 37(2):100405, 2024. e-Pub 2024. PMID: 38104893.
Cai, L, Roos, J, Miranda, PA, Liljas, B, Rule, S, Wang, L. Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma. Journal of Medical Economics 27(1):1552-1557, 2024. e-Pub 2024. PMID: 39461001.
Patel, RP, Ghilardi, G, Zhang, Y, Chiang, YH, Xie, W, Guruprasad, P, Kim, KH, Chun, I, Angelos, M, Pajarillo, R, Hong, SJ, Lee, YG, Shestova, O, Shaw, C, Cohen, IJ, Gupta, A, Vu, T, Qian, D, Yang, S, Nimmagadda, A, Snook, AE, Siciliano, N, Rotolo, A, Inamdar, A, Harris, J, Ugwuanyi, O, Wang, L, Carturan, A, Paruzzo, L, Chen, L, Ballard, HJ, Blanchard, T, Xu, C, Abdel-Mohsen, M, Gabunia, K, Wysocka, M, Linette, GP, Carreno, BM, Barrett, DM, Teachey, DT, Posey, AD, Powell, D, Sauter, CT, Pileri, S, Pillai, V, Scholler, J, Rook, AH, Schuster, SJ, Barta, S, Porazzi, P, Ruella, M. CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Science Immunology 9(97), 2024. e-Pub 2024. PMID: 39028827.
Zhang, Y, Patel, RP, Kim, KH, Cho, H, Jo, JC, Jeong, SH, Oh, SY, Choi, YS, Kim, SH, Lee, JH, Angelos, M, Guruprasad, P, Cohen, I, Ugwuanyi, O, Lee, YG, Pajarillo, R, Cho, JH, Carturan, A, Paruzzo, L, Ghilardi, G, Wang, L, Kim, S, Kim, SM, Lee, HJ, Park, JH, Cui, L, Lee, TB, Hwang, IS, Lee, YH, Lee, YJ, Porazzi, P, Liu, D, Lee, Y, Kim, JH, Lee, JS, Hyunyoon, D, Chung, J, Ruella, M. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma. Molecular cancer 22(1), 2023. e-Pub 2023. PMID: 38066564.
Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang M, Cohen JB, Churnetski M, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast M, Fenske T, Rao Gari SN, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Ristow K, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Adv 7(24):7393-7401, 2023. e-Pub 2023. PMID: 37874912.
Li Y, Lee HH, Jiang VC, Che Y, McIntosh J, Jordan A, Vargas J, Zhang T, Yan F, Simmons ME, Wang W, Nie L, Yao Y, Jain P, Wang M, Liu Y. Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins. Cell Death Dis 14(11):714, 2023. e-Pub 2023. PMID: 37919300.
Fang X, Liu X, Chinchilli VM, Wang M, Wang HG, Dokholyan NV, Shen C, Lee JJ, Zhou S. REAP-2: An interactive quantitative tool for robust and efficient dose-response curve estimation. J Clin Transl Sci 7(1):e219, 2023. e-Pub 2023. PMID: 38028338.
Zeng D, Fang Y, Fei Y, Liang R, Ye H, Liang Y, Sun X, Wang M, Huang H, Qiu L, Che Y, Liu P, Wang Y, Pan T, Lv Y, Deng J, Yi S, He Y, Xiao L, Lv H, Feng J, Zhang H, Zhou H, Zou D, Cai Q. Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE. Int J Cancer 153(5):1016-1025, 2023. e-Pub 2023. PMID: 37204683.
Song Y, Zhou K, Zou D, Li D, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Zhou D, Tam CS, Simpson D, Wang M, Phillips TJ, Opat S, Fang C, Sun S, Zhu J. Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis. Cancer Med 12(18):18643-18653, 2023. e-Pub 2023. PMID: 37705497.
Hill, H, Jain, P, Ok, CY, Sasaki, K, Chen, H, Wang, L, Chen, K. Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma. Cancer Research Communications 3(8):1435-1446, 2023. e-Pub 2023. PMID: 37538987.
Khanlari M, Mo H, Kim DH, Sakhdari A, Young KH, Jain P, Wang M, Li S, Kanagal-Shamanna R, Miranda RN, Vega F, Medeiros LJ, Ok CY. Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features. Am J Surg Pathol 47(8):849-858, 2023. e-Pub 2023. PMID: 37288826.
Hill HA, Jain P, Ok CY, Sasaki K, Chen H, Wang ML, Chen K. Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma. Cancer Res Commun 3(8):1435-1446, 2023. e-Pub 2023. PMID: 37538987.
Li L, Nie L, Jordan A, Cai Q, Liu Y, Li Y, Che Y, Vargas J, Chen Z, Leeming A, Wang W, Yao Y, Wang M, Jiang VC. Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. Haematologica 108(6):1616-1627, 2023. e-Pub 2023. PMID: 36420799.
Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, Dahiya S, Beitinjaneh AM, Jacobs MT, Mcguirk JP, Vose JM, Goy A, Andreadis C, Hill BT, Dorritie KA, Oluwole OO, Deol A, Paludo J, Shah B, Wang T, Banerjee R, Miklos DB, Rapoport AP, Lekakis L, Ghobadi A, Neelapu SS, Lin Y, Wang ML, Jain MD. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol 41(14):2594-2606, 2023. e-Pub 2023. PMID: 36753699.
Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med 29(4):906-916, 2023. e-Pub 2023. PMID: 36914893.
Munoz J, Wang M. Glabellar mass in a case of mantle-cell lymphoma treated by CAR T-cell therapy. Lancet 401(10381):1037-1038, 2023. e-Pub 2023. PMID: 36965964.
Bijou I, Liu Y, Lu D, Chen J, Sloan S, Alinari L, Lonard DM, O'Malley BW, Wang M, Wang J. Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. Res Sq, 2023. e-Pub 2023. PMID: 36945511.
Jiang VC, Liu Y, Lian J, Huang S, Jordan A, Cai Q, Lin R, Yan F, McIntosh J, Li Y, Che Y, Chen Z, Vargas J, Badillo M, Bigcal JN, Lee HH, Wang W, Yao Y, Nie L, Flowers CR, Wang M. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. J Clin Invest 133(3):e165694, 2023. e-Pub 2023. PMID: 36719376.
Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):745-755, 2023. e-Pub 2023. PMID: 35952327.
Che Y, Liu Y, Yao Y, Hill HA, Li Y, Cai Q, Yan F, Jain P, Wang W, Rui L, Wang M. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations. Blood Cancer J 13(1):27, 2023. e-Pub 2023. PMID: 36797243.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol 43(3):555-567, 2023. e-Pub 2023. PMID: 35658525.
Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, Switchenko JM, Kahl B, Maddocks K, Grover NS, Qi K, Parisi L, Daly K, Zhu A, Salles G. Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. J Clin Oncol 41(3):541-554, 2023. e-Pub 2023. PMID: 35763708.
Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2023. PMID: 36068929.
Petersohn S, Salles G, Wang M, Wu J, Wade SW, Simons C, Bennison C, Siddiqi R, Peng W, Kloos I, Castaigne G, Hess G. Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England. J Med Econ 25(1):730-740, 2022. e-Pub 2022. PMID: 35611697.
Eyre TA, Shah NN, Dreyling M, Jurczak W, Wang Y, Cheah CY, Song Y, Gandhi M, Chay C, Sharman J, Andorsky DJ, Messersmith HM, Ruppert AS, Muthig VA, Ito R, Wang ML. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naïve mantle cell lymphoma. Future Oncol 18(36):3961-3969, 2022. e-Pub 2022. PMID: 36377973.
Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med 3(11):100720, 2022. e-Pub 2022. PMID: 36384092.
Cohen, JB, Shah, N, Alencar, AJ, Gerson, JN, Patel, MR, Fakhri, B, Jurczak, W, Tan, XN, Lewis, KL, Fenske, TS, Coombs, CC, Flinn, IW, Lewis, DJ, Gouill, SL, Lia Palomba, M, Woyach, JA, Pagel, JM, Lamanna, N, Barve, M, Ghia, P, Eyre, TA, Zinzani, PL, Ujjani, CS, Koh, Y, Izutsu, K, Lech-Maranda, E, Tam, CS, Sundaram, S, Yin, M, Nair, BC, Tsai, D, Balbas, M, Mato, A, Cheah, CY, Wang, L. MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia 22:S394-S395, 2022. e-Pub 2022. PMID: 36164120.
Ito, R, Eyre, TA, Shah, N, Gouill, SL, Dreyling, M, Vandenberghe, E, Jurczak, W, Wang, Y, Cheah, CY, Gandhi, M, Chay, C, Sharman, JP, Andorsky, D, Song, YQ, Stark, A, Muthig, V, Wang, L. MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress). Clinical Lymphoma, Myeloma and Leukemia 22:S395-S396, 2022. e-Pub 2022. PMID: 36164121.
Jiang VC, Hao D, Jain P, Li Y, Cai Q, Yao Y, Nie L, Liu Y, Jin J, Wang W, Lee HH, Che Y, Dai E, Han G, Wang R, Rai K, Futreal A, Flowers C, Wang L, Wang M. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer 21(1):185, 2022. e-Pub 2022. PMID: 36163179.
Zhou S, Liu X, Fang X, Chinchilli VM, Wang M, Wang HG, Dokholyan NV, Shen C, Lee JJ. Robust and Efficient Assessment of Potency (REAP) as a quantitative tool for dose-response curve estimation. Elife 11:e78634, 2022. e-Pub 2022. PMID: 35921131.
Siddiqi T, Coutre S, McKinney M, Barr PM, Rogers K, Mokatrin A, Valentino R, Szoke A, Deshpande S, Zhu A, Arango-Hisijara I, Osei-Bonsu K, Wang M, O'Brien S. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Lymphoma 63(7):1580-1588, 2022. e-Pub 2022. PMID: 35227147.
Steiner RE, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, Pinnix CC, Feng L, Rondon G, Claussen C, Palaskas N, Karimzad K, Ahmed S, Neelapu SS, Shpall E, Wang M, Vega F, Westin J, Nastoupil LJ, Deswal A. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica 107(7):1555-1566, 2022. e-Pub 2022. PMID: 34758610.
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, JÁ H, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M, Investigators S. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med 386(26):2482-2494, 2022. e-Pub 2022. PMID: 35657079.
Jain P, Han X, Wang M, Tang G. Smudge cells in CD200+, TP53 mutated leukemic mantle cell lymphoma. Blood Res 57(2):85, 2022. e-Pub 2022. PMID: 35551107.
Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Research Group MC, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol 23(3):406-415, 2022. e-Pub 2022. PMID: 35074072.
Wang YN, Lee HH, Wei Y, Chu YY, Xia W, Wang M, Yu D, Hung MC. An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response. STAR Protoc 3(1):101198, 2022. e-Pub 2022. PMID: 35243381.
Huang S, Liu Y, Chen Z, Wang M, Jiang VC. PIK-75 overcomes venetoclax resistance via blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma. Am J Cancer Res 12(3):1102-1115, 2022. e-Pub 2022. PMID: 35411248.
Zhang X, Zhang R, Ren C, Xu Y, Wu S, Meng C, Pataer A, Song X, Zhang J, Yao Y, He H, Chen H, Ma W, Wang J, Meric-Bernstam F, Champlin RE, Heymach JV, Rooney CM, Swisher SG, Vaporciyan AA, Roth JA, You MJ, Wang M, Fang B. Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv 6(3):891-901, 2022. e-Pub 2022. PMID: 34861697.
Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang ML. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol 40(2):202-212, 2022. e-Pub 2022. PMID: 34797699.
Wang ML, Barrientos JC, Fruman RR, Mei M, Barr PM, Choi MY, Vos S, Kallam A, Patel K, Kipps TJ, Rule S, Flanders K, Jessen KA, Ren H, Riebling PC, Graham P, King L, Thurston A, Sun M, Schmidt EM, Lannutii BJ, Johnson DM, Miller LL, Spurgeon SE. Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. NEJM Evid 1(1):1-11, 2022. e-Pub 2022. PMID: 38319241.
Wang Y, Zhou S, Qi X, Yang F, Maurer MJ, Habermann TM, Witzig TE, Wang ML, Nowakowski GS. Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. Blood Cancer J 12(1):1, 2022. e-Pub 2022. PMID: 34987165.
Martinez-Baquero, D, Sakhdari, A, Mo, H, Kim, DH, Kanagal Shamanna, R, Li, S, Young, KH, O'Malley, DP, Dogan, A, Jain, P, Wang, L, McDonnell, TJ, Miranda, R, Vega Vazquez, F, Medeiros, LJ, Ok, CY. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Modern Pathology 34(12):2183-2191, 2021. e-Pub 2021. PMID: 34376807.
Tashakori M, Kim DH, Kanagal-Shamanna R, Vega F, Miranda RN, Jain P, Wang M, Medeiros LJ, Ok CY. Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases. Hum Pathol 118:60-68, 2021. e-Pub 2021. PMID: 34655612.
Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. Leuk Lymphoma 62(14):3452-3462, 2021. e-Pub 2021. PMID: 34365878.
Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant 56(12):2911-2921, 2021. e-Pub 2021. PMID: 34413469.
Furman RR, Byrd JC, Owen RG, O'Brien SM, Brown JR, Hillmen P, Stephens DM, Chernyukhin N, Lezhava T, Hamdy AM, Izumi R, Patel P, Baek M, Christian B, Dyer MJS, Streetly MJ, Sun C, Rule S, Wang M, Ghia P, Jurczak W, Pagel JM, Sharman JP. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia 35(11):3201-3211, 2021. e-Pub 2021. PMID: 33907299.
Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. Transplant Cell Ther 27(9):720-728, 2021. e-Pub 2021. PMID: 34452722.
Zhou Z, Jain P, Lu Y, Macapinlac H, Wang ML, Son JB, Pagel MD, Xu G, Ma J. Computer-aided detection of mantle cell lymphoma on 18F-FDG PET/CT using a deep learning convolutional neural network. Am J Nucl Med Mol Imaging 11(4):260-270, 2021. e-Pub 2021. PMID: 34513279.
Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, M W, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. e-Pub 2021. PMID: 34264268.
Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil L, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang ML, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins M, Johnson N, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers C, Westin J, Neelapu SS. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
Goyal RK, Jain P, Nagar SP, Le H, Kabadi SM, Davis K, Kaye JA, Du XL, Wang M. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leuk Lymphoma 62(6):1325-1334, 2021. e-Pub 2021. PMID: 33966583.
Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, Kim WS, Rule S, Atwal SK, Wei R, Novotny W, Huang J, Wang M, Trotman J. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv 5(12):2577-2585, 2021. e-Pub 2021. PMID: 34152395.
Wang L, Tang G, Medeiros JL, Xu J, Huang W, Yin CC, Wang M, Jain P, Lin P, Li S. MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica 106(5):1381-1389, 2021. e-Pub 2021. PMID: 32273477.
Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, Ok CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriquez A, Thirumurthi S, Jain P, Wagner-Bartak N, Hill H, Nomie K, Flowers C, Futreal A, Wang L, Wang M. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun 12(1):2877, 2021. e-Pub 2021. PMID: 34001881.
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet 397(10277):892-901, 2021. e-Pub 2021. PMID: 33676628.
Zhao X, Wang MY, Jiang H, Lwin T, Park PM, Gao J, Meads MB, Ren Y, Li T, Sun J, Fahmi NA, Singh S, Sehgal L, Wang X, Silva AS, Sotomayor EM, Shain KH, Cleveland JL, Wang M, Zhang W, Qi J, Shah BD, Tao J. Transcriptional programming drives ibrutinib-resistance evolution in mantle cell lymphoma. Cell Rep 34(11):108870, 2021. e-Pub 2021. PMID: 33730585.
Dreyling M, Tam CS, M W, Smith SD, Ladetto M, Huang H, Novotny W, Co M, Romano A, Holmgren E, Huang J, Gouill SL. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol 17(3):255-262, 2021. e-Pub 2021. PMID: 32985902.
Wu W, Wang W, Franzen CA, Guo H, Lee J, Li Y, Sukhanova M, Sheng D, Venkataraman G, Ming M, Lu P, Gao A, Xia C, Li J, Zhang LL, Jiang VC, Wang ML, Andrade J, Zhou X, Wang YL. Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2. Blood Adv 5(1):185-197, 2021. e-Pub 2021. PMID: 33570628.
Jain P, Tang G, Li S, Wang M. "Triple hit" SOX11-, MME+, TP53 mutated high-grade pleomorphic mantle cell lymphoma. Am J Hematol 96(1):165-166, 2021. e-Pub 2021. PMID: 32356355.
Simons CL, Malone D, Wang M, Maglinte GA, Inocencio T, Wade SW, Bennison C, Shah B. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States. J Med Econ 24(1):421-431, 2021. e-Pub 2021. PMID: 33634729.
Wang M, Jain P, Chi TL, Chen SE, Heimberger A, Weathers SP, Zheng L, Rao AV, Rossi JM. Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33067318.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839-852, 2020. e-Pub 2020. PMID: 32888407.
Guo WH, Qi X, Yu X, Liu Y, Chung CI, Bai F, Lin X, Lu D, Wang L, Chen J, Su LH, Nomie KJ, Li F, Wang MC, Shu X, Onuchic JN, Woyach JA, Wang ML, Wang J. Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. Nat Commun 11(1):4268, 2020. e-Pub 2020. PMID: 32848159.
Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4(16):3943-3951, 2020. e-Pub 2020. PMID: 32822484.
Badillo M, Nava D, Rosa M, Chen W, Guerrero M, Wang M. Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma. Clin J Oncol Nurs 24(4):392-398, 2020. e-Pub 2020. PMID: 32678359.
Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica 105(7):1907-1913, 2020. e-Pub 2020. PMID: 31601688.
Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv 4(13):2871-2883, 2020. e-Pub 2020. PMID: 32589728.
Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma 61(6):1-8, 2020. e-Pub 2020. PMID: 31971032.
Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
Navsaria L, Badillo A, Wang M. Second Cancers in a Patient with Gastric MALT Lymphoma. Case Rep Med 2020:1213596, 2020. e-Pub 2020. PMID: 32508929.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 382(14):1331-1342, 2020. e-Pub 2020. PMID: 32242358.
Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. e-Pub 2020. PMID: 32191807.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. e-Pub 2020. PMID: 32023374.
Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma 61(2):1-9, 2020. e-Pub 2020. PMID: 31533521.
Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica 105(1):e26-e28, 2020. e-Pub 2020. PMID: 31073068.
Zhu F, Guo H, Bates PD, Zhang S, Zhang H, Nomie KJ, Li Y, Lu L, Seibold KR, Wang F, Rumball I, Cameron H, Hoang NM, Yang DT, Xu W, Zhang L, Wang M, Capitini CM, Rui L. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. Leukemia 33(12):2898-2911, 2019. e-Pub 2019. PMID: 31123343.
Fu S, Wang M, Zhao H, Li R, Lairson DR, Giordano SH, Zhao B, Du XL. Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma. Clin Lymphoma Myeloma Leuk 19(11):e616-e623, 2019. e-Pub 2019. PMID: 31563564.
Miao Y, Lin P, Saksena A, Xu J, Wang M, Romaguera J, Yin CC, Medeiros LJ, Li S. CD5-negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Patients. Am J Surg Pathol 43(8):1052-1060, 2019. e-Pub 2019. PMID: 31045891.
Ning MS, Pinnix CC, Chapman BV, Gunther JR, Milgrom SA, Khoury JD, Jain P, Chen WY, Oriabure ON, Badillo MR, Wang LM, Dabaja BS. Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma. Blood Adv 3(13):2035-2039, 2019. e-Pub 2019. PMID: 31289030.
Saksena A, Yin CC, Xu J, Li J, Zhou J, Wang SA, Lin P, Tang G, Wang L, Wang M, Miranda RN, Medeiros LJ, Li S. CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form and a better prognosis. Hum Pathol 89:71-80, 2019. e-Pub 2019. PMID: 31054894.
Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol 185(5):874-882, 2019. e-Pub 2019. PMID: 30919940.
Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, Haun R, Lan R, Mackintosh SG, Mao X, Song X, Zhang J, Pham LV, Lorenzi PL, Marszalek J, Heffernan T, Draetta G, Jones P, Futreal A, Nomie K, Wang L, Wang M. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med 11(491), 2019. e-Pub 2019. PMID: 31068440.
Xu J, Wang L, Li J, Saksena A, Wang SA, Shen J, Hu Z, Lin P, Tang G, Yin CC, Wang M, Medeiros LJ, Li S. SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients. Am J Surg Pathol 43(5):710-716, 2019. e-Pub 2019. PMID: 30768440.
Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, JÁ H, Qi K, Deshpande S, Parisi L, Wang M. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis. Haematologica 104(5):e211-e214, 2019. e-Pub 2019. PMID: 30442728.
Salles G, Gopal AK, Minnema MC, Wakamiya K, Feng H, Schecter JM, Wang M. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. Clin Lymphoma Myeloma Leuk 19(5):275-284, 2019. e-Pub 2019. PMID: 30795996.
Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv 3(9):1356-1367, 2019. e-Pub 2019. PMID: 31036721.
Romaguera JE, Lee HJ, Tarapore R, Prabhu V, Allen J, Schalop L, Zloza A, Ok CY, Sadimin ET, Schenkel J, Badillo M, Wang M. Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment. Br J Haematol 185(1):133-136, 2019. e-Pub 2019. PMID: 29740811.
Guo H, Zeng D, Zhang H, Bell T, Yao J, Liu Y, Huang S, Li CJ, Lorence E, Zhou S, Gong T, Jiang C, Ahmed M, Yao Y, Nomie KJ, Zhang L, Wang M. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene 38(11):1802-1814, 2019. e-Pub 2019. PMID: 30361685.
Li CJ, Jiang C, Liu Y, Bell T, Ma W, Ye Y, Huang S, Guo H, Zhang H, Wang L, Wang J, Nomie K, Zhang L, Wang M. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Mol Cancer Ther 18(2):267-277, 2019. e-Pub 2019. PMID: 30413649.
Fu S, Wang M, Li R, Lairson DR, Zhao B, Du XL. Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995-2013: Findings from Texas and national SEER areas. Cancer Epidemiol 58:89-97, 2019. e-Pub 2019. PMID: 30528835.
Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang ML, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. J Clin Oncol 37(6):471-480, 2019. e-Pub 2019. PMID: 30615550.
Wang Y, Wang R, Zhang S, Song S, Jiang C, Han G, Wang M, Ajani J, Futreal A, Wang L. iTALK: an R Package to Characterize and Illustrate Intercellular Communication. bioRxiv The Preprint Server for Biology, 2019.
Nooka AK, Wang M, Yee AJ, Kaufman JL, Bae J, Peterkin D, Richardson PG, Raje NS. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA Oncol 4(12):e183267, 2018. e-Pub 2018. PMID: 30128502.
Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang M. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578-587, 2018. e-Pub 2018. PMID: 30175400.
Li L, Zhang J, Chen J, Xu-Monette ZY, Miao Y, Xiao M, Young KH, Wang S, Medeiros LJ, Wang M, Ford RJ, Pham LV. B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. Blood 132(17):1805-1817, 2018. e-Pub 2018. PMID: 30209121.
Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, Venkataraman G, Zhang H, Alikhan M, Lu P, Guo A, Galanina N, Andrade J, Wang M, Wang YL. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv 2(16):2039-2051, 2018. e-Pub 2018. PMID: 30115641.
Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, Kanakry JA, Ali SA, Mikkilineni L, Feldman SA, Stroncek DF, Hansen BG, Lawrence J, Patel R, Hakim F, Gress RE, Kochenderfer JN. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. J Clin Oncol 36(22):2267-2280, 2018. e-Pub 2018. PMID: 29812997.
Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin J, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res 24(16):3967-3980, 2018. e-Pub 2018. PMID: 29666304.
Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang M. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol 182(3):404-411, 2018. e-Pub 2018. PMID: 29785709.
Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer 124(12):2561-2569, 2018. e-Pub 2018. PMID: 29723393.
Ye H, Desai A, Gong T, Zeng D, Nomie K, Chen W, Wang W, Romaguera J, Wang M. Spontaneous regression of mantle cell lymphoma: a report of four cases. Cancer Commun (Lond) 38(1):30, 2018. e-Pub 2018. PMID: 29843782.
Dimopoulos M, Wang M, Maisnar V, Minarik J, Bensinger W, Mateos MV, Obreja M, Blaedel J, Moreau P. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol 11(1):49, 2018. e-Pub 2018. PMID: 29615082.
Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One 13(3):e0191461, 2018. e-Pub 2018. PMID: 29538376.
Xu J, Medeiros LJ, Saksena A, Wang M, Zhou J, Li J, Yin CC, Tang G, Wang L, Lin P, Li S. CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases. Oncotarget 9(14):11441-11450, 2018. e-Pub 2018. PMID: 29545910.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 391(10121):659-667, 2018. e-Pub 2018. PMID: 29241979.
Hu Z, Sun Y, Schlette EJ, Tang G, Li S, Xu J, Yin CC, Young KH, Patel KP, Miranda RN, Goswami M, Wang M, Jorgensen JL, Medeiros LJ, Wang SA. CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol 31(2):327-336, 2018. e-Pub 2018. PMID: 28984300.
Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk 18(1):e103-e108, 2018. e-Pub 2018. PMID: 29196178.
Fu S, Wang M, Lairson DR, Li R, Zhao B, Du XL. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas. Oncotarget 8(68):112516-112529, 2017. e-Pub 2017. PMID: 29348844.
Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, Barnett E, Bravo MC, Martin P. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol 10(1):171, 2017. e-Pub 2017. PMID: 29096668.
Liu Y, Yin Y, Zhang Z, Li CJ, Zhang H, Zhang D, Jiang C, Nomie K, Zhang L, Wang M, Zhao G. Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity. Eur J Med Chem 138:543-551, 2017. e-Pub 2017. PMID: 28704757.
Jain P, Milgrom SA, Patel KP, Nastoupil L, Fayad L, Wang M, Pinnix CC, Dabaja BS, Smith GL, Yu J, Hu S, Bueso Ramos CE, Kanagal-Shamanna R, Medeiros LJ, Oki Y, Fowler N. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol 178(3):403-412, 2017. e-Pub 2017. PMID: 28382648.
Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li C, Wang J, Fang B, Wang J, Li L, Badillo M, Ahmed M, Thirumurthi S, Huang SY, Shao Y, Lam L, Yi Q, Wang YL, Wang M. B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy. Clin Cancer Res 23(15):4212-4223, 2017. e-Pub 2017. PMID: 28348046.
Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang M, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood 130(4):472-477, 2017. e-Pub 2017. PMID: 28522441.
Kuruvilla J, Savona M, Baz R, Mau-Sorensen PM, Gabrail N, Garzon R, Stone R, Wang M, Savoie L, Martin P, Flinn I, Jacoby M, Unger TJ, Saint-Martin JR, Rashal T, Friedlander S, Carlson R, Kauffman M, Shacham S, Gutierrez M. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood 129(24):3175-3183, 2017. e-Pub 2017. PMID: 28468797.
Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 39(6):1095-1100, 2017. e-Pub 2017. PMID: 28370694.
Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil S. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget 8(25):41620-41630, 2017. e-Pub 2017. PMID: 28404929.
Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, Nowak AJ, Jain N, Zhang L, Wang M, Khoury JD, Coarfa C, Crews CM, Bhalla KN. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia 32(2):343-352, 2017. e-Pub 2017. PMID: 28663582.
Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist 22(5):549-553, 2017. e-Pub 2017. PMID: 28408615.
Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, Zhang L, Fu K, Bi C, Li J, Jiang H, Meads MB, Jacobson T, Silva M, Distler A, Darville L, Zhang L, Han Y, Rebatchouk D, Di Liberto M, Moscinski LC, Koomen JM, Dalton WS, Shain KH, Wang M, Sotomayor E, Tao J. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun 8:14920, 2017. e-Pub 2017. PMID: 28416797.
Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol 177(2):263-270, 2017. e-Pub 2017. PMID: 28340281.
Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):750-758, 2017. e-Pub 2017. PMID: 27983760.
Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH. Assessment of CD37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood 128(26):3083-3100, 2016. e-Pub 2016. PMID: 27760757.
Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, Amin HM, Wang M, Marcucci G, Weisenburger DD, Rosen ST, Pham LV, Ngo VN. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget 7(45):73558-73572, 2016. e-Pub 2016. PMID: 27713153.
Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122(20):3145-3151, 2016. e-Pub 2016. PMID: 27351173.
Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol 175(2):290-299, 2016. e-Pub 2016. PMID: 27448187.
Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špicka I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression free survival of high-risk patients in multiple myeloma. Blood 128(9):1174-80, 2016. e-Pub 2016. PMID: 27439911.
Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN. T cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128(13):1688-700, 2016. e-Pub 2016. PMID: 27412889.
Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals Oncol 27(7):1317-1323, 2016. e-Pub 2016. PMID: 27091808.
Lu J, Hou J, Liu KY, Parmar S, De La Fuente A, Andersson B, Yan C, Zhou D, Tan D, Ritchie D, Wu D, Shpall E, Laport GG, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Issaragrisil S, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Rosengarten R, Steuernagle J, Xiao JH, Orlowski R, Chim CS. Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma 57(7):1-5, 2016. e-Pub 2016. PMID: 26887657.
Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, Woo TF, Wong AF, Papadopoulos KP, Niesvizky R, Badros AZ, Vij R, Jagannath S, Siegel D, Wang M, Ahmann GJ, Kirk CJ. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. Br J Haematol 173(6):884-95, 2016. e-Pub 2016. PMID: 27071340.
Liu Y, Yin Y, Zhang J, Nomie K, Zhang L, Yang D, Wang ML, Zhao G. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors. Arch Pharm (Weinheim) 349(5):356-62, 2016. e-Pub 2016. PMID: 26991997.
Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J 6(2):e396, 2016. e-Pub 2016. PMID: 26871714.
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal 9(415):ra17, 2016. e-Pub 2016. PMID: 26884599.
Li H, Hu J, Wu S, Wang L, Cao X, Zhang X, Dai B, Cao M, Shao R, Zhang R, Majidi M, Ji L, Heymach JV, Wang M, Pan S, Minna J, Mehran RJ, Swisher SG, Roth JA, Fang B. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget 7(3):3548-58, 2016. e-Pub 2016. PMID: 26657290.
Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang M, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 172(1):80-8, 2016. e-Pub 2016. PMID: 26648336.
Wang M, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 17(1):48-56, 2016. e-Pub 2016. PMID: 26640039.
Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 16(1):36-42, 2016. e-Pub 2016. PMID: 26702475.
Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 2015. e-Pub 2015. PMID: 26260306.
Zhang L, Bi E, Hong S, Qian J, Zheng C, Wang M, Yi Q. CD4+ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma. Oncotarget 6(34):36032-40, 2015. e-Pub 2015. PMID: 26447613.
Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang M, Saenz DT, Krieger S, Bradner JE, Bhalla KN. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood 126(13):1565-74, 2015. e-Pub 2015. PMID: 26254443.
Wang M, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. Blood 126(6):739-45, 2015. e-Pub 2015. PMID: 26059948.
Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol 171(4):463-470, 2015. e-Pub 2015. PMID: 26213141.
Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström's Macroglobulinemia. Clin Cancer Res 21(11):2538-45, 2015. e-Pub 2015. PMID: 25748087.
Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol 8:63, 2015. e-Pub 2015. PMID: 26048374.
Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 26(6):1175-9, 2015. e-Pub 2015. PMID: 25712454.
Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant 50(5):668-72, 2015. e-Pub 2015. PMID: 25730192.
Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in Standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 2015. e-Pub 2015. PMID: 25445468.
Hao C, Wang L, Peng S, Cao M, Li H, Hu J, Huang X, Liu W, Zhang H, Wu S, Pataer A, Heymach JV, Eterovic AK, Zhang Q, Shaw KR, Chen K, Futreal A, Wang M, Hofstetter W, Mehran R, Rice D, Roth JA, Sepesi B, Swisher SG, Vaporciyan A, Walsh GL, Johnson FM, Fang B. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett 357(1):179-85, 2015. e-Pub 2015. PMID: 25444907.
Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang M, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor. J Clin Oncol 33(6):540-9, 2015. e-Pub 2015. PMID: 25154820.
Huang X, Cao M, Wang L, Wu S, Liu X, Li H, Zhang H, Wang RY, Sun X, Wei C, Baggerly KA, Roth JA, Wang M, Swisher SG, Fang B. Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380. Oncotarget 6(1):345-54, 2015. e-Pub 2015. PMID: 25514600.
Pham LV, Vang MT, Tamayo AT, Lu G, Challagundla P, Jorgensen JL, Rollo AA, Ou Z, Zhang L, Wang M, Ford RJ. Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease. Leuk Lymphoma 56(1):186-93, 2015. e-Pub 2015. PMID: 24611650.
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špicka I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A, Investigators A. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142-52, 2015. e-Pub 2015. PMID: 25482145.
Haque W, Voong KR, Shihadeh F, Arzu I, Pinnix C, Mazloom A, Medeiros LJ, Romaguera J, Rodriguez A, Wang M, Allen P, Dabaja B. Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients. Clin Lymphoma Myeloma Leuk 14(6):474-9, 2014. e-Pub 2014. PMID: 25108680.
Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 2014. e-Pub 2014. PMID: 25439689.
Cai Q, Chen Y, Zou D, Zhang L, Badillo M, Zhou S, Lopez E, Jiang W, Huang H, Lin T, Romaguera J, Wang M. Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Oncotarget 5(17):7368-80, 2014. e-Pub 2014. PMID: 25228589.
Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 2014. e-Pub 2014. PMID: 24943107.
Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst 106(9), 2014. e-Pub 2014. PMID: 25214559.
Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH. Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant 49(8):1036-41, 2014. e-Pub 2014. PMID: 24887378.
Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood 124(7):1038-46, 2014. e-Pub 2014. PMID: 24920586.
Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, Wang M, Qazilbash MH, Baladandayuthapani V, Berry D, Orlowski RZ, Lee MH, Yeung SC. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 111(3):628-36, 2014. e-Pub 2014. PMID: 24921909.
Wang M, Popplewell LL, Collins RH, Winter JN, Goy A, Kaminski MS, Bartlett NL, Johnston PB, Lister J, Fanning SR, Tuscano JM, Beck JT, Kaya H, Robeva A, Fan J, Klimovsky J, Cheung W, Cherfi A, O'Connor OA. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol 165(4):510-8, 2014. e-Pub 2014. PMID: 24579926.
Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol 7(1):41, 2014. e-Pub 2014. PMID: 24886772.
Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123(14):2204-2208, 2014. e-Pub 2014. PMID: 24425802.
Alexanian R, Wang M, Delasalle K, Wang S, Qazilbash M, Handy B, Weber D. Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplant 49(3):422-5, 2014. e-Pub 2014. PMID: 24317125.
Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 28(2):373-83, 2014. e-Pub 2014. PMID: 23760401.
Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 2013. e-Pub 2013. PMID: 24117234.
Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol 6:92, 2013. e-Pub 2013. PMID: 24326130.
Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J, Sun L, Blonska M, You Y, Yang J, Lin X, Rollo A, Tamayo AT, Lee J, Ford RJ, Zhao X, Kwak LW, Yi Q, Wang M. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther 12(11):2494-504, 2013. e-Pub 2013. PMID: 23990113.
Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 122(18):3122-8, 2013. e-Pub 2013. PMID: 24014245.
Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 8(10):e76781, 2013. e-Pub 2013. PMID: 24204673.
Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 12(3):235-239, 2013. e-Pub 2013. PMID: 17558699.
Chen Z, Pittman EF, Romaguera J, Fayad L, Wang M, Neelapu SS, McLaughlin P, Kwak L, McCarty N. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. PLoS One 8(8):e69126, 2013. e-Pub 2013. PMID: 23936317.
Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implications. Exp Hematol 41(8):719-30, 2013. e-Pub 2013. PMID: 23648290.
Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507-16, 2013. e-Pub 2013. PMID: 23782157.
Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Ferreri AJ, Winter JN, Go RS, Piris MA, Møller MB, Wu L, Wang M, Ramos KS, Medeiros LJ, Young KH. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 121(22):4529-40, 2013. e-Pub 2013. PMID: 23515929.
Alexanian R, Delasalle K, Wang M. High frequencies of response after limited primary therapy for multiple myeloma. Clin Lymphoma Myeloma Leuk 13(2):119-22, 2013. e-Pub 2013. PMID: 23260599.
Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia 227(9):1902-9, 2013. e-Pub 2013. PMID: 23545991.
Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res 19(8):2248-56, 2013. e-Pub 2013. PMID: 23447001.
Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, Ford RJ, Pham LV. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 41(1):67-78, 2013. e-Pub 2013. PMID: 22986101.
Fu W, Delasalle K, Wang J, Song S, Hou J, Alexanian R, Wang M. Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma. Am J Clin Oncol 35(6):562-5, 2012. e-Pub 2012. PMID: 21694573.
Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, Wang M, Yi Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 120(18):3783-92, 2012. e-Pub 2012. PMID: 22968454.
Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14):2817-25, 2012. e-Pub 2012. PMID: 22833546.
Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood 120(16):3260-70, 2012. e-Pub 2012. PMID: 22932796.
Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 2012. e-Pub 2012. PMID: 22015451.
Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 158(6):739-48, 2012. e-Pub 2012. PMID: 22845873.
Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R, Kwak L, Rustveld L, Du XL, Wang M. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: A large population-based study. Cancer 118(15):3793-800, 2012. e-Pub 2012. PMID: 22139816.
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, Working Group OBOTIM, Working Group IM, Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26(1):149-57, 2012. e-Pub 2012. PMID: 21799510.
Zhao L, Ji W, Ou G, Lv J, Liang J, Feng Q, Zhou Z, Wang M, Yin W. Risk factors for radiation-induced lung toxicity in patients with non-small cell lung cancer who received postoperative radiation therapy. Lung Cancer 77(2):326-30, 2012. e-Pub 2012. PMID: 22512813.
Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab in patients with relapsed and refractory mantle cell lymphoma: a phase I/II clinical trial. Lancet Oncol 13(7):716-23, 2012. e-Pub 2012. PMID: 22677155.
Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 119(24):5661-70, 2012. e-Pub 2012. PMID: 22555973.
Liu X, Guo W, Wu S, Wang L, Wang J, Dai B, Kim ES, Heymach JV, Wang M, Girard L, Minna J, Roth JA, Swisher SG, Fang B. Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol 83(10):1456-64, 2012. e-Pub 2012. PMID: 22387047.
Sharma M, Khan H, Thall PF, Orlowski RZ, Jr BR, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-15, 2012. e-Pub 2012. PMID: 21887685.
Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, Kwak LW, McCarty N. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma (MCL) via manipulation of tissue transglutaminase activities. Blood 119(11):2568-78, 2012. e-Pub 2012. PMID: 22294726.
Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 2012. e-Pub 2012. PMID: 22231283.
Sun L, Zhang L, Qian J, Yang J, Yi Q, Dong W, Wang M. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leuk Res 36(3):363– 368, 2012. e-Pub 2012. PMID: 22000823.
Jung HJ, Chen Z, Fayad L, Wang M, Romaguera J, Kwak LW, McCarty N. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. Exp Hematol 40(2):107-118, 2012. e-Pub 2012. PMID: 22024108.
Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber D, Wang M, Orlowski R, Thomas S, Shah J, Qureshi S, Dinh Y, Popat U, Anderlini P, Hosing C, Giralt S, Champlin R, Qazilbash M. Feasibility of autologous hematopoietic stem cell transplantation in patients aged ≥70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 2012. e-Pub 2012. PMID: 21780997.
Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 118(15):4140-9, 2011. e-Pub 2011. PMID: 21844567.
Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res 17(18):5945-52, 2011. e-Pub 2011. PMID: 21813633.
Cao Y, Lan Y, Qian J, Zheng Y, Hong S, Li H, Wang M, Kwak LW, Lin D, Yang J, Yi Q. Targeting cell surface β2 -microglobulin by pentameric IgM antibodies. Br J Haematol 154(1):111-21, 2011. e-Pub 2011. PMID: 21554263.
Tan CH, Wang M, Fu WJ, Vikram R. Nodular extramedullary multiple myeloma involvement of the liver presenting as hypervascular lesions on CT. Ann Acad Med Singapore. Ann Acad Med Singapore 40(7):329-3, 2011. e-Pub 2011. PMID: 21870026.
Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang M, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol 86(6):484-7, 2011. e-Pub 2011. PMID: 21477075.
Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ. Evidence of a Role for Activation of Wnt/β-catenin Signaling in the Resistance of Plasma Cells to Lenalidomide. J Biol Chem 286(13):11009-11020, 2011. e-Pub 2011. PMID: 21189262.
Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene 30(11):1329-40, 2011. e-Pub 2011. PMID: 21057542.
Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q, Wang M. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 35(3):380-6, 2011. e-Pub 2011. PMID: 21047686.
Hunsucker S, Valeria Magarotto V, Kornblau S, Wang M, Weber DM, Thomas SK, Shah J, Voorhees P, Xie H, Cornfeld M, Nemeth JA, Orlowski R. Blockade of interleukin-6 signaling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152(5):579-92, 2011. e-Pub 2011. PMID: 21241278.
Wen J, Feng Y, Bjorklund C, Wang M, Orlowski RZ, Shi Z, Liao B, OHare J, Zu Y, Schally A, Chang C. Luteinizing hormone-releasing hormone (LHRH)-I antagonist Cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther 10(1):148-58, 2011. e-Pub 2011. PMID: 21062912.
Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons PJ, McCarty N. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res 5(3):212-25, 2010. e-Pub 2010. PMID: 20851072.
Ross WA, Egwim CI, Wallace MJ, Wang M, Madoff DC, Lee JH. Outcomes in lymphoma patients with obstructive jaundice: a cancer center experience. Dig Dis Sci 55(11):3271-7, 2010. e-Pub 2010. PMID: 20632106.
Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-52, 2010. e-Pub 2010. PMID: 20805315.
Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol 151(1):47-53, 2010. e-Pub 2010. PMID: 20735402.
Harousseau JL, Dimopoulos MA, Wang M, Corso A, Chen C, Attal M, Spencer A, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 95(10):1738-44, 2010. e-Pub 2010. PMID: 20460639.
Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant 16(8):1122-9, 2010. e-Pub 2010. PMID: 20178853.
Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide– dexamethasone (BLD). Hematology 15(2):70-73, 2010. e-Pub 2010. PMID: 20423566.
Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplantation 45(3):498-504, 2010. e-Pub 2010. PMID: 19633690.
Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(31):5213-8, 2009. e-Pub 2009. PMID: 19770379.
Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG, al [, M] IW. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23(10):1904-12, 2009. e-Pub 2009. PMID: 19554029.
Qian J, Hong S, Wang S, Zhang L, Sun L, Wang M, Yang J, Kwak LW, Hou J, Yi Q. Myeloma cell line-derived, pooled heat shock proteins as a broad vaccine for immunotherapy of multiple myeloma. Blood 114(18):3880-9, 2009. e-Pub 2009. PMID: 19654406.
Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114(17):3625-8, 2009. e-Pub 2009. PMID: 19710503.
Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 84(9):553-9, 2009. e-Pub 2009. PMID: 19565649.
Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-816, 2009. e-Pub 2009. PMID: 19539212.
Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, Yi Q. Cyclin D1 as a universally-expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia 23(7):1320-1328, 2009. e-Pub 2009. PMID: 19225534.
Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):718-23, 2009. e-Pub 2009. PMID: 19450756.
Wang M, Burau KD, Fang S, Wang H, Du XL. Ethnic variations in diagnosis, treatment, socioeconomic status and survival in a large population-based cohort of elderly patients with non-Hodgkin's Lymphoma. Cancer 113(11):3231-3241, 2008. e-Pub 2008. PMID: 18937267.
Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a Phase II randomized trial. Biol Blood Marrow Transplant 14(12):1401-7, 2008. e-Pub 2008. PMID: 19041063.
Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112(12):4445-4451, 2008. e-Pub 2008. PMID: 18799726.
Wang M, Fayad L, Hagemeister F, McLaughlin P, Rodriguez A, Cabanillas F, Younes A, Neelapu S, Goy A, Zhou Y, Wang J, Beasley V, Kwak L, Kantarjian H, Romaguera J. Phase II trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed/refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-2741, 2008. e-Pub 2008. PMID: 18973182.
Zhou Y, Wang H, Fang W, Romaguera J, Zhang Y, Delasalle K, Kwak L, Yi Q, Du X, Wang M. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113(4):791-798, 2008. e-Pub 2008. PMID: 18615506.
Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW, Yi Q. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 14(7):2154-2160, 2008. e-Pub 2008. PMID: 18381957.
Wang M, Han XH, Zhang L, Yang J, Qian JF, Shi YK, Kwak LW, Romaguera J, Yi Q. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 22(1):179-85, 2008. e-Pub 2008. PMID: 17898787.
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Knight RD. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133-42, 2007. e-Pub 2007. PMID: 18032763.
Rohatgi N, Du XL, Coker AL, Moye L, Wang M, Fang S. Chemotherapy and survival for patients with multiple myeloma: Findings from a large nationwide and population-based cohort. Am J Clin Oncol 30(5):540-548, 2007. e-Pub 2007. PMID: 17921717.
Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, Kwak LW, Yi Q. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 110(8):3028-35, 2007. e-Pub 2007. PMID: 17644731.
Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 13(9):1066-72, 2007. e-Pub 2007. PMID: 17697969.
Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12(3):252-65, 2007. e-Pub 2007. PMID: 17785206.
Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD, Epstein J, Kwak LW, Yi Q. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110(5):1587-94, 2007. e-Pub 2007. PMID: 17515399.
Dang NH, Fayad L, McLaughlin P, Romaguera JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker P, Wang M, Rodriguez MA, Ton A, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin's lymphoma. Br J Haematol 138(4):502-505, 2007. e-Pub 2007. PMID: 17608763.
Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Samaniego F, Romaguera J, Yi Q. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood 109(12):5455-62, 2007. e-Pub 2007. PMID: 17317853.
Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39(5):279-83, 2007. e-Pub 2007. PMID: 17262062.
Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad, II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194(10):1394-7, 2006. e-Pub 2006. PMID: 17054068.
Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 42(17):2976-81, 2006. e-Pub 2006. PMID: 17008093.
Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 10(4):295-307, 2006. e-Pub 2006. PMID: 17045207.
Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels B, Smith TL, Cabanillas F. High rate of durable remissions after treatment of newly diagnosed aggressive mantle cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate/cytarabine. J Clin Oncol 23(28):7013-23, 2005. e-Pub 2005. PMID: 16145068.
Wang M, Weber DM, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 79(3):194-7, 2005. e-Pub 2005. PMID: 15981221.
Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal B, Estrov Z. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 93(1):70-80, 2005. e-Pub 2005. PMID: 15970928.
Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23(4):667-75, 2005. e-Pub 2005. PMID: 15613697.
Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer 101(7):1508-13, 2004. e-Pub 2004. PMID: 15378497.
Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22(20):4095-102, 2004. e-Pub 2004. PMID: 15353540.
Leroy MJ, Degerman E, Taira M, Murata T, Wang LH, Movsesian M, Meacci E, Manganiello VC. Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry 35(31):10194-10202, 1996. e-Pub 1996. PMID: 8756484.
Kusui T, Hellmich MR, Wang LH, Evans RL, Benya RV, Battey JF, Jensen RT. Characterization of gastrin-releasing peptide receptor expressed in Sf9 insect cells by baculovirus. Biochemistry 34(25):8061-75, 1995. e-Pub 1995. PMID: 7794919.
Benya, RV, Wada, E, Battey, JE, Fathi, Z, Wang, LH, Mantey, SA, Coy, DH, Jensen, RT. Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: Analysis of binding, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors. Mol Pharm 42(2):8061-75, 1994. e-Pub 1994. PMID: 1336112.
Wang LH, Mantey SA, Lin JT, Frucht H, Jensen RT. Ligand binding, internalization, degradation and regulation by guanine nucleotides of bombesin receptor subtypes: A comparative study. Biochim Biophys Acta 1175(2):232-42, 1993. e-Pub 1993. PMID: 8380344.
Wang LH, Battey JF, Wada E, Lin JT, Mantey S, Coy DH, Jensen RT. Activation of neuromedin B-preferring bombesin receptors on rat glioblastoma C-6 cells increases cellular Calcium and phosphoinositides. Biochem J 286(Pt2):641-8, 1992. e-Pub 1992. PMID: 1326946.
Coy DH, Jiang NY, Kim SH, Moreau JP, Lin JT, Frucht H, Qian JM, Wang LH, Jensen RT. Covalently-cyclized agonist and antagonist analogues of bombesin and related peptides. J Biol Chem 266(25):16441-7, 1991. e-Pub 1991. PMID: 1715866.
Coy D, Wang LH, Jiang NY, Jensen R. Short chain bombesin pseudopeptides with potent bombesin receptor antagonist activity in rat and guinea pig pancreatic acinar cells. Eur J Pharmacol 190:31-8, 1990. e-Pub 1990. PMID: 1963850.
Rowley WH, Sato S, Huang SC, Collado-Escobar DM, Beaven MA, Wang LH, Martinez J, Gardner JD, Jensen RT. Cholecystokinin-induced formation of inositol phosphates in pancreatic acini. Am J Physiol 259:G655-65, 1990. e-Pub 1990. PMID: 1699431.
Wang LH, Coy DH, Taylor JE, Jiang NY, Moreau JP, Huang SC, Frucht H, Haffar BM, Jensen RT. Des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists or agonists. J Biol Chem 265(26):15695-703, 1990. e-Pub 1990. PMID: 1697594.
von Schrenck T, Wang LH, Coy DH, Villanueva ML, Mantey S, Jensen RT. Potent bombesin receptor antagonists distinguish receptor subtypes. Am J Physiol 259:G468-73, 1990. e-Pub 1990. PMID: 2169207.
Coy DH, Wang LH, Jensen RT. Bombesin agonists, partial agonists and antagonists-unexpected biological profiles among medicinally interesting analogues. Actualities de Chimie Therapeutique, Dix-Huiteme Serie (26 mes Recontes Interionales de Chimie Therapeutique, Montpellier France:157-165, 1990. e-Pub 1990.
Wang LH, Coy DH, Taylor JE, Jiang NY, Kim SH, Moreau JP, Huang SC, Mantey SA, Frucht H, Jensen RT. Desmethionine alkylamide bombesin analogues: A new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells. Biochemistry 29(3):616-22, 1990. e-Pub 1990. PMID: 1692477.
Coy DH, Taylor JE, Jiang NY, Kim SH, Wang LH, Huang SC, Moreau JP, Gardner JD, Jensen RT. Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. J Biol Chem 264(25):14691-7, 1989. e-Pub 1989. PMID: 2475489.
Coy DH, Taylor JE, Jiang NY, Wang LH, Huang SC, Qian JM, Moreau JP, Jensen RT. Developing receptor antagonists of neuropeptides-the bombesin/GRP and substance P systems. Peptides. Neuropeptides and Their Receptors, Alfred Benzon Symposium 29 29:376-385, 1989. e-Pub 1989.
Coy DH, Taylor JE, Jiang NY, Kim SH, Wang LH, Huang SC, Moreau JP, Jensen RT. Short-chain bombesin receptor antagonists with IC50's for cellular secretion and growth approaching the picomolar region peptides. Proceedings of the 11th American Peptide Symposium Escom Science Publishers:65-8, 1989. e-Pub 1989.

Invited Articles

Wang Y, Zhang LL, Champlin RE, Wang ML. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther 97(5):455-468, 2015. e-Pub 2015. PMID: 25669675.
Zhang KJ, Wang M. Potential effects of CRM1 inhibition in mantle cell lymphoma. Chin J Cancer Res 24(4):374-87, 2012. e-Pub 2012. PMID: 23357869.
Alexanian R, Delasalle K, Wang M, Thomas S, Weber D. Curability of multiple myeloma. Bone Marrow Res 2012:916479:916479, 2012. e-Pub 2012. PMID: 22675638.
Papathomas TG, Venizelos I, Dunphy CH, Said JW, Wang M, Campo E, Swerdlow SH, Chan JC, Bueso-Ramos CE, Weisenburger DD, Medeiros LJ, Young KH. Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications. Hum Pathol 43(4):467-80, 2012. e-Pub 2012. PMID: 22221705.
Wang M. Comparative mechanisms of action of proteasome inhibitors. Oncology Supplement(2):1-6, 2011. e-Pub 2011. PMID: 25188479.
Zhou Y, Garcia MK, Chang DZ, Chiang J, Lu J, Yi Q, Romaguera J, Delasalle K, Alexanian A, Guo Y, Forman A, Fang W, Wang M. Multiple myeloma, painful neuropathy, acupuncture?. Am J Clin Onc 32(3):319-325, 2009. e-Pub 2009. PMID: 19887992.
Zhou Y, Zhang L, Romaguera J, Delasalle K, Han X, Du X, Kwak L, Yi Q, Wang M. Immunotherapy in mantle cell lymphoma. Am J Hem 83(2):144-149, 2008. e-Pub 2008. PMID: 17722077.
Mullen EC, Wang M. Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia. Clin J Oncol Nurs 11(1):87-95, 2007. e-Pub 2007. PMID: 17441400.
Wang M, Nguyen C, Alexanian A. Effective new agents for multiple myeloma. Case Studies in Myeloma, Physicians' Education Resource 2(2):1-7, 2006. e-Pub 2006.
Wang M, Younes A. Testicular lymphoma: a mysterious link between the testis and the brain. Clin Lymphoma 3:173-4, 2002. e-Pub 2002. PMID: 12521395.

Review Articles

Sotomayor, EM, Wang, L, de Fend, LQ, Vose, J, Martin, P. Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma. Oncology (United States) 38(2):51-67, 2024. e-Pub 2024. PMID: 38421601.
Ng WL, Wang Y, Bock AM, Jevremovic D, Wang ML, Nowakowski GS. Review of management options for mantle cell lymphoma in pregnancy. Leuk Lymphoma 64(6):1194-1198, 2023. e-Pub 2023. PMID: 37035894.
Beitinjaneh A, Kaufman A, Wang Y, Jain P, Srour SA, Wang M. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?. Curr Treat Options Oncol 23(11):1614-1625, 2022. e-Pub 2022. PMID: 36227407.
Khan M, Hagemeister F, Wang M, Ahmed S. A review of pathobiology and therapies for classic Hodgkin lymphoma. Blood Rev 55:100949, 2022. e-Pub 2022. PMID: 35396126.
Munoz JL, Wang Y, Jain P, Wang M. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner. Curr Oncol Rep 24(10):1299-1311, 2022. e-Pub 2022. PMID: 35596920.
Muñoz J, Wang Y, Jain P, Wang M. Zanubrutinib in lymphoproliferative disorders: a comprehensive review. Ther Adv Hematol 13:20406207221093980, 2022. e-Pub 2022. PMID: 35651781.
Jain P, Wang M. Mantle cell lymphoma in 2022 - A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol 97(5):638-656, 2022. e-Pub 2022. PMID: 35266562.
Eyre TA, Cheah CY, Wang ML. Therapeutic options for relapsed/refractory mantle cell lymphoma. Blood 139(5):666-677, 2022. e-Pub 2022. PMID: 34679161.
Lu, P, Hill, H, Navsaria, L, Wang, L. CAR-T and other adoptive cell therapies for B cell malignancies. J Natl Cancer Cent 1(3):88-96, 2021. e-Pub 2021. PMID: 39036373.
Jain P, Dreyling M, Seymour JF, Wang M. High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management. J Clin Oncol 38(36):4302-4316, 2020. e-Pub 2020. PMID: 33074750.
Jain P, Wang M. Blastoid mantle cell lymphoma. Hematol Oncol Clin North Am 34(5):941-956, 2020. e-Pub 2020. PMID: 32861288.
Jung D, Jain P, Yao Y, Wang M. Advances in the assessment of minimal residual disease in mantle cell lymphoma. J Hematol Oncol 13(1):127, 2020. e-Pub 2020. PMID: 32972438.
Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol 94(6):710-725, 2019. e-Pub 2019. PMID: 30963600.
Zeng D, Desai A, Yan F, Gong T, Ye H, Ahmed M, Nomie K, Romaguera J, Champlin R, Li S, Wang M. Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). Am J Clin Oncol 42(3):304-316, 2019. e-Pub 2019. PMID: 29419530.
Jurczak W, Dlugosz-Danecka M, Wang M. Acalabrutinib for adults with mantle cell lymphoma. Expert Rev Clin Pharmacol 12(3):1-9, 2019. e-Pub 2019. PMID: 30638402.
Ahmed M, Lorence E, Wang J, Jung D, Zhang L, Nomie K, Wang M. Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma. Sci Signal 12(567), 2019. e-Pub 2019. PMID: 30723172.
Ye H, Desai A, Zeng D, Romaguera J, Wang M. Frontline Treatment for Older Patients with Mantle Cell Lymphoma. Oncologist 23(11):1337-1348, 2018. e-Pub 2018. PMID: 29895632.
Ye H, Desai A, Huang S, Jung D, Champlin R, Zeng D, Yan F, Nomie K, Romaguera J, Ahmed M, Wang M. Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy. J Exp Clin Cancer Res 37(1):150, 2018. e-Pub 2018. PMID: 30005678.
Zhang Z, Zhang D, Liu Y, Yang D, Ran F, Wang ML, Zhao G. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors. Arch Pharm (Weinheim) 351(7):e1700369, 2018. e-Pub 2018. PMID: 29741794.
Balaji S, Ahmed M, Lorence E, Yan F, Nomie K, Wang M. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma. J Hematol Oncol 11(1):83, 2018. e-Pub 2018. PMID: 29907126.
Merolle MI, Ahmed M, Nomie K, Wang M. The B cell receptor signaling pathway in mantle cell lymphoma. Oncotarget 9(38):25332-25341, 2018. e-Pub 2018. PMID: 29861875.
Wang Y, Nowakowski GS, Wang M, Ansell SM. Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. J Hematol Oncol 11(1):57, 2018. e-Pub 2018. PMID: 29685160.
Steiner RE, Romaguera J, Wang M. Current trials for frontline therapy of mantle cell lymphoma. J Hematol Oncol 11(1):13, 2018. e-Pub 2018. PMID: 29374487.
Ye H, Desai A, Zeng D, Nomie K, Romaguera J, Ahmed M, Wang M. Smoldering mantle cell lymphoma. J Exp Clin Cancer Res 36(1):185, 2017. e-Pub 2017. PMID: 29246179.
Zhang K, Desai A, Zeng D, Gong T, Lu P, Wang M. Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting. Oncotarget 8(6):10748-10759, 2017. e-Pub 2017. PMID: 27863374.
Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 7(45):74380-74392, 2016. e-Pub 2016. PMID: 27602582.
Ahmed M, Li L, Pinnix C, Dabaja B, Nomie K, Lam L, Wang M. ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma. Crit Rev Oncol Hematol 107:14-19, 2016. e-Pub 2016. PMID: 27823642.
Ahmed M, Zhang L, Nomie K, Lam L, Wang M. Gene mutations and actionable genetic lesions in mantle cell lymphoma. Oncotarget 7(36):58638-58648, 2016. e-Pub 2016. PMID: 27449094.
Wang Y, Sanchez L, Siegel DS, Wang M. Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol 9(1):55, 2016. e-Pub 2016. PMID: 27417553.
Sanchez L, Wang Y, Siegel DS, Wang M. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol 9(1):51, 2016. e-Pub 2016. PMID: 27363983.
Cheah CY, Fowler NH, Wang M. Breakthrough therapies in B-cell non-Hodgkin lymphoma. Annals Onc, 2016. e-Pub 2016. PMID: 26802148.
Cheah CY, Seymour JF, Wang ML. Mantle Cell Lymphoma. J Clin Oncol 34(11):1256-69, 2016. e-Pub 2016. PMID: 26755518.
Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, Andersson BS, Qazilbash MH, Champlin RE, Berenson JR, Guan X, Wang M. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. J Natl Cancer Inst 108(3), 2016. e-Pub 2016. PMID: 26582244.
Chen Y, Wang M, Romaguera J. Current regimens and novel agents for mantle cell lymphoma. Br J Haematol 167(1):3-18, 2014. e-Pub 2014. PMID: 24974852.
Desai M, Newberry K, Ou Z, Wang M, Zhang L. Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Ther Adv Hematol 5(3):91-101, 2014. e-Pub 2014. PMID: 24883181.
Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol 93(4):541-56, 2014. e-Pub 2014. PMID: 24375125.
Desai M, Newberry KJ, Romaguera J, Zhang L, Ou Z, Wang M. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy. J Hematol Oncol 6:55, 2013. e-Pub 2013. PMID: 23915913.
Hoeller S, Zhou Y, Kanagal-Shamanna R, Xu-Monette ZY, Hoehn D, Bihl M, Swerdlow SH, Rosenwald A, Ott G, Said J, Dunphy CH, Bueso-Ramos CE, Lin P, Wang M, Miranda RN, Tzankov A, Medeiros LJ, Young KH. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol 44(1):110-21, 2013. e-Pub 2013. PMID: 22944294.
Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-8, 2010. e-Pub 2010. PMID: 20528872.
Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S, IMWG. International Myeloma Working Group (IMWG) guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23(10):1716-30, 2009. e-Pub 2009. PMID: 19494840.
Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG, IMWG. International myeloma working group (IMWG) consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 23(9):1545-56, 2009. e-Pub 2009. PMID: 19421229.
Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG, IMWG. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23(2):215-24, 2009. e-Pub 2009. PMID: 19020545.
Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, Munshi NC. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol 5(10 Suppl 15):7-19, quiz 21-2, 2007. e-Pub 2007. PMID: 18000495.
Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J. Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 6(7):983-91, 2006. e-Pub 2006. PMID: 16831071.
Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 40(4):3-7, 2003. e-Pub 2003. PMID: 15015890.

Professional Educational Materials

Wang M. Noncytotoxic First-Line Therapy for Mantle Cell Lymphoma. OncoLog, 2017.

Editorials

Wang M. Express Delivery of Next-Generation CAR T Cells with Preserved Naive and Stemness Phenotypes for the Treatment of Aggressive Lymphomas. Cancer Discov 13(9):1961-1963, 2023. PMID: 37671474.
Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. PMID: 35533245.
Wang M. Winning the battle at the front lines: lenalidomide plus rituximab— a promising initial treatment for mantle cell lymphoma. ASCO POST, 2016.
Wang M. New kid on the block: ONC201 in NHL. Cell Cycle 14(22):0, 2015. PMID: 26102059.
Zhang L, Newberry KJ, Wang M. Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment. Expert Rev Clin Immunol 9(6):495-7, 2013. PMID: 23730878.
O’Brien SM, Wang M. Highlights in B-cell malignancies from the 2012 American Society of Hematology (ASH) Meeting. Clinical Advances in Hematology & Oncology 11(4 suppl6):1-19, 2013. PMID: 25602090.
Ke XY, Wang YF, Yang YH, Wang LH. Multiple myeloma: past, present and future. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(2):231-239, 2008. PMID: 18426640.
Hou J, Wang M. Current status and future directions in the treatment of multiple myeloma. Chin Med J (Engl) 120(19):1651-4, 2007. PMID: 17935663.

Abstracts

Rahal Z, Zhou T, Yang S, Serrano A, Feng J, Sinjab A, Le JT, Sun X, Wang M, Hu W, Zang J, Bruno T, Tran HT, Swisher SG, Leung CH, Lin HY, Lee JJ, Wang J, Heymach JV, Gibbons DL, Wistuba II, Weissferdt A, Burks JK, Solis LM, Kadara H, Cascone T. Multimodal spatial transcriptomics and proteomics analysis of the resectable NSCLC ecosystem following neoadjuvant chemoimmunotherapy. Cancer Research (AACR 2024 annual meeting abstract), 2024. e-Pub 2024.
Chong G, Morschhauser F, Herrera A, K-S E, Kim T, Wang M, Hall C, Cader F, Beyfuss K, Cheung P, Quan W, Sharma S, Marmor Y, Saeh J, JMariz J. AZD0466 in patients with advanced non-Hodgkin lymphoma: Efficacy and safety in an open-label phase 1 trial. Cancer Research (AACR 2024 annual meeting abstract), 2024. e-Pub 2024.
Liu Y, H-H L, McIntosh J, Li Y, Zhang T, Wang W, Kostura MJ, Wang M. The integrated stress activator BTM-3566 overcomes therapeutic resistance in mantle cell lymphoma. Cancer Research (AACR 2024 annual meeting abstract), 2024. e-Pub 2024.
Jiang V, Xue Y, Kim H, McIntosh J, Chen H, Zhang T, Liu Y, Zhou J, Wang M. Targeting CDK9 with a novel potent and selective inhibitor, YX0798, in CAR-T-relapsed mantle cell lymphoma models. Cancer Research (AACR 2024 annual meeting abstract), 2024. e-Pub 2024.
Dutta R, Lee HH, Leshchenko V, Shukla R, Liu Y, Jin J, Wang M, Parekh S. SOX11 regulates BCR signaling via the PAX5/CD19 axis in MCL. Cancer Research (AACR 2024 annual meeting abstract), 2024. e-Pub 2024.
Jiang, V, Liu Y, Cai Q, McIntosh J, Li Y, Chen Z, Lee H, Wang W, Yao Y, Nie L, Wang M. BTK and MALT1 are critical for cell adhesion and dissemination in mantle cell lymphoma. Cancer Research (AACR 2023 Annual Meeting Abstract), 2023. e-Pub 2023.
Hill H, Jain P, Chi O, Sasaki K, Chen H, Wang M, Chen K. Integrative Prognostic Machine-Learning Models in Mantle Cell Lymphoma. AACR 2023 (Annual Meeting Abstract), 2023. e-Pub 2023.
Jain P, et al, Wang M, Nair R. Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Jiang V, et al, Wang M. Targeting the HSP90-MYC-CDK9 axis to overcome dual resistance to BTK Inhibition and CAR-T therapy in mantle cell lymphoma. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Mato A, et al, Wang M, et al, Danilov AV. NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Wang M, et al., Jurczak W. Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Gaitonde P, et al, Wang ML. Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Niar R, et al, Wang ML, et al, Iyer S. CAR-T outcomes in patients with EBV-positive DLBCL. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Yao Y, Liu Y, Che Y, Li Y, Lee H, Wang M, McIntosh J. Modulating Immunometabolism to Reinvigorate T-Cell Effector Function and Antitumor Immunity in the Mantle Cell Lymphoma Microenvironment. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Shah NV, Wang M, et al, Mato A. Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Song Y, Wang M, et al, Zhu J. Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Che Y, Wang W, Liu Y, Lee H, Li Y, Chen Z, McIntosh J, Jiang C, Yao Y, Wang M. HSP27 Promotes Mantle Cell Lymphoma Growth and Mediates Resistance to Venetoclax. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Wang M, et al, Mato A. Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Spurgeon S, et al, Wang M. Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Nze C, et al, Wang M, et al, Flowers C. Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Lee H, et al, Wang ML, et al, Kipps T. Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL), Chronic lymphocytic leukemia (CLL), or marginal zone lymphoma (MZL). Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Palomba ML, et al, Wang ML, et al Cheah CY. Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Agbedia O, et al, Wang ML, et al Iyer S. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Munoz J, et al, Wang M. Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL). Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Hassoun H, Wang M, Anderson K. Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Nie L, Liu Y, Jiang C, Che Y, Jin J, Cai Q, Wang W, Li Y, Jordan A, McIntosh J, Vargas J, Yao Y, Lee H, Wang M. Establishment of a Patient-Derived Organoid Culture Platform for Mantle Cell Lymphoma Drug Sensitivity and CAR T Cell Anti-Tumor Activity Assay. Blood (ASH 2022 Annual Meeting Abstract) 140(Suppl 1), 2022. e-Pub 2022.
Cohen JB, Shah NN, Alencar AJ, Gerson JN, Patel MR, Fakhri B, Jurczak W, Tan XN, Lewis KL, Fenske T, Coombs CC, Flinn IW, Lewis DJ, Gouill SL, Palomba ML, Woyach JA, Pagel JM, Lamanna N, Barve MA, Ghia P, Eyre TA, Zinzani PL, Ujjani CS, Koh Y, Izutsu K, Lech-Maranda E, Tam CS, Sundaram S, Yin M, Nair B, Tsai DE, Balbas M, Mato AR, Cheah CY, Wang ML. MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study. Proceedings of the Society of Hematologic Oncology 2022 Annual Meeting 22 Suppl 2:S394-S395, 2022. e-Pub 2022. PMID: 36164120.
Ito R, Eyre TA, Shah NN, Gouill SL, Dreyling M, Vandenberghe E, Jurczak W, Wang Y, Cheah CY, Gandhi M, Chay C, Sharman J, Andorsky DJ, Song Y, Stark A, Muthig V, Wang ML. MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress). Proceedings of the Society of Hematologic Oncology 2022 Annual Meeting 22 Suppl 2:S395-S396, 2022. e-Pub 2022.
Wang M, Thompson P, et al, Spurgeon S. Phase 1 dose escalation and cohort expansion study of the anti-ROR1 antibody-drug conjugate zilovertamab vedotin (MK-2140) for the treatment of non-Hodgkin lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Abramson J, Palomba L, Gordon L, Lunning M, Wang M, Arnason J, Purev E, Maloney D, Andreadis C, Sehgal A, Solomon S, Ghosh N, Kostic A, Kim Y, Ogasawara K, Dehner C, Siddiqi T. Two-year follow-up of Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphomas (LBCL). Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Li Y, Liu Y, Che Y, Jordan A, McIntosh J, Leeming A, Anderson C, Cidado J, Jin J, Changying V, Wang M. Dual targeting Bcl-2 by venetoclax and Mcl-1 By AZD5991 to overcome therapeutic resistance in aggressive R/R mantle cell lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Wang Y, Jain P, et al, Wang M, Jain M. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real world experience from the US lymphoma CAR T consortium. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Pinnix C, Jain P, Wang M, Samaniego F, Fowler N, Flowers C, et al, Esmaeli B. Phase II trial of response adapted ultra-low dose (ULD) orbital radiation therapy for indolent B cell lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Malpica-Castillo L, Feng L, Xu J, Nair R, Elias A, Jain P, et al, Wang M, Neelapu S, Flowers C, Iyer S. Long-term outcome patterns and risk factors for early mortality and disease progression in ALK-positive anaplastic large cell lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Li Y, Liu Y, Che Y, McIntosh J, Jordan A, Leeming A, Andersen C, Cidado J, Jin J, Jiang V, Wang M. Combination therapy of Bcl-2/XL dual inhibitor AZD0466 with acalabrutinib to overcome therapeutic resistance in aggressive R/R mantle cell lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Jiang V, Cai Q, Hao D, Liu Y, Li Y, Che Y, McIntosh J, Jordan A, Chen Z, Leeming A, Nie L, Wang L, Wang M. Single cell transcriptomic profiling of patient-derived xenografts of mantle cell lymphoma reveals a special tumor cell population: seed cells for disease dissemination and progression. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Wang M, Yin M, Nair B, Balbas M, Tsai D, Mato AR, Cheah CY. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma: updated results from the Phase 1/2 BRUIN study. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Kamel S, et al, Wang M, Pan T, Lee HJ. Radiomic phenotypes of high and low lesion SUV components for the prediction of refractory disease in Hodgkin’s lymphoma patients treated with ABVD based therapy. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Che Y, Liu Y, Li Y, McIntosh J, Jordan A, Chen Z, Yan F, Wang W, Jin J, Jiang V, Yao Y, Wang M. Abemaciclib in combination with copanlisib to overcome therapeutic resistance in mantle cell lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Jin J, Li Y, Liu Y, Jordan A, McIntosh J, Vargas J, Che Y, Yao Y, Wang M. Bispecific CD19-CD20 CAR-T cells with glycogen synthase kinase (GSK)-3β inhibitor TWS119 treatment have superior therapeutic effects on mantle cell lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Nair R, Deen N, Ahmed S, Miranda R, Fowler N, Fayad L, Steiner R, Hagemeister F, Rodriguez MA, Lee H, Strati P, Malpica-Castillo L, Chihara D, Jain P, Gunther J, Flowers C, Medeiros J, Nieto Y, Ramdial J, Neelapu S, Nastoupil L, Green M, Wang M, Vega F, Feng L, Iyer S, Westin J. Outcome of patients with T-cell histiocyte rich B cell lymphoma: single institution series. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Liu Y, Jiang V, Yan F, McIntosh J, Jordan A, Li Y, Che Y, Cai Q, Wang W, Nie L, Wang M. Pirtobrutinib Overcomes Ibrutinib and Venetoclax Resistance in Mantle Cell Lymphoma Program. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Wang M, Robak T, Maddocks K, Phillips T, Smith S, Gallinson D, Calvo R, Wun C, Munugalavadla V, Jurczak W. Safety and efficacy of acalabrutinib plus venetoclax and rituximab in patients with treatment-naïve (TN) mantle cell lymphoma (MCL). Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Lee HJ, et al, Wang M, Jamieson C, Kipps T. Phase 1b/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Chihara D, Wang M, Neelapu S, Fowler N. Ten year follow-up of the MD Anderson Cancer Center Phase 2 study of rituximab in combination with lenalidomide (R2) for patients with low tumor burden follicular lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Jain P, Nomie K, Segodin V, Egorov E, Yao Y, Navasaria L, Hill H, Kotlov N, Kanagal-Shamanna R, Young C, Vega F, Li S, Che Y, Li Y, Svekolkin V, Bagaev A, Frenkel F, Attaulakhanov R, Fowler N, Flowers C, Wang M. Immune-depleted tumor microenvironment signature is associated with BTK inhibitor resistance in mantle cell lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Eyere T, et al, Yin M, Balbas M, Kherani J, Wang M. BRUIN MCL-321: A Phase 3 open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor-naïve mantle cell lymphoma (trial in progress). Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Nie L, Liu Y, Che Y, Li Y, Wang W, Jin J, Cai Q, Vargas J, McIntosh J, Jordan A, Jiang V, Yao Y, Wang M. Establishment of patient-derived organoid culture platform of mantle cell lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Wang M, Jain P, Lee H, Young C, Hill H, Navasaria L, Kanagal-Shamanna R, Malpica-Castillo L, Nair R, Iyer S, Samaniego F, Chen W, Oriabure O, Feng L, Thirumurthi S, Santos D, Tang G, Vega F, Li S, Avellaneda M, Badillo M, Flowers C. Ibrutinib plus rituximab and venetoclax (IRV) followed by risk-stratified observation or short course R-Hypercvad/MTX in young patients with previously untreated mantle cell lymphoma – Phase-II Window-2 clinical trial. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Yao Y, Liu Y, Che Y, Li Y, McIntosh J, Jordan A, Jin J, Wang M. ROR1-targeted CAR T cells to overcome resistance to BTK inhibition and CD19-targeted CAR T cell therapy in mantle cell lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Yan F, Jiang V, Cai Q, Jain P, Li Y, Liu Y, McIntosh J, Jordan A, Zhao Z, Simon L, Wang M. Dynamic reprogramming and evolution associated with sequential resistance to ibrutinib and CAR T therapy in mantle cell lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Svoboda J, et al, Wang M, Pagel J. Clinician-Based Performance Status and Its Correlation with Patient-Reported Outcomes: Findings from a Prospective Observational Study in Patients with Mantle Cell Lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Yao Y, Che Y, Liu Y, Li Y, Jordan A, McIntosh J, Jin J, Wang M. Genetic modification with BCL2L1 and BCL6 enhanced persistence and potency of bispecific CD19/CD22 CAR T cells against mantle cell lymphoma. Blood (ASH 2021 Annual Meeting Abstract) 138(Suppl 1), 2021. e-Pub 2021.
Yao Y, Wang M. Exploiting PRMT5, a metabolic and epigenetic regulator, as a novel therapeutic target in mantle cell lymphoma. AACR Annual Meeting 2020, 2020. e-Pub 2020.
Jiang C, Wang M. Single-cell RNA-seq reveals heterogeneity, clonal evolution and strategies to overcome ibrutinib-venetoclax dual resistance in mantle cell lymphoma. AACR Annual Meeting 2020, 2020. e-Pub 2020.
Liu Y, Zhao S, Jiang C, Yao Y, Murfin KP, Grundman H, Zhang L, Nomie K, Wang L, Wang M. The Development of a Precision Medicine Platform to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 134(Suppl 1), 2019. e-Pub 2019.
Yao Y, Liu Y, Zhang H, Leeming A, McIntosh JM, Jain P, Zhang L, Nomie K, Wang ML. Identify AMPK-Mediated Autophagy and Oxphos As a Novel Metabolic Vulnerability for Targeted Therapy in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 134(Suppl 1), 2019. e-Pub 2019.
Wang ML, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. Blood (ASH Annual Meeting Abstract) 134(Suppl), 2019. e-Pub 2019.
Zhang L, Guo H, Zhang H, Yao Y, Liu Y, Zhang S, Rui L, Wang L, Nomie K, Wang ML. Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 134(Suppl 1), 2019. e-Pub 2019.
Nomie K, Kotlov N, Svekolkin V, Bagaev A, Cai Q, Falahat J, Moghrabi O, Frenkel F, Attaulakhanov R, Leeming A, Jung D, Hill H, Murfin KP, Chen Z, Hartig K, Badillo M, Jain P, Zhang L, Wang M. Tumor Microenvironment Molecular Signatures That Define Therapeutic Resistance in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 134(Suppl 1), 2019. e-Pub 2019.
Wang ML, Jain P, Lee HJ, Hagemeister FB, Samaniego F, Westin JR, Nastoupil LJ, Chen W, Nomie K, Zhang S, Moghrabi O, Zhao S, Kanagal-Shamanna R, Ok CY, Oriabure O, Nogueras González GM, Jung D, Navsaria L, Uy A, Pedersen A, Zhang L, Jiang C, Lei F, Yao Y, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Patel K, Yin CC, Avellaneda M, Badillo M, Fayad L, Neelapu SS, Fowler NH, Romaguera JE, Wang L. Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) – Results of Phase-II Window-1 Clinical Trial. Blood (ASH Annual Meeting Abstract) 134(Suppl), 2019. e-Pub 2019.
Jiang C, Zhang S, Huang S, Liu Y, Zhang R, Leeming A, McIntosh JM, Lee W, Nomie K, Wang L, Wang ML. Pdox Models Empower Preclinical Drug Evaluation and Mechanistic Studies Via Faithful Recapitulation of the Pathology, Complex Heterogeneity, Genetic-Transcriptomic Landscape, and Therapeutic Response of Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 134(Suppl 1), 2019. e-Pub 2019.
Wang M, Jain P, Zhang S, Nomie K, Wang L, Oriabure O, Nogueras Gonzales G, Zhang L, Wagner-Bartak N, Hagemeister F, Samaniego F, Westin J, Lee HJ, Nastoupil L, Ok C, Kanagal-Shamanna R, Chen W, Thirumurthi S, Santos D, Badillo M, Fayad L, Neelapu S, Fowler N, Romaguera J. Ibrutinib with rituximab (IR) and short course R-HyperCVAD/MTX is very efficacious in previously untreated young pts with mantle cell lymphoma (MCL). 15-ICML 37(S2 Suppl):42-43, 2019. e-Pub 2019.
Anand K, Burns E, Sano D, Pingali SR, Westin J, Nastoupil LJ, Lee HJ, Samaniego F, Parmar S, Wang M, Hawkins M, Adkins S, Fayad L, Steiner R, Nair R, Ahmed S, Fowler NH, Neelapu SS, Iyer SP. Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS. 2019 ASCO Annual Meeting 37(Suppl), 2019. e-Pub 2019.
Tam CS, Wang M, Simpson D, Opat S, Cull G, Munoz J, Phillips TJ, Kim W, Atwal S, Wei R, Huang J, Elstrom R, Trotman J. Updated Safety and Efficacy Data in the Phase 1 Trial of Patients with Mantle Cell Lymphoma (MCL) Treated with Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib (BGB-3111). 15-ICML 37(S2 Suppl):245-247, 2019. e-Pub 2019.
Jain P, Romaguera J, Nomie K, Zhang S, Wang L, Oriabure O, Wagner‐Bartak N, Zhang L, Hagemeister F, Samaniego F, Westin J, Lee HJ, Nastoupil L, Iyer S, Parmar S, Ok C, Kanagal‐Shamanna R, Chen W, Thirumurthi S, Santos D, Badillo M, Fayad L, Neelapu S, Fowler N, Wang M. Combination of ibrutinib with rituximab (IR) is highly effective in previously untreated elderly (>65 years) patients (pts) with mantle cell lymphoma (MCL) – phase II trial. 15-ICML 37(S2 Suppl):42, 2019. e-Pub 2019.
Zhang R, Lee W, Huang S, Liu Y, Leeming AH, McIntosh JM, Nomie KJ, Jiang CV, Wang M. Copanlisib and Volasertib overcome ibrutinib-venetoclax resistance via targeting PI3K-AKT signaling and G2/M cell cycle transition in mantle cell lymphoma. 15-ICML 37(S2 Suppl):126-127, 2019. e-Pub 2019.
Wang M, Gordon LI, Palomba ML, Abramson JS, Andreadis C, Ghosh N, Lunning M, Maloney D, Farazi T, Garcia J, Xie B, Newhall K, Dehner C, Siddiqi T. Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001. 2019 ASCO Annual Meeting 37(S2 Suppl):301-303, 2019. e-Pub 2019.
Yang F, Wang Y, Nowakowski GS, Wang M, Chintakuntlawar AV, Halfdanarson TR, Pagliaro LC, Wei J, Liu B, Molina JR, Markovic S. Association of sex, age and ECOG performance status with cancer immunotherapy efficacy in randomized controlled trials. 2019 ASCO Annual Meeting 37(Suppl), 2019. e-Pub 2019.
Jain P, Kanagal‐Shamanna R, Zhang S, Ok C, Nogueras Gonzalez G, Gonzalez‐Pagan O, Ghorab A, Boddu P, Chen W, Ju Lee H, Nomie K, Fayad L, Westin J, Nastoupil L, Patel K, Ahmed S, Iyer SP, Parmar S, Champlin R, Neelapu S, Medeiros JL, Romaguera J, Fowler N, Wang L, Wang ML. Comprehensive analysis of prognostic factors, outcomes and mutation profile in patients with aggressive histology (blastoid/pleomorphic) or transformed mantle cell lymphoma. 15-ICML 37(S2 Suppl):238-239, 2019. e-Pub 2019.
Strati P, Ahmed MA, Fowler NH, Hagemeister FB, Fayad L, Rodriguez MA, Samaniego F, Wang M, Westin J, Romaguera JE, Noorani M, Phansalkar K, Cheah C, Feng L, Davis RE, Nastoupil LJ, Neelapu SS. Prognostic value of baseline SUVmax in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy. 2019 ASCO Annual Meeting 37(Suppl), 2019. e-Pub 2019.
Willis L, Tanzola M, Caracio R, Lucero KS, Shah BD, Woyach JA, Furman RR, Wang M, Brown JR. Targeting B-cell malignancies: Impact of an educational curriculum on BTK inhibitors. 2019 ASCO Annual Meeting 37(Suppl), 2019. e-Pub 2019.
Wang Y, Zhou S, Yang F, Nowakowski GS, Habermann TM, Wang M, Witzig TE. Efficacy of frontline treatment regimens in follicular lymphoma: A network meta-analysis of phase III randomized controlled trials. 2019 ASCO Annual Meeting 37(Suppl), 2019. e-Pub 2019.
Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, Wu K, Bishton M, Collins G, Eliadis P, Peyrade F, Freise K, Sukbuntherng J, Lee Y, Dobkowska E, Fedorov V, Neuenburg J, Tam C. Results From the Safety Run-In Period of the SYMPATICO Study Evaluating Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma. 15-ICML 37(S2 Suppl):333-335, 2019. e-Pub 2019.
Strati P, Ahmed M, Fowler N, Hagemeister F, Fayad L, Rodriguez M, Samaniego F, Wang M, Westin JR, Romaguera J, Noorani M, Phansalkar K, Cheah C, Feng L, Davis RE, Nastoupil L, Neelapu SS. Prognostic value of pre-treatment PET scan in patients with follicular lymphoma receiving frontline therapy. 15-ICML 37(S2 Suppl):53-54, 2019. e-Pub 2019.
Guo H, Zhang H, Nomie K, Zhang L, Murfin KP, Wang M. Establishment and characterization of a novel MYC/BCL2 double-hit high-grade B-cell lymphoma cell line HLA-3. AACR Annual Meeting 2019 79(13), 2019. e-Pub 2019.
Liang R, Wang JH, Liu F, Duan XH, Hao XC, Zhang L, Wang M, Liu X, Guo YH, Wang Z, Tang H, Yang L. Research of miR-30b in Cisplatin Resistance of Human NK/T Cell Lymphoma Lines SNK-6 and YTS Cells By Targeting CCL22. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):5302, 2018. e-Pub 2018.
Ye H, Huang S, Jung D, Jiang C, Nomie K, Zhang L, Wang M. Simultaneous Inhibition of BCL-2 and PI3K Signaling Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):2950, 2018. e-Pub 2018.
Phillips TJ, Smith SD, Jurczak W, Robak T, Stevens D, Farber CM, Pagel JM, Maddocks KJ, Flinn IW, Jedrzejczak WW, Goy A, Zinzani PL, Zaucha J, Coleman M, Chen T, Lee SK, Liang W, Seto A, Wang M. Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstract) 132(Suppl 1):4144, 2018. e-Pub 2018.
Tam CS, Wang M, Simpson D, Opat S, Cull G, Munoz J, Phillips TJ, Kim WS, Hilger J, Huang J, Novotny W, Trotman J. Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):1592, 2018. e-Pub 2018.
Ahmed M, Guo H, Zhang S, Sehgal L, Jain P, Kanagal-Shamanna R, Ok CY, Leeming A, Yao Y, Zhang L, Nomie K, Wang L, Wang M. Unravelling the Heterogeneity of Mantle Cell Lymphoma Ecosystem By Single Cell RNA Sequencing. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):4118, 2018. e-Pub 2018.
Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Nogueras González GM, Ahmed M, Gonzalez-Pagan O, Ghorab A, Boddu PC, Chen W, Lee HJ, Badillo M, Nomie K, Fayad L, Nastoupil LJ, Champlin RE, Neelapu SS, Patel K, Medeiros LJ, Romaguera JE, Fowler NH, Wang L, Wang M. Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):1599, 2018. e-Pub 2018.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah BD, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Gouill SLE, Oberic L, Robak T, Dua R, Frigault MM, Izumi R, Nguyen D, Patel P, Yin M, Jurczak W. Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):2876, 2018. e-Pub 2018.
Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Ahmed M, Nava D, Badillo M, Nomie K, Patel K, Lee HJ, Hagemeister FB, Fayad L, Nastoupil LJ, Medeiros LJ, Neelapu SS, Romaguera JE, Fowler NH, Wang L, Wang M. Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):4151, 2018. e-Pub 2018.
Wang W, Carrie F, Guo H, Lee J, Li Y, Sukhanova M, Sheng D, Venkataraman G, Mei M, Lu P, Gao A, Xia C, Jia L, Zhang L, Wang M, Andrade J, Xiaoyan Z, Wang YLL. Inhibition of B-Cell Receptor Signaling Disrupts Cell Adhesion in Mantle Cell Lymphoma Via RAC2. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):1369, 2018. e-Pub 2018.
Sano D, Nastoupil LJ, Fowler NH, Fayad L, Hagemeister FB, Lee HJ, Samaniego F, Wang M, Rodriguez MA, Iyer SP, Parmar S, Steiner R, Nair R, Adkins S, Arafat S, Rao A, Vallejo L, Hawkins M, Chen Y, Westin JR, Neelapu SS. Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):96, 2018. e-Pub 2018.
Fowler NH, Jain P, Nastoupil LJ, Hagemeister FB, Forbes SG, Lagrone L, Fayad L, Lee HJ, Davis RE, Westin JR, Wang M, Neelapu SS, Samaniego F. Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R2) in Previously Untreated Follicular Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):1594, 2018. e-Pub 2018.
k N, Zhang L, y Y, Liu Y, Zhang S, Zhang H, Guo H, Ahmed M, Badillo M, Wang L, Wang M. Ibrutinib-Resistant Mantle Cell Lymphoma Undergoes Metabolic Reprogramming Towards Oxphos. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):41, 2018. e-Pub 2018.
Jain P, Nastoupil LJ, Kanagal-Shamanna R, Nogueras González GM, Noorani M, Romaguera JE, Fayad L, Samaniego F, Westin JR, Medeiros LJ, Neelapu S, Wang M, Fowler NH. Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):1600, 2018. e-Pub 2018.
Guo H, Yao Y, Zhang H, Lorence E, Ahmed M, Ping L, Nomie K, Zhang L, Wang M. FoxM1-Mediated Signaling Promotes the Progression of Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):4176, 2018. e-Pub 2018.
Zhang L, Zhang H, Guo H, Sun Y, Feng N, Marszalek JR, Ahmed M, Nomie K, Wang M. A Novel Patient-Derived Xenograft Model of Secondary CD20- CNS Lymphoma for Mechanistic and Therapeutic Exploration. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):1669, 2018. e-Pub 2018.
Yao Y, Liu Y, Guo H, Ahmed M, Bhuiyan S, Nomie K, Zhang L, Wang M. Metabolic Profiling Identifies De Novo Nucleotide Synthesis As a Potential Metabolic Vulnerability for Targeted Therapy Against Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 132(Suppl 1):2945, 2018. e-Pub 2018.
Fu S, Wang M, Zhao H, Li R, Lairson D, Giordano S, Zhao B, Du X. Effects of Rituximab, Bortezomib, and Bendamustine on the Survival in Medicare Beneficiaries with Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 18:S273-S274, 2018. e-Pub 2018.
Jiang C, Huang S, Liu Y, Nomie K, Zhang L, Wang M. Dual targeting of BTK and PLK1 causes lethal synergistic effects in mantle cell lymphoma. 2018 AACR Annual Meeting 78(13), 2018. e-Pub 2018.
Ahmed M, Lorence E, Guo H, Huang S, Zhang V, Zhang H, Zhang L, Nomie K, Wang M. Pan-cancer Pathways Gene Expression Profiling in Mantle Cell Lymphoma Reveals Upregulation of DNA Damage Repair Genes in Ibrutinib-Resistant Tumor. 2018 AACR Annual Meeting 78(13), 2018. e-Pub 2018.
Barta SK, Rasco DW, Chen AI, Elkins S, Wang M, Denis LJ, Toker S, Usansky H, Reddy S, Rao NS. Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myeolfibrosis (MF), chronic lymphocytic leukemia (CLL) and solid tumors. 2018 ASCO Annual Meeting 36(Suppl), 2018. e-Pub 2018.
Fu S, Wang M, Zhao H, Li R, Lairson DR, Giordano SH, Du XL. Effects of bendamustine, bortezomib, and rituximab on 1-year survival rates in elderly patients newly diagnosed with mantle cell lymphoma. 2018 ASCO Annual Meeting 36(Suppl), 2018. e-Pub 2018.
Wang M, Locke FL, Munoz J, Goy A, Holmes HE, Siddiqi T, Flinn I, McSweeney PA, Reagan PM, Hill BT, Jacobson CA, Rizzieri DA, Heffner LT, Jaglowski SM, Miklos DB, Shaughnessy P, Unabia S, Rossi JM, Jiang Y, Jain RK. ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma. 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
Abramson JS, Gordon LI, Palomba ML, Lunning MA, Arnason JE, Forero-Torres A, Wang M, Maloney DG, Sehgal A, Andreadis C, Purev E, Solomon SR, Ghosh N, Albertson TM, Xie B, Garcia J, Siddiqi T. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. 2018 ASCO Annual Meeting 36(Suppl), 2018. e-Pub 2018.
Abramson JS, Siddiqi T, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Wang M, Forero-Torres A, Albertson T, Dehner C, Garcia J, Li D, Xie B, Maloney DG. High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium 36(Suppl 5S), 2018. e-Pub 2018.
Siddiqi T, Abramson JS, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Wang M, Forero-Torres A, Maloney DG, Heipel M, Smith J, Brown W, Karimi M, Xie B, Li D, Albertson T, Garcia J, Dave K, DeVries T, Sutherland C. Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study). 2018 ASCO-SITC Clinical Immuno-Oncology Symposium 36(Suppl 5S), 2018. e-Pub 2018.
Jain P, Kanagal-Shamanna R, Ghorab A, Nastoupil L, Fayad LE, Medeiros J, Hu S, Neelapu SS, Westin JJ, Oki Y, Wang M, Fowler NH. Characteristics, Treatments, and Outcomes of Patients with Lymphomatoid Granulomatosis—MD Anderson Cancer Center Experience. Blood (2017 ASH Annual Meeting Abstract) 130(2852), 2017. e-Pub 2017.
Romaguera JE, Lee HJ, Tarapore R, Prabhu VV, Allen JE, Schalop L, Zloza A, Ok CY, Badillo M, Wang M. Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment. Blood (2017 ASH Annual Meeting Abstract) 130(5163), 2017. e-Pub 2017.
j B, Lam N, Wang M, Stroncek D, Maric I, Stetler-Stevenson M, Yuan C, Hartman S, Kanakry JA, Pavletic SZ, Feldman SA, Lawrence J, Patel R, Hansen B, Gress RE, Kochenderfer JN. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor with a CD28 Costimulatory Moiety Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. Blood (ASH Annual Meeting Abstract) 130(Suppl 1):524, 2017. e-Pub 2017.
Maloney DG, Abramson JS, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Wang M, Forero A, Albertson T, Garcia J, Li D, Xie B, Siddiqi T. Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration. Blood (ASH Annual Meeting Abstract) 130(Suppl 1):1552, 2017. e-Pub 2017.
Huang S, Jiang C, Guo H, Wang J, Liu Y, Li CJ, Lopez E, Zhang H, Lorence EA, Merolle M, Balaji S, Ahmed M, Nomie K, Zhang L, Wang M. Resistance Mechanisms Underlying Venetoclax Resistance in Mantle Cell Lymphoma. Blood (2017 ASH Annual Meeting Abstract) 130(2749), 2017. e-Pub 2017.
Byrd JC, Owen R, O'Brien SM, Brown JR, Hillmen P, Bitman B, Chernyukhin N, Hamdy A, Izumi R, Patel P, Schwartz-Sagi L, Tucker E, Fowler N, Streetly MJ, Wiestner A, Rule S, Wang M. Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies. Blood (2017 ASH Annual Meeting), 2017. e-Pub 2017.
Tam CS, Simpson D, Opat S, Kin WS, Wang M, Cull G, Johnston PB, Munoz J, Lee WS, Marton P, Gottlieb D, Wang L, Huang J, Hilger J, Xue L, Ro S, Trotman J. Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma. Blood (2017 ASH Annual Meeting Abstract) 130(152), 2017. e-Pub 2017.
Jaing C, Huang S, Liu Y, Li C, Guo H, Wang J, Lopez E, Zhang H, Lorence EA, Merolle M, Balaji S, Ahmed M, Nomie K, Lin X, Zhang L, Wang M. Targeting the Paracaspase MALT1: A Potential Therapy to Overcome Ibrutinib Resistance in Relapsed/Refractory Mantle Cell Lymphoma Patients. Blood (2017 ASH Annual Meeting Abstract) 130(574), 2017. e-Pub 2017.
Manasanch EE, Lee HC, Patel KK, Weber DM, Lee HJ, Thomas SK, Chen W, Oriagure O, Badillo M, Graham V, Lei F, McCarthy MS, Orlowski RZ, Wang M. A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma. Blood (2017 ASH Annual Meeting Abstract) 130(3090), 2017. e-Pub 2017.
Zhang L, Nomie K, Zhang S, Liu Y, Guo H, Huang S, Wang J, Lopez E, Zhang H, Lorence EA, Merolle M, Balaji S, Ahmed M, Jiang C, Wang L, Wang M. Molecular Pathways Associated with Ibrutinib Resistance in Mantle Cell Lymphoma. Blood (2017 ASH Annual Meeting Abstract) 130(2738), 2017. e-Pub 2017.
Siddiqi T, Abramson JS, Li D, Brown W, Devries T, Dave K, Garcia J, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Wang M, Forero-Torres A, Maloney DG, Albertson T, Sutherland CL. Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017. Blood (2017 ASH Annual Meeting Abstract) 130(193), 2017. e-Pub 2017.
Becnel MR, Nastouil L, Davis RE, Hagemesiter FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Claret L, Forbes SG, Feng L, Samaniego F, Neelapu SS, Fowler N. Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial. Blood (2017 ASH Annual Meeting Abstract) 130(4040), 2017. e-Pub 2017.
Guo H, Zhang H, Ahmed M, Liu Y, Huang S, Zhang V, Wang J, Lopez E, Lorence EA, Wang J, Balaji S, Merolle M, Jiang C, Nomie K, Wang M, Zhang L. FoxM1: A New Therapeutic Target for Mantle Cell Lymphoma. Blood (2017 ASH Annual Meeting Abstract) 130(1469), 2017. e-Pub 2017.
Wang Y, Wang Y, Thanarajasingam G, Thompson CA, Habermann TM, Nowakowski GS, Wang M. Second Primary Malignancies in Patients with Non-Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstract) 130(Suppl 1):2152, 2017. e-Pub 2017.
Gerson JN, Barta SK, Villa D, Gerrie AS, Li S, Medeiros J, Wang M, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Fenske TS, Rao SN, Maddocks KJ, Bond DA, Lansigan F, Burns T, Donovan AM, Mehta A, Reddy N, Landsburg DJ, Glenn M, Inwards DJ, Ristow K, Karmali R, Kaplan J, Umyarova E, Pulluri B, Amengual JE, Lue JK, Caimi P, Cohen JB, Calzada O, Handorf E, Anderson JK, Chapani P, Bachanova V, Rajguru S, Churnetski MC, Diefenbach C, Bast M, Kovach AE. Consolidation with Autologous Hematopoietic Cell Transplant in First Remission Improves Overall Survival in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era. Blood (ASH Annual Meeting Abstract) 130(341), 2017. e-Pub 2017.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Wang M, Forero A, Maloney DG, Albertson T, Garcia J, Li D, Xie B, Siddiqi T. High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort. Blood (2017 ASH Annual Meeting Abstract) 130(581), 2017. e-Pub 2017.
Strati P, Oki Y, Fayad LE, Nastoupil L, Fowler NH, Hagemesiter FB, Kwak LW, Lee HJ, Wang M, Westin JR, Ruben C, Wesson E, Fanale MA. A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas. Blood (2017 ASH Annual Meeting Abstract) 130(4074), 2017. e-Pub 2017.
Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, Hernandez-Rivas JA, Londhe A, Clow F, Deshpande S, Parisi L Wang M. Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis. Blood (2017 ASH Annual Meeting Abstract) 130(151), 2017. e-Pub 2017.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas RO, Smith SD, Damaj G, Doorduijin JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Gouill SL, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Slatter JG Jurczak W. Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study. Blood (2017 ASH Annual Meeting Abstract) 130(155), 2017. e-Pub 2017.
Wang Y, Wang Y, Wang M, Thanarajasingam G, Thompson C, Nowakowski G, Habermann T, Ansell S, Witzig T. Clinical Characteristics and Outcome of Transformed Diffuse Large B-Cell Lymphoma in the Rituximab Era: A SEER Database Analysis. Proceedings of the Society of Hematologic Oncology 2017 Annual Meeting, 2017. e-Pub 2017.
Wang M. Chemotherapy for MCL Debate: The Positive Side. Proceedings of the Society of Hematologic Oncology 2017 Annual Meeting, 2017. e-Pub 2017.
Huang S, Bell T, Liu Y, Guo H, Li C, Ahmed M, Lam L, Zhang H, Chen Z, Wang ML, Zhang L, Nomie K. Preclinical examination of the effects of MT-3724, an engineered toxin body targeting CD20, in mantle cell lymphoma. AACR Annual Meeting 77(13 Suppl), 2017. e-Pub 2017.
Hu B, Loghavi S, Fayad L, Noorani M, Fowler NH, Hagemeister FB, Lee HJ, Nastoupil LJ, Neelapu SS, Fanale MA, Samaniego F, Turturro F, Wang M, Davis RE, Westin JR, Medeiros LJ, Oki Y. Outcomes of de novo CD5+ diffuse large b-cell lymphoma (DLBCL) in the rituximab (R) era. 2017 ASCO Annual Meeting 35(Suppl), 2017. e-Pub 2017.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Forero-Torres A, Wang M, Albertson TM, Allen T, Sutherland C, Xie B, Garcia J, Siddiqi T. CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001). 2017 ASCO Annual Meeting 35(Suppl), 2017. e-Pub 2017.
Chen W, Zeng D, Desai A, Badillo M, Feng L, Yan F, Nomie K, Ping L, Ye H, Liang Y, Lee H, Oki Y, Romaguera J, Wang M. Improved outcome for patients with relapsed/refractory mantle cell lymphoma (MCL) who stop ibrutinib +/− rituximab for reasons other than progression of disease. 14-ICML 35(S2 Suppl):360, 2017. e-Pub 2017.
Tam CS, Rule S, Le Gouill S, Vitolo U, Tsao LC, Cavazos N, Beaupre DM, Wang M. Phase 3 Study of Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). 17th International Conference on Malignant Lymphoma (ICML), Lugano 35(S2):421-422, 2017. e-Pub 2017.
Rasco DW, O'Rourke TJ, Chen AI, Wang M, Tolcher AW, Rao NS, Denis LJ, Reddy S, Barta SK. Clinical activity, safety and tolerability of ASN002, a dual SYK/JAK inhibitor, in patients non-Hodgkin lymphoma (NHL) and solid tumors. 2017 ASCO Annual Meeting 35(Suppl), 2017. e-Pub 2017.
Bell T, Zhang H, Ahmed M, Guo H, Li CJ, Liu Y, Lam LT, Chen Z, Wang J, Zhang V, Nomie K, Zhang L, Wang M. Patient-Derived Xenograft Model in B-Cell Lymphoma: A Platform for a Personalized Clinical Trial. Blood (2016 ASH Annual Meeting Abstract) 128(1839), 2016. e-Pub 2016.
Liu Y, Bell T, Zhang H, Sun Y, Li CJ, Feng N, Huang S, Guo H, Wang J, Ahmed M, Zhang V, Lam LT, Nomie K, Zhang L, Di Francesco ME, Marszalek J, Wang M. Targeting Oxphos Pathway Against Ibrutinib Resistance to Mantle Cell Lymphoma. Blood (2016 ASH Annual Meeting Abstract) 128(290), 2016. e-Pub 2016.
Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Medeiros J, Davis RE, Oki Y. The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma. Blood (2016 ASH Annual Meeting Abstracts) 128(4153), 2016. e-Pub 2016.
Sathyanarayanan V, Oki Y, Issa AK, Ahmed MA, Noorani M, Fanale MA, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler N, Turturro F, Davis ER, Rodriguez A, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience. Blood (2016 ASH Annual Meeting Abstract) 128(106), 2016. e-Pub 2016.
Nooka AK, Wang M, Yee AJ, Thomas SK, O'Donnell EK, Shah JJ, Kaufman JL, Peterkin D, Lonial S, Richardson PG, Raje N. Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood (2016 ASH Annual Meeting Abstract) 128(2124), 2016. e-Pub 2016.
Wang M, Lee HJ, Thirumurthi S, Chuang HH, Hagemeister, FB, Westin JR, Fayad LE, Samaniego F, Turturro F, Chen W, Oriabure O, Huang SY, Li S, Zhang L, Badillo M, Hartig KH, Ahmed M, Nomie K, Lam LT, Addison AA, Romaguera JE. Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial. Blood (2016 ASH Annual Meeting), 2016. e-Pub 2016.
Jain P, Kanagal-Shamanna R, San Lucas F, Wang M, Romaguera JE, Fayad LE, Oki Y, Westin JR, Medeiros J, Fowler N. Characteristics, outcomes and pattern of mutations in follicular lymphoma patients who progressed on BTK inhibitors. Blood (2016 ASH Annual Meeting) 128(22):2975, 2016. e-Pub 2016.
Huo H, Huang S, Liu Y, Li CJ, Wang J, Zhang V, Ahmed M, Lam LT, Zhang H, Nomie K, Zhang L, Wang M. Genetic and Molecular Characterization of Ibrutinib-Resistant Mantle Cell Lymphoma: Designing Innovative Therapeutic Strategies. Blood (2016 ASH Annual Meeting Abstract) 128(1838), 2016. e-Pub 2016.
Boyle JN, Kim CR, Guo H, Bell T, Huang S, Li CJ, Liu Y, Zhang H, Wang J, Zhang V, Ahmed M, Lam LT, Nomie K, Zhang L, Zeng D, Wang M. CUDC-907: An Oral HDAC/PI3K Dual Inhibitor with Strong Preclinical Efficacy in MCL Model. Blood (2016 ASH Annual Meeting Abstract) 128(4183), 2016. e-Pub 2016.
Simar KA, Sathyanarayanan V, Issa AK, Ahmed MA, Noorani M, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil L, Fowler N, Turturro F, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience. Blood (2016 ASH Annual Meeting Abstract) 128(4208), 2016. e-Pub 2016.
Sun B, Fiskus W, Zhang L, Raina K, Coleman K, Winkler J, Qian Y, Crew A, Shen A, Saenz DT, Mill CP, Wang M, Crews C, Bhalla KN. Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells. Blood (2016 ASH Annual Meeting Abstract) 128(1058), 2016. e-Pub 2016.
Jain P, Kanagal-Shamanna R, Lucas FS, Wang M, Romaguera JE, Fayad LE, Oki Y, Westin JR, Medeiros J, Fowler N. Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib). Blood (2016 ASH Annual Meeting Abstracts) 128(2975), 2016. e-Pub 2016.
Wang M, Pasi KJ, Pabinger I, Kerlin BA, Kulkarni R, Nolan B, Liesner R, Brown SA, Hanabusa H, Tsao E, Winding B, Lethagen S, Jain N. Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia. Blood (2016 ASH Annual Meeting Abstract) 128(3791), 2016. e-Pub 2016.
Wang M, Martin P, Phillips T, Goy A, Lossos IS, Rule SA, Hamadani M, Ghosh N, Reeder CB, Barnett E, Casadebaig Bravo M, Schuster SJ. Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study. 58th ASH Annual Meeting 128(22):1786, 2016. e-Pub 2016.
Huang S, Nastoupil LJ, Guo H, Bell T, Ahmed M, Li CJ, Wang J, Liu Y, Zhang V, Kim CR, Boyle JN, Lorence EA, Lam LT, Chen Z, Zhang H, Shuttleworth SJ, Nomie K, Wang M, Zhang L. Pre-Clinical Evaluation of the PI3K-p110β/δ Inhibitor KA2237 in Mantle Cell Lymphoma. Blood (2016 ASH Annual Meeting Abstracts) 128(1837), 2016. e-Pub 2016.
Li CJ, Liu Y, Bell T, Wang J, Guo H, Ahmed M, Zhang H, Lam LT, Nomie K, Wang L, Liang Z, Wang M. Novel Bruton's Tyrosine Kinase Inhibitor Bgb-3111 Demonstrates Potent Activity in Mantle Cell Lymphoma. Blood (2016 ASH Annual Meeting Abstract) 128(5374), 2016. e-Pub 2016.
Saksena A, Miao Y, Lin P, Wang M, Yin CC, Li J, Medeiros LJ, Li S. CD5 Negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Cases. Blood (2016 ASH Annual Meeting Abstract) 128(2964), 2016. e-Pub 2016.
Bhalla K, Sun B, Fiskus W, Zhang L, Saenz D, Mill C, Wang M. Novel BRD4-Degrading Proteolysis Targeting Chimera (PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma (MCL) Cells. Proceedings of the Society of Hematologic Oncology 2016 Annual Meeting, 2016. e-Pub 2016.
Zhang L, Pham L, Zhang H, Xie J, Tao W, Bell T, Chen Z, Fang B, Wang M, Nomie K. B-cell lymphoma patient-derived xenograft models: The road to personalized therapy. AACR Annual Meeting 2016 22(16 Suppl), 2016. e-Pub 2016.
Zhang L, Pham L, Zhang H, Xie J, Tao W, Bell T, Chen Z, Nomie K, Fang B, Wang M. Overcoming primary ibrutinib resistance in mantle cell lymphoma. AACR Annual Meeting 2016 76(14 Suppl), 2016. e-Pub 2016.
Rule S, Dreyling M, Hess G, Auer R, Brad K, Cavazos, N, Liu B, Clow F, Goldberg J, Beaupre D, Vermeulen J, Wildgust M, Wang M. Overall Survival Outcomes in Patients with Mantle Cell Lymphoma Treated with Ibrutinib in a Pooled Analysis of 370 Patients from Three International Open Label Studies. 21st EHA Conference, 2016. e-Pub 2016.
Locke FL, Wang M, Siddiqi T, Castro JE, Shah BD, Lee HJ, Budde LE, Choi MY, Anasetti C, Champlin RE, Forman SJ, Kipps TJ, Bot A, Jiang Y, Elias M, Wiezorek JS, Go WY. ZUMA-2: A phase 2 multicenter study evaluating the efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with relapsed/refractory mantle cell lymphoma (r/r MCL). 2016 ASCO Annual Meeting, 2016. e-Pub 2016.
Issa A, Sathyanarayanan V, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler NH, Turturro F, Noorani M, Ahmed MA, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnel T, Pinnix CC, Fayad L, Westin JR. Outcomes of Diffuse Large B-cell Lymphoma with MYC and/or BCL2 Protein Expression Treated with Intensive Chemotherapy. 2016 ASCO Annual Meeting, 2016. e-Pub 2016.
Lee HJ, Andreeff M, Benes C, Allen JE, Lee S, Oster W, Wang M. First-in-class Small Molecule ONC201 in B-cell Malignancies. 2016 ASCO Annual Meeting 34(Suppl), 2016. e-Pub 2016.
Wang M, Martin P, Phillips T, Goy A, Lossos IS, Rule S, Hamadani M, Ghosh N, Kuzma C, Reeder CB, Barnett E, Bravo MC, Schuster S. Efficacy and Safety of Lenalidomide in Mantle Cell Lymphoma Patients who Relapsed, were Refractory to, or Progressed after Treatment with Ibrutinib: The MCL-004 Study. 21st Congress EHA 2016, 2016. e-Pub 2016.
Avet-Loiseau, Fonseca R, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosinol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos M, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Obreja M, Moreau P. Efficacy and Safety by Cytogenetic Risk Status: Phase 3 Study (ASPIRE) of. 21st Congress of the European-Hematology-Association, 2016. e-Pub 2016.
Dimopoulos MA, Stewart KA, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Obreja M, Aggarwal S, Moreau P, Palumbo A. Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis of Response and Progression-Free Survival Hazard Ratio Over Time. 21st EHA Conference, 2016. e-Pub 2016.
Shah JJ, Feng L, Weber D, Thomas SK, Wang M, Turturro F, Qazilbash MH, Shah N, Bashir O, Popat UR, Manasanch EE, Munoz SC, Landry A, Mendoza K, Nieto Y, Champlin RE, Orlowski RZ. Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood (2015 ASH Annual Meeting Abstract) 126(23):3155, 2015. e-Pub 2015.
Chen C, Garzon R, Gutierrez M, Jacoby MA, Brown P, Flinn I, Stone RM, Savoie ML, Baz R, Gabrail NY, Wang M, Martin P, Siegel D, Mau-sorensen M, Andreef M, Marshall T, Saint-Martin JR, Carlson R, Shacham S, Kauffman M, Kuruvilla J. Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330). Blood (2015 ASH Annual Meeting Abstracts) 126(258), 2015. e-Pub 2015.
Chihara D, Ahmed MA, Oki Y, Westin JR, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez A, Fowler N, Wang M, Fayad LE, Davis RE, Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). 57th Annual ASH Meeting & Exposition, 2015. e-Pub 2015.
Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosinol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Tonda M, Obreja M, Moreau P. Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire. Blood (2015 ASH Annual Meeting Abstracts) 126(731), 2015. e-Pub 2015.
Pham L, Zhang L, Tao W, Zhao D, Zhang H, Xie J, Wang J, Nomie K, Wang M. Developing Novel Therapeutic Strategies to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma. Blood (2015 ASH Annual Meeting Abstracts) 126(707), 2015. e-Pub 2015.
Jain P, Patel KP, Futreal A, Gumbs C, Hu S, Ramos CB, Wang M, Romaguera J, Fayad LE, Orlowski RZ, Medeiros J, Fowler N. Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS). Blood (2015 ASH Annual Meeting Abstracts) 126(2700), 2015. e-Pub 2015.
Shah JJ, Feng L, Thomas SK, Weber D, Wang M, Manasanch EE, Mendoza K, Orlowski RZ. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood (2015 ASH Annual Meeting Abstract) 126(23):376, 2015. e-Pub 2015.
Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Tonda M, Obreja M, Moreau P. Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). Blood (2015 ASH Annual Meeting Abstract) 126(23):731, 2015. e-Pub 2015.
Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood (2015 ASH Annual Meeting Abstract) 126(23):2738, 2015. e-Pub 2015.
Sun B, Fiskus W, Saenz DT, Krieger S, Zhang L, Parmar S, Wang M, Bhall KN. BET Protein Bromodomain Antagonist-Based Combinations Exert Synergistic Pre-Clinical Activity Against Ibrutinib-Sensitive or -Resistant Human Mantle Cell Lymphoma (MCL) Cells. Blood (2015 ASH Annual Meeting Abstracts) 126(3704), 2015. e-Pub 2015.
Nooka AK, Wang W, Yee AJ, Thomas SK, O'Donnell EK, Shah JJ, Kaufman JL, Lonial S, Richardson PG, Raje NS. Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood (2015 ASH Annual Meeting Abstract) 126(4246), 2015. e-Pub 2015.
Wang Y, Wagner-Bartak N, Zhou S, Fowler N, Dela Rosa ML, Zhao D, Romaguera JE, Neelapu SS, Hagemeister FB, Fanale MA, Oki Y, Shah JJ, Thomas SK, Hosing CM, Zhang L, Badillo M, Chen W, Cai Q, Zou D, Champlin RE, Fayad LE, Lee HJ, Wang M. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. Blood (2015 ASH Annual Meeting Abstracts) 126(3969), 2015. e-Pub 2015.
Ali SA, Shi V, Wang M, Stroncek D, Maric I, Brudno JN, Stetler-Stevenson M, Rose JJ, Feldman S, Hansen B, Hakim FT, Gress RE, Kochenderfer JN. Remissions of multiple myeloma during a first-in-humans clinical trial of T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor. Blood (2015 ASH Annual Meeting Abstract) 126(23):LBA-1, 2015. e-Pub 2015.
Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguea A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. Blood (2015 ASH Annual Meeting Abstracts) 126(3984), 2015. e-Pub 2015.
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen J, Wang Z, Ma W, Lee H, Orlowski RZ, Sarbassov DD, Neelapu SS, McDonnell TJ, Miranda RN, Wang W, Kantarjian HM, Konopleva M, Davis RE, Andreeff M. ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response. Blood (2015 ASH Annual Meeting Abstract) 126(2051), 2015. e-Pub 2015.
Wang B, Zhang L, Pham L, Tao W, Zhang H, Xie J, Chen W, Cai Q, Zou D, Zhao D, Sun X, Liang R, Wang J, Nomie K, Fowler N, Wang M. The Identification of Novel Therapies for the Treatment of Follicular Dendritic Cell Sarcoma. Blood (2015 ASH Annual Meeting Abstract) 125(5126), 2015. e-Pub 2015.
Poggesi I, Sardu ML, Marostica E, Sukbuntherng J, Chang BY, de Jong J, de Trixhe XW, Vermeulen A, De Nicolao G, O'Brien SM, Byrd JC, Advani RH, James DF, Deraedt W, Beaupre D, Wang M. Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies. AACR Annual Meeting 2014 21(17 Suppl), 2015. e-Pub 2015.
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov DD, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. First-in-class Anti-tumor Agent ONC201 Induces Apoptosis in Hematological Malignancies with Wild Type and Mutant p53. Proceedings of the Society of Hematologic Oncology 2015 Annual Meeting, 2015. e-Pub 2015.
Pinnnix CC, Dabaja BS, Milgrom S, Smith G, Abou Z, Shank J, Romaguera J, Turturro F, Fowler N, Fayad L, Nastoupil L, Westin J, Neelapu S, Rodriguez MA, Fanale MA, Hagemesiter F, Lee, HJ, Oki Y, Wang M, Samaniego F, Morrell GG, Chi L, Esmaeli B. Ultra Low Dose Radiation Therapy for the Definitive Management of Ocular Adnexal B-Cell Lymphoma. 13th International Conference on Malignant Lymphoma (ICML), Lugano, 2015. e-Pub 2015.
Garzon R, Wang M, Kuruvilla J, Gutierrez M, Savoie L, Mau-Sørensen M, Flinn I, Baz R, Martin P, Gabrail N, Goy A, Brown P, Rashal T, Carlson R, Elloul S, Friedlander S, Saint-Martin J, Frenkel R, Raza-Mirza M, Norori S, Shacham S, Kauffman M, Wagner-Johnston N. Selinexor shows activity in double-hit diffuse large B-cell lymphoma in pre-clinical models and in patients with relapsed/refractory double-hit DLBCL. 13-ICML 33:179-180, 2015. e-Pub 2015.
Wang M, Lee HJ, Chuang H, Hagemeister FB, Westin JJ, Fayad LE, Samaniego F, Turturro F, Chen W, Zhang L, Badillo M, Dela Rosa M, Addison A, Romaguera JE. Ibrutinib in combination with rituximab for relapsed mantle cell lymphoma: An update from a Phase II clinical trial. 13th International Conference on Malignant Lymphoma, Lugano, 2015. e-Pub 2015.
Lee HJ, Kim P, Badillo M, Romaguera J, Wang M. Atrial Fibrillation in Ibrutinib Treated Relapsed Mantle Cell Lymphoma, Clinical and Laboratory Analysis of Risk Factors. 13-ICML 33:208, 2015. e-Pub 2015.
Ahmed MA, Chihara D, Vargas N, Ma L, Fayad LE, Oki Y, Hagemeister FB, Romaguera JE, Turturro F, Fowler N, Rodriguez MA, Samaniego F, Fanale MA, Nastoupil L, Wang M, Lee HJ, Kwak LW, Noorani M, Davis RE, Westin JR, Neelapu SS. Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma After Second Salvage Therapy: MD Anderson Experience. 13-ICML 33:279-280, 2015. e-Pub 2015.
Wang Y, Shen Y, Yang F, Sanchez LJ, Guan X, Tsu-Shih Chang V, Wang M. Rituximab maintenance Therapy in B-cell lymphoma: A meta-analysis. 2015 ASCO Annual Meeting 33(Suppl), 2015. e-Pub 2015.
Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Yasuhiro O. Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL). 2015 ASCO Annual Meeting 33(Suppl), 2015. e-Pub 2015.
Wang Y, Dela Rosa M, Zhou S, Badillo M, Addison A, Zhang L, Lee HJ, Romaguera JE, Wang M. Lenalidome in combination with rituximab for relapsed or refractory mantle cell lymphoma: Updated analysis of a phase 2 trial. 2015 ASCO Annual Meeting 33(Suppl), 2015. e-Pub 2015.
Phansalkar K, Ahmed MA, Fowler N, Ma L, Noorani M, Lee ST, Feng L, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale MA, Wang M, Oki Y, Turturro F, Westin JR, Nastoupil LJ, Kwak LW, Davis RE, Neelapu SS. R-Bendamustine Vs R-CHOP As Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Blood (2014 ASH Annual Meeting) 124(21):3048, 2014. e-Pub 2014.
Balasubramanian S, Schaffer M, Deraedt W, Davis C, Stepanchick E, Aquino R, Yuan Z, Kranenburg B, Avivi I, Dreyling M, Rule S, Wang M, Zhuang SH, Rizo A, Lenz G. Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL). Blood (2014 ASH Annual Meeting Abstracts) 124(21), 2014. e-Pub 2014.
Chen Y, Rodriguez MA, Feng L, Bi W, Zhang L, Wang M. Peripheral Absolute Neutrophil, Mmonocyte and Lymphocyte Counts and Clinical Ooutcome in Diffuse Large B-Cell Lymphoma. Blood (2014 ASH Annual Meeting Abstract) 124(21):4416, 2014. e-Pub 2014.
Wang Y, Zhang W, Yang F, Guan X, Kothari N, Chang V, Wang M. Bortezomib-Containing Regimens for Multiple Myeloma Maintenance Therapy: a Meta-Analysis. Blood (2014 ASH Annual Meeting Abstract) 124(21):3473, 2014. e-Pub 2014.
Wang M, Nooka AK, Yee AJ, Thomas SK, O'Donnell E, Shah J, Weber DM, Kaufman JL, Lonial S, Avigan D, Raje N. Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood (2014 ASH Annual Meeting Abstract) 124(21):4737, 2014. e-Pub 2014.
Wang Y, Yang F, Zhang W, Guan X, Kothari N, Chang V, Wang M. The Efficacy and Safety of Immunomodulatory Drugs in Multiple Myeloma Maintenance Therapy: Results of a Meta-Analysis. Blood (2014 ASH Annual Meeting Abstract) 124(21):3477, 2014. e-Pub 2014.
Tsourdinis G, Park H, Sun L, Fokt I, Jayakumar A, Zhang H, Cai Q, Zou D, Fang B, Priebe W, Wang M, Zhang L. Potent Inhibition of the Growth and Induction of Apoptosis of Mantle Cell Lymphoma By the Novel Anthracycline Berubicin in Vitro and in Vivo. Blood (2014 ASH Annual Meeting) 124(21):3106, 2014. e-Pub 2014.
Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani R, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson PW, Spurgeon SE, Zhang L, Baher L, Cheng M, Beaupre DM, Blum KA. Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. Blood (2014 ASH Annual Meeting Abstracts) 124(21), 2014. e-Pub 2014.
Park H, Zhao D, Tsourdinis G, Ou Z, Tamayo AT, Ford RJ, Fang B, Pham LV, Zhang L, Wang M. STAT3 Activation Is Preceded By Two Independent Pathways (BCR-BTK and IL6-JAK) in Mantle Cell Lymphoma. Blood (2014 ASH Annual Meeting Abstract) 124(21):3028, 2014. e-Pub 2014.
Siegel DS, Berdeja JG, Infante JR, Kaufman JL, Wang M, Martin TG, Niesvizky R, Reu FJ, Jagannath S, Rajangam K, Huang M, Vij R. Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010). Blood (2014 ASH Annual Meeting Abstract) 124(21):2134, 2014. e-Pub 2014.
Zhang L, Zhang H, Zhao D, Tsourdinis G, Park H, Tamayo AT, Pham LV, Ford RJ, Fang B, Wang M. Anti-CD20 and B-Cell Receptor-Mediated Growth Inhibition and Apoptosis: A Preclinical Study of Ibrutinib and Rituximab Combination Therapy in Mantle Cell Lymphoma in Vitro and in Vivo. Blood (2014 ASH Annual Meeting Abstract) 124(21):1774, 2014. e-Pub 2014.
Pham LV, Tamayo AT, Pogue E, Lu G, Challagundla P, Jorgensen JL, Zhang L, Wang M, Ford RJ. The Tumor Microenvironment in Mantle Cell Lymphoma (MCL): Novel Targets to Overcome Chemo-Resistance in MCL. Blood (2014 ASH Annual Meeting Abstract) 124(21):494, 2014. e-Pub 2014.
Ahmed MA, Fowler N, Ma L, Noorani M, Phansalkar K, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin JR, Kwak LW, Nastoupil LJ, Cheah C, Feng L, Rohren EM, Davis RE, Neelapu SS. SUVmax on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy. Blood (2014 ASH Annual Meeting Abstract) 124(21):1629, 2014. e-Pub 2014.
Wang M, Goy A, Martin P, Ramchandren R, Alexeeva J, Popat R, Avivi I, Advani R, Le Gouill S, Horowitz N, Yuan Z, Kranenburg B, Rizo A, Zhuang SH, Deraedt W, Rule S. Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy. Blood (2014 ASH Annual Meeting Abstracts) 124(21), 2014. e-Pub 2014.
Samaniego F, Sehgal L, Braun FK, Berkova Z, Romaguera JE, Wang M, Rodriguez MA, Neelapu SS, Mathur R. Molecular Signatures of Tumor-Initiating Cells Unveil Wnt Pathway As a Therapeutic Target in Mantle Cell Lymphoma. Blood (2014 ASH Annual Meeting) 124(21):2148, 2014. e-Pub 2014.
Oki Y, Fanale MA, Romaguera JE, Fayad L, Fowler N, Copeland ARM, Samaniego F, Kwak LW, Neelapu SS, Wang M, Feng L, Younes A. Phase II Study of an AKT Inhibitor MK2206 in Patients with Relapsed or Refractory Lymphoma. Blood (2014 ASH Annual Meeting Abstract) 124(21):3093, 2014. e-Pub 2014.
Tsourdinis G, h P, Sun L, Fokt I, Jayakumar A, Zhang H, Cai Q, Zou D, Fang B, Priebe W, Wang M, Zhang L. Potent Inhibition of the Growth and Induction of Apoptosis of Mantle Cell Lymphoma By the Novel Anthracycline Berubicin in Vitro and in Vivo. Blood (2014 ASH Annual Meeting Abstract) 124(21):3106, 2014. e-Pub 2014.
Wang M, Hagemeister F, Westin JR, Fayad L, Samaniego F, Turturro F, Chen W, Zhang L, Badillo M, DeLa Rosa M, Addison A, Kwak LW, Romaguera JE. Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial. Blood (2014 ASH Annual Meeting Abstract) 124(21):627, 2014. e-Pub 2014.
Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. AACR Annual Meeting 2014 21(17 Suppl), 2014. e-Pub 2014.
Thomas SK, Melendez G, Feng L, Wang M, Neelapu SS, Shah JJ, Orlowski RZ, Weber DM. Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) Waldenström's macroglobulinemia (WM). 2014 ASCO Annual Meeting 32, 2014. e-Pub 2014.
Thomas SK, Mendoza TR, Dougherty PM, Williams LA, Wang XS, Prasad S, Shah N, Shah JJ, Wang M, Weber DM, Orlowski RZ, Giralt S, Cleeland CS. A phase 2 trial of minocycline versus placebo to prevent neuropathy in patients (pts) with multiple myeloma (MM). 2014 ASCO Annual Meeting 32, 2014. e-Pub 2014.
Nastoupil LJ, Neelapu SS, Samaniego F, Hagemeister FB, Romaguera JE, Kwak LW, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, McLaughlin P, Fowler N. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. 2014 ASCO Annual Meeting 32, 2014. e-Pub 2014.
Orlowski RZ, Zaman S, Thomas SK, Alexanian R, Shah JJ, Weber DM, Wang M, Holloway AN, Baladandayuthapani V, Lin HY, Fu M, Stellrecht CM, Morales de Partovi C, Gandhi V. Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM). Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Dominici EM, Lopez ER, Vang MT, Tamayo AT, Ou Z, Rollo A, Zhang L, Wang J, Strickland LM, Wang M, Ford RJ, Pham LV, Kirk CJ. Carfilzomib, a Second-Generation Proteasome Inhibitor, In Combination With The Btk Inhibitor Ibrutinib As a Novel Therapeutic Regimen For Treating Double Hit DLBCL. Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Romaguera RE, Fanale MA, Samaniego F, Fayad LE, Hagemeister FB, McLaughlin P, Rodriguez MA, Weaver P, Hartig K, Badillo M, Kwak LW, Younes A, Pro B, Wang M. Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL). Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Shah JJ, Feng L, Thomas SK, Weber DM, Wang M, Hilder B, Alexanian R, Orlowski RZ. Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM). Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Oki Y, Noorani M, Davis RE, Neelapu SS, Rodriguez A, Hagemeister FB, Folwer N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, Fayad LE. Double Hit Lymphoma: M.D. Anderson Experience. Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Shah RA, Mohite S, Baladandayuthapani V, Thomas SK, Weber DM, Wang M, Alexanian R, Qazilbash MH, Popat UR, Champlin RE, Shah N, Bashir Q, Parmar S, Nieto Y, Ahmed S, Orlowski RZ, Shah JJ. Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Pham LV, Vang MT, Tamayo AT, Ou Z, Rollo A, Zhang L, Dominici EM, Lopez ER, Pham J, Wang J, Strickland LM, Wang M, Ford RJ. The Role Of Mir-155 In Controlling Key Growth and Survival Pathways In ABC-Subtype DLBCL. Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Brett LK, Axelrod M, Ou Z, Zhang L, Gordon V, Lopez ER, Tamayo AT, Ford RJ, Pham LV, Weber MJ, Williamsn ME, Wang M. Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL). Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Vij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DS. Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma. Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Alagappan A, Shah RA, Thomas SK, Weber DM, Wang M, Alexanian R, Orlowski RZ, Shah JJ. Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib. Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Zhang L, Ou Z, Wang J, Dominici EM, Zhang H, Ford RJ, Wang M, Pham LV. Ibrutinib Overcomes Carfilzomib Resistance In Immunoproteasome-Deficient Mantle Cell Lymphoma. Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Nieto Y, Shah N, Popat UR, Jones RB, Bashir Q, Bassett R, Valdez BC, Andersson BS, Parmar S, Orlowski RZ, Shah JJ, Thomas SK, Wang M, Champlin RE, Qazilbash M. High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma. Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Cai Q, Chen Y, Zou D, Badillo M, Zhou S, Zhang L, Lopez ER, Jiang W, Huang H, Lin T, Wang M. Novel Combination Of Lenalidomide-Rituximab Provides An Effective Bridge To Stem Cell Transplantation In Relapsed and/Or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphomas: A Single Center Experience. Blood (2013 ASH Annual Meeting Abstracts) 122(21):3056, 2013. e-Pub 2013.
Lopez ER, Dominici EM, Vang MT, Tamayo AT, Ou Z, Rollo A, Zhang L, Wang J, Strickland LM, Kirk CJ, Kauffman M, Shacham S, Wang M, Pham LV, Ford RJ. Selective Inhibitor Of Nuclear Exports (SINE) KPT-330 In Combination With The Novel Proteasome Inhibitor Carfilzomib As a Novel Therapeutic Regimen For Treating Aggressive B-Cell Lymphomas. Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Ou Z, Pham LV, Vang MT, Zhang L, Wang J, Strickland LM, Lopez ER, Dominici EM, Rollo A, Tamayo AT, Ford RJ, Wang M. Targeting BCR Activated STAT3 By Ibrutinib In Mantle Cell Lymphoma. Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Thomas SK, Haygood TM, Qazilbash MH, Melendez AG, Galvis R, Delasalle KB, Feng L, Richards TA, Samaniego F, Wang L, Shah JJ, Orlowski RZ, Weber DM. A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM). Blood (2013 ASH Annual Meeting Abstracts) 122(21):4396, 2013. e-Pub 2013.
Kongtim P, Qazilbash M, Shah JJ, Orlowski RZ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin RE, Parmar S. Autologous Stem Cell Transplantation Improves Survival For High Risk Cardiac Amyloidosis. Blood (2013 ASH Annual Meeting Abstracts) 122(21), 2013. e-Pub 2013.
Kabadi SM, Goyal RK, Nagar SP, Davis KL, Le H, Du XL, Jain P, Wang M, Romaguera JE, Kaye JA. Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy. Blood (ASH Annual Meeting Abstract) 134(Suppl), 2013. e-Pub 2013.
Wang M, Rule S, Martin P, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford JA, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry KJ, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy J, Chang BY, Beaupre DM, Kunkel LA, Goy A, Blum KA. Updated interim results of an international, multicenter, phase 2 study of ibrutinib (PCI-32765) in relapsed or refractory (R/R) mantle cell lymphoma (MCL). 12th International Conference on Malignant Lymphoma (ICML), 2013. e-Pub 2013.
Wang M, Leo G, Rule S, Goy A, Hermine O, Rizo A, Zhuang SH, Dreyling M. A Phase 3 Study of Ibrutinib in Combination with Bendamustine and Rituximab (BR) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma (MCL). 12th International Conference on Malignant Lymphoma (ICML), 2013. e-Pub 2013.
Wang M, Leo G, Rule S, Goy A, Hermine O, Rizo A, Zhuang SH, Dreyling M. A Phase 3 Study of Ibrutinib in Combination with Bendamustine and Rituximab (BR) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma (MCL). 2013 ASCO Annual Meeting, 2013. e-Pub 2013.
Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Niesvizky R. Final results from the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma. 2013 ASCO Annual Meeting 31, 2013. e-Pub 2013.
Wang M, Gordon LI, Rule S, Goy A, Hermine O, Rizo A, Zhuang SH, Dreyling MH. A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL). 2013 ASCO Annual Meeting 31, 2013. e-Pub 2013.
Ou Z, Zhang L, Newberry K, Sun L, Christopher KJ, Rollo A, Tamayo A, Lee J, Ford RJ, Wang M, Pham LV. The bruton's tyrosine kinase inhibitor ibrutinib synergized with the proteasome inhibitor carfilzomib and overcame immunoproteasome-mediated carfilzomib resistance in mantle cell lymphoma. AACR Annual Meeting 2013 73(8 Suppl), 2013. e-Pub 2013.
Blonska M, Pan D, Ou Z, Zhang L, Lin X, Wang M. Nuclear accumulation of c-Rel transcription factor is correlated with the proteasome inhibitor resistance in mantle cell lymphoma. AACR Annual Meeting 2013 73(8 Suppl), 2013. e-Pub 2013.
Han X, Wang S, Shi Y, Wang M, Zhang L, Fang B, McCauley D, Kauffman M, Shacham S. Novel SINE CRM1 antagonists for non-small cell lung cancer (NSCLC) in vitro and in vivo. AACR Annual Meeting 2013 73(8 Suppl), 2013. e-Pub 2013.
Samaniego F, Wise JF, Tao RH, Zhu H, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Romaguera JE, Fayad L, Wang M, McLaughlin P, McDonnell TJ, Patel KP, Neelapu SS, Kwak LW, Berkova Z. Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin. Blood (2012 ASH Annual Meeting Abstracts) 120, 2012. e-Pub 2012.
Shah JJ, Orlowski RZ, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Popat UR, Parmar S, Shah N, Bashir Q, Champlin RE, Weber DM. Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma. Blood (2012 ASH Annual Meeting Abstracts) 120, 2012. e-Pub 2012.
Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Falane MA, Fayad LE, Orlowski RZ, Wang M, Turturro F, Oki Y, Lacerte LC, Samaniego F. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. Blood (2012 ASH Annual Meeting Abstracts) 120, 2012. e-Pub 2012.
Wang M, Popplewell L, Collins RH, Winter JN, Goy A, Robeva A, Pirotta N, Fan J, Klimovsky J, O'Connor OA. Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib. Blood (2012 ASH Annual Meeting Abstracts) 120, 2012. e-Pub 2012.
Thomas SK, Delasalle KB, Shah JJ, Wang L, Orlowski RZ, Weber DM. Impact of Rituximab On the Treatment of Waldenström's Macroglobulinemia (WM). Blood (2012 ASH Annual Meeting Abstracts) 120(21):2734, 2012. e-Pub 2012.
Shah JJ, Weber DM, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat UR, Hilder B, Orlowski RZ. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood (2012 ASH Annual Meeting Abstracts) 120(21):4082, 2012. e-Pub 2012.
Shah JJ, Baladandayuthapani V, Weber DM, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Champlin RE, Shah N, Bashir Q, Popat UR, Nieto Y, Ahmed S, Parmar S, Orlowski RZ. Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma. Blood (2012 ASH Annual Meeting Abstracts) 122(21), 2012. e-Pub 2012.
Oki Y, Westin JR, Fowler N, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood (2012 ASH Annual Meeting Abstracts) 120, 2012. e-Pub 2012.
Pham LV, Rollo A, Tamayo AT, Lee J, Zuo Z, Sun L, Zhang L, Ou Z, Fayad LE, Wang M, Ford RJ. Biological Significance of the Immumoproteasome Subunits Mecl-1 and LMP-2 in Diffuse Large B-Cell Lymphoma. Blood (2012 ASH Annual Meeting Abstracts) 120, 2012. e-Pub 2012.
Wang M, Rule SA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, McGreivy J, Clow F, Stevens-Grogan M, Kunkel L, Blum KA. Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up. Blood (2012 ASH Annual Meeting Abstracts) 120, 2012. e-Pub 2012.
Dorkhom SJ, Zaman S, Thomas SK, Alexanian R, Shah JJ, Weber DM, Wang M, Anderson ML, Baladandayuthapani V, Lin YH, Fu M, Stellrecht CM, Morales de Partovi C, Gandhi VV, Orlowski RZ. Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma. Blood (2012 ASH Annual Meeting Abstracts) 120, 2012. e-Pub 2012.
Shah JJ, Hegde A, Zhou X, Thomas SK, Wang M, Weber DM, Alexanian R, Orlowski RZ, Vadhan-Raj S. Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE. Blood (2012 ASH Annual Meeting Abstracts) 120, 2012. e-Pub 2012.
Siegel DS, Wang M, Martin TG, Infante JR, Kaufman JL, Ranjangam K, Huang M, Bilotti E, Vij R. A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials. Blood (2012 ASH Annual Meeting Abstracts) 120, 2012. e-Pub 2012.
Wang M, Martin P, Blum KA, Kahl BS, Maeda LS, Advani R, Williams ME, Rule S, Rodriguez S, Pang CF, Hedrick E, Goy A. The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. 2012 Highlights of ASH in North America Oral presentation, Atlanta, 2012. e-Pub 2012.
Parmar S, Howell J, Wang M, Khan MA, Bashir Q, Shah JJ, Shah N, Popat UR, Giralt SA, Orlowski RZ, Qazilbash M. High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up. Blood (2012 ASH Annual Meeting Abstracts) 120, 2012. e-Pub 2012.
Kuiatse I, Thomas SK, Weber DM, Stein AM, Wang M, Shah JJ, Treon SP, Ansell SM, Orlowski RZ. Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia. Blood (2012 ASH Annual Meeting Abstracts) 120, 2012. e-Pub 2012.
Shah JJ, Thomas SK, Weber DM, Wang M, Alexanian R, Qazilbash MH, Bashir Q, Parmar S, Shah N, Popat UR, Orlowski RZ. Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood (2012 ASH Annual Meeting Abstracts) 120, 2012. e-Pub 2012.
Liang R, Wang Z, Chen QX, Bai XQ, Yan GQ, Yang L, Zhang T, Guo Y, Wang L. Analysis of Clinical and Pathological Features of 117 Chinese Cases of Natural Killer/T Cell Lymphoma. Blood (2012 ASH Annual Meeting Abstract) 120(21):5105, 2012. e-Pub 2012.
Lee S, Arastu-Kapur S, Kellerman L, Woo T, Wong A, Papadopoulos K, Niesvizky R, Badros A, Vij R, Jagannath S, Siegel D, Wang M, Ahmann G, Kirk C. Potent Inhibition of Select Proteasome Subunits by Carfilzomib in Multiple Myeloma and Solid Tumor Patients is Associated with Patient Response. 17th Congress of the European Hematology Association (EHA), 2012. e-Pub 2012.
Lonial S, Baz RC, Wang M, Talpaz M, Liu G, Berg D, Gupta N, Di Bacco A, Hui AM, Richardson PGG. Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM). 2012 ASCO Annual Meeting 30(Suppl), 2012. e-Pub 2012.
DiCapua Siegel DS, Martin T, Singhal S, Wang M, Vij R, Jakubowiak AJ, Jagannath S, Lonial S, Kukreti V, Bahlis NJ, Alsina M, Chanan-Khan AAA, Buadi F, Reu FJ, Somlo G, Kunkel LA, Rajangam K, Chang YL, Orlowski RZ, Stewart AK, Consortium (MMRC) MR. Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1. 2012 ASCO Annual Meeting 30(Suppl), 2012. e-Pub 2012.
Patel KK, Orlowski RZ, Weber DM, Wang M, Thomas SK, Shah JJ, Turturro F, Alexanian R, Delasalle K. Prognostic value of serum lactate dehydrogenase in symptomatic multiple myeloma. 2012 ASCO Annual Meeting 30(Suppl), 2012. e-Pub 2012.
Siegel D, Martin T, Wang M, Vij R, Jakubowiak A, Jagannath S, Lonial S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu F, Somlo G, Kunkel L, Wear S, Rajangam K, Chang Y, Orlowski R, Stewart K. Response Rates to Single-Agent Carfilzomib in Patients Double Refractory or Intolerant to Bortezomib and Immunomodulators in Trial PX-171-003-A1. 17th Congress of the European Hematology Association (EHA), 2012. e-Pub 2012.
Wang M, Sun L, Fokt I, Zhang L, Jayakumar A, Priebe W. Effect of berubicin, the 4'-o-benzylated doxorubicin analog, on growth inhibition and apoptosis in multiple myeloma. 2012 ASCO Annual Meeting 30, 2012. e-Pub 2012.
Thompson MA, Wei C, Moyer AM, Cunningham JM, Wang M, Fayad L, Feng L, Rodriguez MA, Cabanillas F, Kantarjian HM, Kwak LW, Romaguera JE. Single Nucleotide Polymorphisms (SNPs) in Genes for Glutathione-related Metabolism, Cyclin D1, and DNA Repair as Predictive Biomarkers in Mantle Cell Lymphoma Patients Treated with R-HyperCVAD with Ten Year Clinical Follow-up. Blood (2011 ASH Annual Meeting Abstract) 118, 2011. e-Pub 2011.
Ou Z, Pham LV, Zhang L, Tamayo AT, Lee J, Zhang K, Wang J, Phan J, Li C, Sun L, Ford RJ, Wang M. Single-Agent Bruton's Tyrosine Kinase (Btk) Inhibitor and Single-Agent Carfilzomib Induce Cell Apoptosis, Arrest Cell Growth and Downregulate NF-Kb Activity In Mantle Cell Lymphoma. Blood (2011 ASH Annual Meeting Abstract) 118, 2011. e-Pub 2011.
Vij R, Kaufman JL, Jakubowiak AJ, Wang M, Jagannath S, Kukreti V, McDonagh KT, Alsina M, Bahlis NJ, Belch AR, Reu FJ, Gabrail NY, Matous J, Vesole DH, Orlowski RZ, Wear S, Kunkel L, Wong AF, Lee P, Stewart K. Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM. Blood (2011 ASH Annual Meeting Abstract) 118, 2011. e-Pub 2011.
Wang L, Qian J, Lu Y, Li H, Hong S, Bao H, He D, Liu Z, Zheng Y, He J, Lan Y, Li Y, Neelapu S, Yang J, Wang M, Zhen C, Yi Q. Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells. Blood (2011 ASH Annual Meeting Abstract) 118, 2011. e-Pub 2011.
Wang M, Siegel DS, Jakubowiak AJ, Wong AF, Dixon S, Renau TE, Vij R. The Speed of Response to Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: An Exploratory Analysis of Results From 2 Multicenter Phase 2 Clinical Trials. Blood (2011 ASH Annual Meeting Abstract) 118, 2011. e-Pub 2011.
Ponader S, Balasubramanian S, Pham LV, Chen J, Tamayo AT, Wang M, O'Brien S, Wierda WG, Keating MJ, Ford RJ, Burger JA. Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target,. Blood (2011 ASH Annual Meeting Abstract) 118, 2011. e-Pub 2011.
Richardson PG, Baz R, Wang L, Jakubowiak AJ, Berg D, Liu G, Gupta N, Di Bacco A, Hui AM, Lonial S. Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study. Blood (2011 ASH Annual Meeting Abstract) 118(21):301, 2011. e-Pub 2011.
Jakubowiak AJ, Siegel DS, Singhal S, Martin T, Lonial S, Kukreti V, Bahlis N, Khan AC, Alsina M, Somlo G, Buadi FK, Reu RJ, Song KW, Kunkel L, Wear SM, Wong AF, Orlowski RZ, Stewart AK, Jagannath S, Wang M. Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. Blood (2011 ASH Annual Meeting Abstract) 118, 2011. e-Pub 2011.
Zhang L, Qian J, Ou Z, Sun L, Zhang K, Pham LV, Kirk CJ, Ford RJ, Yi Q, Wang M. Carfilzomib, An Irreversible Proteasome Inhibitor, Induces Long-Term Growth Inhibition of Mantle Cell Lymphoma In Vivo,. Blood (2011 ASH Annual Meeting Abstract) 118, 2011. e-Pub 2011.
Singhal S, Siegel DS, Martin T, Vij R, Wang M, Jakubowiak AJ, Lonial S, Kukreti V, Zonder JA, Wong AF, McCulloch L, Badros AZ, Niesvizky R, Orlowski RZ, Stewart AK, Kotlovker D, Jagannath S. Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. Blood (2011 ASH Annual Meeting Abstract) 118, 2011. e-Pub 2011.
Wang M, Martin P, Blum KA, Kahl BS, Maeda LS, Advani R, Williams ME, Rule S, Rodriguez S, Pang CF, Hedrick E, Goy A. The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. Blood (2011 ASH Annual Meeting Abstract) 118, 2011. e-Pub 2011.
Zhang K, Pham LV, Zhang L, Tamayo AT, Ou Z, McCauley D, Shacham S, Kauffman M, Ford RJ, Wang M. Novel CRM-1 Inhibitors for Therapy In Mantle Cell Lymphoma. Blood (2011 ASH Annual Meeting Abstract) 118, 2011. e-Pub 2011.
Khouri IF, Saliba RM, Valverde R, Samuels BI, Korbling M, Alousi AM, Anderlini P, Bashir Q, De Lima M, Hosing C, Kebriaei P, Nieto Y, Popat UR, Qazilbash M, Neelapu S, Fowler NH, Samaniego F, Wang L, Champlin R, Macapinlac HA. Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. Blood (2011 ASH Annual Meeting Abstract) 118(21):662, 2011. e-Pub 2011.
Wang M, Fowler N, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Zhang L, Sun L, Badillo M, Bejarano M, Champlin R, Kwak L, Feng L, Byrne C, Bell N, Zeldis J, Romaguera J, Fayad L. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in a cohort of patients with DLBCL and grade 3 follicular lymphoma: a completed phase II clinical trial. 16th Congress of the European Hematology Association (EHA), 2011. e-Pub 2011.
Romaguera JE, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad LE, Feldman T, Fowler N, Orlowski R, Smith J, Ford P, Ekaney M, Kwak LW, Goy A. Phase I-II Study of Bortezomib in Combination with R-HCVAD and R-Methotrexate/ Cytarabine (R-MA) in Untreated Mantle Cell Lymphoma (MCL). 11-ICML 22(Suppl 4):iv163, 2011. e-Pub 2011.
Wang M, Bensinger M, Martin T, Alsina M, Siegel DS, Gabrail NY, Hari P, Singhal S, Vescio RA, Assouline SE, Kunkel LA, Vallone M, Wong A, Niesvizk R. PX-171-006: a Phase (Ph) 2 Multicenter Dose Expansion Study of Carfilzomib (CFZ), Lenalidomide (LEN), and Low-dose Dexamethasone (loDex) in Relapsed and/or Refractory Multiple Myeloma (R/R MM). 2011 ASCO Annual Meeting, 2011. e-Pub 2011.
Niesvizky R, Bensinger W, Martin T, Alsina M, Siegel DS, Gabrail NY, Hari P, Singhal S, Vescio RA, Assouline SE, Kunkel LA, Vallone M, Wong A, Wang M. An update on the phase 1b/2 dose-escalation study of carfilzomib with lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. 16th Congress of the European Hematology Association (EHA), 2011. e-Pub 2011.
Kaufman JL, Vesole DH, Stewart A, Jakubowiak AJ, Jagannath S, Kukreti V, Mcdonagh KT, Alsina M, Reu FJ, Orlowski RZ, Kunkel L, Le MH, Vij R, Wang M. Updated Results for Bortezomib (BTZ)-naïve Patients (Pts) Enrolled in PX-171-004, an Ongoing Open-label, Phase (Ph) 2 Study of Carfilzomib (CFZ), in Relapsed Multiple Myeloma. 11th International Conference on Malignant Lymphoma (ICML), Lugano, 2011. e-Pub 2011.
Jakubowiak AJ, Martin T, Singhal S, Wang M, Vij R, Jagannath S, Lonial S, Kukreti V, Buadi F, Kunkel L, Bray L, Vallone M, Consortium (MMRC) MMR, Orlowski RZ, Siegel DS. Responses to Single-Agent Carfilzomib (CFZ) are Not Affected by Cytogenetics in Patients (PTS) with Relapsed and Refractory Multiple Myeloma (R/R MM). 11-ICML 22(Suppl 4):iv122, 2011. e-Pub 2011.
Wang M, Wang H, Chen Y, Li F, Delasalle K, Alexanian R, Kwak L, Rustveld L, Du X. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: A large population-based study. (Haematologica) 16th Congress of the European Hematology Association 96(s2):402, 2011. e-Pub 2011.
Romaguera JE, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad LE, Feldman T, Fowler N, Orlowski RZ, Smith J, Ford P, Ekaney M, Kwak LW, Goy A. Phase I/II Study of Bortezomib in Combination with R-HCVAD and R-Methotrexate/Cytarabine (R-MA) in Untreated Mantle Cell Lymphoma (MCL). 11th International Conference on Malignant Lymphoma (ICML), Lugano 22, 2011. e-Pub 2011.
Siegel S, Kaufman J, Wang M, Martin T, Jagannath S, Niesvizky R, Reu F, Alsina M, Badros A, Gabrail N, Kukreti V, Singhal S, Le M, Kotlovker D, Bomba D, Hannah A, Vij R. A Summary of Safety and Efficacy Data Achieved With Long-Term Carfilzomib (CFZ) Treatment in Patients With Relapsed and/or Refractory Multiple Myeloma (R/R MM). 16th Congress of the European Hematology Association (EHA), 2011. e-Pub 2011.
Fowler N, Hagemeister F, McLaughlin P, Kwak LW, Romaguera J, Fanale M, Neelapu S, Fayad LE, Orlowski RZ, Wang M, Pro B, Lacerte L, Samaniego F. Lenalidomide Plus Rituximab is a Highly Effective and Well-Tolerated Biologic Therapy in Untreated Indolent B-Cell Non-Hodgkins Lymphoma. 11th International Conference on Malignant Lymphoma (ICML), Lugano 22, 2011. e-Pub 2011.
Jagannath S, Singhal S, Siegel D, Martin T, Wang M, Vij R, Jakubowiak A, Lonial S, Kukreti V, Bahlis N, Chanan-Khan A, Alsina M, Somlo G, Buadi F, Reu F, Song K, Kunkel L, Wong A, Vallone M, Orlowski R, Stewart A. Long-Term Follow-Up in PX-171-003-A1, An Open-Label Single-Arm Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (R/R MM): Analysis by Subgroups of Interest. 16th Congress of the European Hematology Association (EHA), 2011. e-Pub 2011.
Wang M, Bensinger W, Martin T, Alsina M, Siegel DSD, Gabrail NY, Hari P, Singhal S, Vescio RA, Assouline SE, Kunkel LA, Vallone M, Wong A, Niesvizky R. Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM). 2011 ASCO Annual Meeting 29(Suppl), 2011. e-Pub 2011.
Cai Z, Wang L, Qian J, Bao H, Yang Y, Zhao Y, He D, Lu P, Li Y, Yang L, Wang M Yi Q. Mantle Cell Lymphoma Cells Express B7 Family Molecules and B7-H1 Expression are Up-Regulated After Interferon-Gamma And LPS Exposure Via Mek-Dependent Pathway in Mantle Cell Lymphoma Cells. 16th Congress of the European Hematology Association (EHA), 2011. e-Pub 2011.
Wang M, Siegel DS, Kaufman JL, Jakubowiak AJ, Stewart AK, Jagannath S, Kukreti, V, McDonagh, KT, Alsina M, Bahlis NJ, Belch A, Reu FJ, Gabrail NY, Matous JV, Rosen P, Lee P, Shustik C, Doner K, Orlowski RZ, Kunkel L, Wong A F, Vij R. Single-agent carfilzomib achieves high response rates in patients with bortezomib-naive relapsed multiple myeloma (MM): updated results from study PX-171-004. 16th Congress of the European Hematology Association (EHA) 2011, 2011. e-Pub 2011.
Wang M, Fayad L, Wagner-Bartak N, Hagemeister F, Neelapu S, Finale M, Younes A, Cabanillas F, Zhang L, Champlin R, Kwak L, Feng L, Bell N, Zeldis J, Romaguera J. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in relapsed/refractory mantle cell lymphoma: a completed phase I/II clinical trial. 11th International Conference on Malignant Lymphoma (ICML), Lugano, 2011. e-Pub 2011.
Niesvizky R, Lonial S, Kumar S, Bensinger W, Baz R, Jakubowiak A, Zimmerman T, Berenson J, Wang M, Reeder C, Liu G, Hui AM, Berg D, Gupta N, Richardson P. Evaluation of Twice-Weekly and Weekly Dosing of the Investigational Agent MLN 9708, An Oral Proteasome Inhibitor, In Patients With Relapsed/Refractory Multiple Myleoma: Phase 1 Dose Escalation Studies. 16th Congress of the European Hematology Association (EHA), 2011. e-Pub 2011.
Wang M, Garcia K, Zhou Y, You B, Guo Y, Forman A, Chiang J, Orlowski R, Shah J, Alexanian R, Thomas S, Qazilbash M, Badilo M, Chen Y, Delasalle K, Green V, Romaguera J, Cohen L. Electroacupuncture is an effective therapeutic modality for bortezomib- or thalidomide-induced peripheral neuropathy in patients with multiple myeloma: A Pilot Study. 13th International Myeloma Workshop (IMW), 2011. e-Pub 2011.
Wang M, Stewart AK, Kaufman JL, Jakubowiak A, Jagannath S, Kukreti V, Mcdonagh K, Alsina M, Bahlis N, Belch A, Reu FJ, Gabrail N, Matous JV, Vesole DH, Orlowski RZ, Kunkel LA, Le MH, Lee P, Rosen PJ, Sebag M, Vij R, consortium (MMRC) MMR. Carfilzomib (CFZ) produces a high single-agent response rate with minimal neuropathy even in relapsed multiple myeloma (MM) patients (Pts) with high-risk disease. 13th International Myeloma Workshop (IMW), 2011. e-Pub 2011.
Richardson PG, Baz R, Wang M, Jakubowiak AJ, Berg D, Liu G, Gupta N, Bacco AD, Hui AM, Lonial S. Phase I dose-escalation study of investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed or refractory (Rel/Ref) multiple myeloma (MM). 13th International Myeloma Workshop (IMW), 2011. e-Pub 2011.
Jakubowiak AJ, Martin T, Singhal S, Wang M, Vij R, Jagannath S, Lonial S, Kukreti V, Buadi F, Kunkel LA, Bray L, Vallone M, Wong AF, Orlowski RZ, Siegel DS, research consortium MM. Effects of cytogenetics on responses and survival in patients with relapsed and refractory multiple myeloma (R/R MM) treated with single-agent carfilzomib (CFZ). 13th International Myeloma Workshop (IMW), 2011. e-Pub 2011.
Lu G, Li S, Alseraye F, Muddasani R, Abruzzo L, Wang M, You MJ, Medeiros LJ. Plasma Cell Myeloma with IGHV Deletion: A Subset of Patients with Poor Prognosis. United States and Canadian Academy of Pathology, 2011. e-Pub 2011.
diCapua Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Jagannath S, Lonial S, Kukreti V, Bahlis NJ, Alsina M, Chanan-Khan AA, Somlo G, Buadi F, Reu FJ, Zonder JA, Song K, Stadtmauer E, Wong AF, Vallone M, Chang YL, Kauffman M, Orlowski RZ, Stewart AK, Singhal SB, MMRC T. Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM). Blood (2010 ASH Annual Meeting) 116(21):985, 2010. e-Pub 2010.
Batty N, Ghonimi E, Feng L, Younes A, Rodriguez A, Wager E, Martinez F, Wang M, McLaughlin P, Fowler N, Hagemeister F. Blood Transfusion and Erythropoiesis Stimulating Agents (ESAs) Use In Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood (2010 ASH Annual Meeting) 116(21):3357, 2010. e-Pub 2010.
Cai Z, Bao H, Lu P, Wang L, He D, Li H, Yang Y, Zhao Y, Yang L, Li Y, Wang M, Yi Q. Triggering of Toll-Like Receptor-4 In Human Multiple Myeloma Cells Promotes Proliferation and Alters Cell Responses to Immune and Chemotherapy Drug Attack. Blood (2010 ASH Annual Meeting) 116(21):1905, 2010. e-Pub 2010.
Wang L, Bao H, Yang Y, Zhao Y, He D, Lu P, Li Y, Yang L, Yi Q, Wang M, Cai Z. Mantle Cell Lymphoma Cells Express B7 Family Molecules and B7-H1 Expression Are up-Regulated After LPS Exposure Via MEK-Dependent and PI3K/Akt-Dependent Pathways In Mantle Cell Lymphoma Cells. Blood (2010 ASH Annual Meeting) 116(21):3114, 2010. e-Pub 2010.
Zhang L, Yang J, Qian J, Neelapu S, Kwak LW, Wang M, Yi Q. Role of Microenvironment In Mantle Cell Lymphoma: IL-6 as An Important Survival Factor for Tumor Cells. Blood (2010 ASH Annual Meeting) 116(21):3929, 2010. e-Pub 2010.
Singhal SB, diCapua Siegel DS, Martin T, Vij R, Wang M, Jakubowiak AJ, Lonial S, Kukreti V, Zonder JA, Wong AF, McCulloch L, Kauffman M, Badros AZ, Niesvizky R, Orlowski RZ, Stewart AK, Jagannath S. Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM). Blood (2010 ASH Annual Meeting) 116(21):1954, 2010. e-Pub 2010.
Shah JJ, Zonder JA, Cohen A, Weber D, Thomas S, Wang M, Kaufman JL, Burt SM, Walker D, Freeman B, Rush SA, Ptaszynski A, Orlowski RZ, Lonial S. A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma. Blood (2010 ASH Annual Meeting) 116(21):1959, 2010. e-Pub 2010.
Zheng Y, Yang J, Zhang L, Qian J, Matthews J, Wang M, Kwak L, Yi Q. Novel PI3K Inhibitor Compound A Induces Myeloma Cell Apoptosis and Shows Synergistic Cytotoxicity with Dexamethasone In Multiple Myeloma. Blood (2010 ASH Annual Meeting) 116(21):4080, 2010. e-Pub 2010.
Martin T, Singhal SB, Vij R, Wang M, Stewart AK, Jagannath S, Lonial S, Jakubowiak AJ, Kukreti V, Bahlis NJ, Alsina M, Chanan-Khan AA, Somlo G, Buadi F, Reu FJ, Zonder JA, Song K, Stadtmauer EA, Wong AF, Vallone M, Chang YL, Kauffman M, Orlowski RZ, diCapua Siegel DS. Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM). Blood (2010 ASH Annual Meeting) 116(21):3031, 2010. e-Pub 2010.
Shah JJ, Orlowski RZ, Alexanian R, Wang M, Thomas S, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat U, Weber D. Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma. Blood (2010 ASH Annual Meeting) 116:1948, 2010. e-Pub 2010.
O'Connor OA, Popplewell L, Winter JN, Yuan R, Robeva A, Cauwel H, Chau Q, Wang M. PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib. Blood (2010 ASH Annual Meeting) 116(21):3963, 2010. e-Pub 2010.
Vij R, Kaufman JL, Jakubowiak AJ, Stewart AK, Jagannath S, Kukreti V, McDonagh KT, Alsina M, Bahlis NJ, Belch A, Reu FJ, Gabrail NY, Matous J, Vesole DH, Orlowski RZ, Le MH, Lee P, Wang M, MMRC T. Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients. Blood (2010 ASH Annual Meeting) 116(21):1938, 2010. e-Pub 2010.
Jakubowiak AJ, Martin T, Singhal SB, Wang M, Vij R, Jagannath S, Lonial S, Kukreti V, Buadi F, Bray L, Vallone M, Kauffman M, Orlowski RZ, diCapua Siegel DS, MMRC T. Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib. Blood (2010 ASH Annual Meeting) 116(21):1942, 2010. e-Pub 2010.
Shah N, Xing D, Lee DA, Cooper LJN, Decker W, Li S, Robinson S, Yang H, Parmar S, Tung S, Wang M, Champlin R, Bollard CM, Shpall EJ. Antigen Presenting Cell-Mediated Ex Vivo Expansion of Human Umbilical Cord Blood Cells Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. Blood (2010 ASH Annual Meeting) 116(21):2100, 2010. e-Pub 2010.
Priebe W, Wang M, Sun L, Fokt I, Bao H, Zhang L, Jayakumar A. Berubicin, A Topoisomerase II Poison With High CNS Uptake, Inhibits Cell Growth and Induces Apoptosis in Diffuse Large B-Cell Lymphomas. 22nd EORTC-NCI-AACR symposium on “Molecular targets and Cancer Therapeutics”, 2010. e-Pub 2010.
Wang M, Sun L, Fokt I, Bao H, Zhang L, Jayakumar A, Priebe W. Berubicin, A Novel Mechanistically Altered Anthracycline Potently Inhibits Cell Growth and Induces Apoptosis in Mantle Cell Lymphoma. 22nd EORTC-NCI-AACR symposium on “Molecular targets and Cancer Therapeutics”, 2010. e-Pub 2010.
Martin T, Niesvizky R, Wang M, Orlowski R, Alsina M, Singhal S, Gabrail N, Vallone M, Bui L, Kauffman M, Bensinger W. Phase 2 Multicenter Dose Expansion Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM). Lymphoma & Myeloma 2010: An International Congress on Hematologic Malignancies, New York, NY,, 2010. e-Pub 2010.
Shah N, Weber DM, Wang M, Thomas S, Shah J, Giralt S, Alexanian R, Orlowski RZ, Qazilbash MH, Avery T. Survival Disparities Between African American and Caucasian Patients With Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation. The 14th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myelomas 10(3):E31, 2010. e-Pub 2010.
Wang M, Bensinger W, Orlowski R, Alsina M, Martin T, Singhal S, Gabrail N, Vallone M, Kauffman M, Niesvizky R. PX-171-006, a phase Ib dose-escalation study of carfilzomib+lenalidomide+low-dose dexamethsaone in relapsed and/or refractory multiple myeloma. 15th Congress of the European Hematology Association (EHA), 2010. e-Pub 2010.
Lonial S, Jagannath S, Martin T, Wang M, Singhal S, Trudel S, Le M, Kirk C, Arastu-Kapur S, Vij R, Siegel D. Carfilzomib, A Novel Proteasome Inhibitor, Exhibits Minimal Neurotoxic and Peripheral Neuropathic Effects in Preclinical and Clinical Studies. 15th Congress of the European Hematology Association (EHA), 2010. e-Pub 2010.
Stewart K, Siegel D, Wang M, Kaufman J, Jakubowiak A, Jagannath S, Kukreti V, McDonagh K, Alsina M, Bahlis N, Belch A, Gabrail N, Le M, Bennett M, Vij R. Results of PX-171-004, An Ongoing Open-Label, Phase II Study of Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myleoma (R/R MM) With or Without Prior Bortezomib Exposure. 15th Congress of the European Hematology Association (EHA), 2010. e-Pub 2010.
Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons P, Nami M. Prospective isolation of clongenic mantle cell lymphoma initiating cells. AACR 101st Annual Meeting 70(8 Suppl), 2010. e-Pub 2010.
Zhang L, Qian J, Yang J, Monette A, Demo S, Yi Q, Wang M. Carfilzomib, an irreversible proteasome inhibitor, induces caspase-dependent apoptosis and inhibits the growth of mantle cell lymphoma in vitro and in tumor-bearing SCID mice. AACR 100th Annual Meeting 2010, 2010. e-Pub 2010.
Wang M, Wang ZQ, Sun L, Ma W, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah JJ, Kornblau S, Davis RE. Long-Term Storage in TRIzol has Little Effect on Microarray-Based Gene Expression Profiling in Primary Myeloma or Acute Myeloid Leukemia Cells. 2010 AACR Annual Meeting, 2010. e-Pub 2010.
Wang M, Niesvizky R, Orlowski R, Alsina M, Martin T, Singhal S, Gabrail N, Vallone M, Bui L, Kauffman M, Bensinger W. Phase 1b Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM). 2010 Lymphoma / Myeloma meeting in NYC, 2010. e-Pub 2010.
Kuhn DJ, Bjorklund CC, Magarotto V, Matthews JA, Wang M, Baladandayuthapani V, and Orlowski RZ. Bortezomib resistance is mediated by increased signaling through the insulin-like growth factor-1akt axis. Blood (2009 ASH Annual Meeting Abstract), 2009. e-Pub 2009.
Bjorklund CC, Kuhn DJ, Matthews JA, Wang M, Baladandayuthapani V, and Orlowski RZ. Activation of the wnt/β-catenin pathway mediates lenalidomide resistance in multiple myeloma. Blood (2009 ASH Annual Meeting Abstract) 114:111, 2009. e-Pub 2009.
Yang J, Cao Y, Zheng Y, Hong S, Li H, Qian J, Matthews JA, Wang M, Kwak LW, and Yi Q. Constitutive Activation of p38 MAPK in Myeloma Cells Contributes to Myeloma-Induced Osteolytic Bone Lesions. Blood (2009 ASH Annual Meeting Abstract) 114:740, 2009. e-Pub 2009.
Hunsucker SA, Magarotto V, Matthews JA, Wang M, Baladandayuthapani V, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, and Orlowski RZ. Inhibition of interleukin-6 signaling with CNTO 328 sensitized plasma cell dyscrasias to the effects of melphalan in association with suppression of signaling through protein kinase B/Akt. Blood (2009 ASH Annual Meeting Abstract) 114, 2009. e-Pub 2009.
Stadtmauer EA, Weber DM, Wang M, Nieszvizky R, Belch A, Prince HM, J F Miguel JF, Facon T, Yu Z, Knight RD, Dimopoulos MA. The quality of response to lenalidomide plus dexamethasone is associated with clinical outcomes in patients with relapsed or refractory multiple myeloma. 2009 ASCO Annual Meeting J Clin Oncol 27(15s), 2009. e-Pub 2009.
Qazilbash M, Saliba R, Pelosini M, Mendoza F, Han E, Wang M, Weber D, Orlowski R, Alousi A, Anderlini P, Hosing C, Kebriaei P, Khouri I Popat U, de Lima M, Champlin R, Giralt S. A randomized Phase II trial of high-dose melphalan, ascorbic acid and arsenic trioxide with or without bortezomib in multiple myeloma. Blood (2008 ASH Annual Meeting) 112(11), 2008. e-Pub 2008.
Kazmi S, Mendoza F, Weber D, Wang M, Hosing C, Khouri I, Anderlini P, de Lima M, Kebriaei, Popat U, Champlin R, Giralt S, Qazilbash M. High-dose topotecan, Melphalan and cyclophosphamide (TMC) with autologous stem cell support for multiple myeloma. Blood (2008 ASH Annual Meeting) 112(11), 2008. e-Pub 2008.
Wang M, Zhang L, Fayad L, Hagemeister F, Neelapu S, Samaniego F, Pro B, Miller S, Knight R, Zeldis J, Yi Q, Romaguera J. Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a Phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. Blood (2008 ASH Annual Meeting) 112(11), 2008. e-Pub 2008.
Silva L, Weber D, Wang M, Han E, Mendoza F, de Lima M, Qazilbash M, Champlin R, Giralt S. 10 years experience with stem cell transplant. 2008 BMT Tandem Meetings 110(11):5112, 2008. e-Pub 2008.
Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samaniego F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J. Lenalidomide (Len) in combination with Rituximab demonstrated early evidence of efficacy in a phase I/II study in relapsed/refractory mantle cell lymphoma (MCL). Blood (2007 ASH Annual Meeting) 110(11):755a, abstr 2562, 2007. e-Pub 2007.
Wang M, Shi Y, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Romaguera J, Kwak L, Yi Q. A SCID-hu in vivo mouse model of human primary mantle cell lymphoma. Blood (2007 ASH Annual Meeting) 110(11):691a, abstr 2337, 2007. e-Pub 2007.
Qazilbash M, Saliba R, Parikh G, Hosing C Mendoza F, Quereshi S, Weber D, Wang M, Flosser T, Couriel D, Kebriaei P, Popat U, Alousi A, de Limia M, Champlin R, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan is safe and effective for autotransplantation for multiple myeloma. Blood (2007 ASH Annual Meeting) 110(11):2661, abstr 942, 2007. e-Pub 2007.
Wright J, Weber D, Thomas S, Wang M, Alexanian R, Hawkins V, Vadhan-Raj S. Characteristics of patients experiencing thromboembolic events during treatment of multiple myeloma: Aspirin may not be adequate as thromboprophylaxis in patients with multiple risk factors. Blood (2007 ASH Annual Meeting) 110(11):557a, abstr 1882, 2007. e-Pub 2007.
Tam CS, Saliba RM, Ledesma C, Korbling M, Fayad LE, Wang M, Alousi A, Housing C, Kebriaei P, Rondon G, Giralt S, Anderlini P, Popat U, Couriel D, Pro V, Samuels B, Hagemeister FB, Champlin RE, Khouri IF. Non-myeloablative allogeneic stem cell transplantation (NMT) overcomes the adverse effects of treatment resistance and high Beta-2-Microglobulin in patients with mantle cell lymphoma (MCL): An analysis of 123 transplantations at the M.D. Anderson Cancer Center. Blood (2007 ASH Annual Meeting) 110(11):149a, abstr 484, 2007. e-Pub 2007.
Giralt S, Thandi R, Qazilbash M, Mendoza F, Han E, Hosing C, Wang M, Thomas S, Alexanian R, Champlin R, Weber D. Retrospective comparison of transplant outcomes in patients with multiple myeloma according to induction therapy wtih thalidomide/dexamethasone (TD) with or without bortezomib (VTD). Blood (2007 ASH Annual Meeting) 110(11):288a, abstr 948, 2007. e-Pub 2007.
Alousi A, Hosing C, Saliba R, Valverde R, Maadani F, Korbling M, Okoroji G, Fayad L, Stachowiak A, Erwin W, Anderlini P, de Limia M, Giralt S, Popat U, Kebriaei P, Ueno N, McLaughlin P, Pro B, Wang M, Rodriguez A, Hagemeister F, Macapinlac H, Podoloff D, Champlin R, Khouri I. Zevalin/BEAM/rituximab vs BEAM/rituximab and autologous stem cell transplantation (ASCT) for relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL): Impact of the IPI and PET status. Blood (2010 ASH Annual Meeting) 110(11):191a, abstr 620, 2007. e-Pub 2007.
Vadhan-Raj S, Weber D, Wang M, Giralt S, Alexanian R, Thomas S, Zhou X, Patel P, Bueso-Ramos C, Newman R, Aggarwal B. Curcumin downregulates NF-КB and related genes in patients with multiple myeloma: Results of a phase 1/2 study. Blood (2007 ASH Annual Meeting) 110(11):357a, abstr 1177, 2007. e-Pub 2007.
Fayad L, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Neelapu S, Kwak L, Romaguera J, Rodriguez MA. R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma (DLBCL) with aggressive features in patients younger than 60 years. Blood (2007 ASH Annual Meeting) 110(11):387a, Abstr 1285, 2007. e-Pub 2007.
Parikh G, Saliba R, Lahoti A, Hosing C, Mendoza F, Qureshi S, Weber D, Wang M, Popat U, Alousi A, Champlin R, Giralt S, Qazilbash M. Autotransplantation in patients with multiple myeloma and concurrent renal failure is safe and feasible and associated with recovery of renal function in >30% of patients. Blood (2007 ASH Annual Meeting) 110(11):5126, 2007. e-Pub 2007.
Wang M, Zhou Y, Wang H, Yi Q, Zhang Y, Alexanian R, Kwak L, Du X. Trend and geographic variations in the incidence of Waldenstrom's Macroglobulinemia in the United States over 17 years from 1988 to 2004. Blood (2007 ASH Annual Meeting) 110(11):5174, 2007. e-Pub 2007.
Thompson MA, Kadia TM, Bekele BN, Wang M, Romaguera J. Cyclin D1 polymorphisms as predictive and prognostic molecular markers in 90 mantle cell lymphoma patients treated with R-HyperCVAD. Blood (2007 ASH Annual Meeting) 110(11), 2007. e-Pub 2007.
Qazilbash M, Saliba R, Parikh G, Hosing C, Mendoza F, Weber D, Wang M, Thomas S, Flosser T, Kebriaei P, Popat U, Alousi A, de Lima M, Champlin R, Giralt S. A non-myeloablative regimen of fludarabine and melphalan is safe and well tolerated for allogeneic transplantation in multiple myeloma. Blood (2007 ASH Annual Meeting) 110(11):3032, 2007. e-Pub 2007.
Zhou Y, Wang H, Du X, Yi Q, Zhang Y, Romaguera J, Wang M. Trend and geographic variations in the incidence of mantle cell lymphoma in the United States over 30 years from 1975 to 2004. Blood (2007 ASH Annual Meeting) 110(11):4514, 2007. e-Pub 2007.
Zhang L, Shi Y, Han X, Yang J, Qian J, Kwak L, Romaguera J, Yi Q, Wang M. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Blood (2007 ASH Annual Meeting) 110(11):4514, 2007. e-Pub 2007.
Zhang L, Shi Y, Han X, Yang J, Qian J, Kwak L, Romaguera J, Yi Q, Wang M. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Blood (2007 ASH Annual Meeting Abstract) 110(11), 2007. e-Pub 2007.
Wang M, Fayad L, Hagemeister F, Neelapu S, Bell N, Byrne C, Knight R, Zeldis J, Kwak L, Romaguera J. A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. 2007 ASCO Annual Meeting 25(18S):8030, 2007. e-Pub 2007.
Zhou Y, Wang H, Zhang Y, Du X, Kwak L, Romaguera J, Wang M. Trend and geographic variations in the incidence of mantle cell lymphoma in the United States from 1975 to 2003. 2007 ASCO Annual Meeting 25(185):8091, 2007. e-Pub 2007.
Thomas SK, Delasalle KB, Gavino M, Wang M, Alexanian R, Weber DM. 2-CDA-cyclophosphamide +/- Rituximab for symptomatic Waldenstrom's Macroglobulinemia. (Haematologica) XIth International Myeloma Workshop & IVth International Workshop on Waldenström’s Macroglobulinemia 92(6):228, (abstr PO-1227), 2007. e-Pub 2007.
Wang M, Delasalle K, Thomas S, Qazilbash M, Giralt S, Weber D, Alexanian R. Early transplant is useful for older patients with multiple myeloma. (Haematologica) XIth International Myeloma Workshop & IVth International Workshop on Waldenström’s Macroglobulinemia 92(6):189, (abstr PO-819), 2007. e-Pub 2007.
Fayad L, Temple S, Pro B, Hagemeister F, Cabanillas F, Samaniego P, McLaughlin P, Wang M, Kwak L, Romaguera J, Rodriguez MA. R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma (DLBCL) with aggressive features: M.D. Anderson experience in 40 patients. 2007 ASCO Annual Meeting 25(18):8058, 2007. e-Pub 2007.
Delasalle K, Wang M, Thomas S, Weber D, Alexanian R. High response rate wtih BCD combination for relapsing multiple myeloma. XIth International Myeloma Workshop & IVth International Workshop on Waldenström’s Macroglobulinemia 92(6):158, (abstr PO-616), 2007. e-Pub 2007.
Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Alexanian R, Yu Z, Zeldis J, Olesnyckyj M, Weber D. Effect of Lenalidomide/Dexamethasone in multiple myeloma despite Thal resistance. (Haematologica) XIth International Myeloma Workshop & IVth International Workshop on Waldenström’s Macroglobulinemia 92(6):172, (abstr PO-662), 2007. e-Pub 2007.
Qazilbash M, Saliba R, Hosing C, Mendoza F, Qureshi S, Weber D, Wang M, Flosser T, Couriel D, de Lima M, Kebriaei P, Popat U, Alousi A, Champlin R, Giralt S. Autologous stem cell transplantation for elderly patients with multiple myeloma. Blood (2006 ASH Annual Meeting) 108(11):450b, (abstr 5422), 2006. e-Pub 2006.
Ahmed B, Saliba RM, Ashraf N, Mendoza F, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Deletion of the short arm of chromosome 1 (del 1p) is the strongest predictor of poor outcome in myeloma patients undergoing an autotransplant. Blood (2006 ASH Annual Meeting) 108(11):884a, (abstr 3101), 2006. e-Pub 2006.
Thomas S, Giralt S, Wang M, Delasalle KB, Gavino M, Rankin K, Alexanian R, Weber DM. Survival outcomes of patients receiving thalidomide-dexamethasone for previously untreated multiple myeloma. Blood (2006 ASH Annual Meeting) 108(11):1019a (abstr 3569), 2006. e-Pub 2006.
Wang M, Delasalle K, Thomas S, Giralt S, Alexanian R. Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood (2006 ASH Annual Meeting) 108(11):123a, (abstr 403), 2006. e-Pub 2006.
Wang M, Oki Y, Pro B, Romaguera J, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Podoloff D, Samuels B, Loyer E, Zhou Y, Younes A. Phase II study of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in patients with relapsed and refractory mantle cell lymphoma (MCL). Blood (2006 ASH Annual Meeting) 108(11):767a, (abstr 2714), 2006. e-Pub 2006.
Wang M, Zhang L, Han X, Yang J, Qian J, Wang S, Hong S, Zhang X, Zhou Y, Romaguera J, Yi Q. Atiprimod inhibits growth of mantle cell lymphoma in vitro and in vivo and induced apoptosis via activation of the mitochondrial pathway. Blood (2006 ASH Annual Meeting) 108(11):712a, (abstr 2514), 2006. e-Pub 2006.
Qazilbash MH, Saliba RM, Davis MS, Mendoza FL, Hosing C, Couriel DR, de Lima M, Kebriaei P, Weber DM, Wang M, Alousi AM, Matthes SG, Jones RB, Champlin RE, Giralt SA. Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma. Blood (2006 ASH Annual Meeting) 108(11):881a, (abstr 3090), 2006. e-Pub 2006.
Qazilbash M, Davis M, Ana A, Roden L, Libunao F, Thall P, Wang X, Couriel D, De Lima M, Hosing C, Kebriaei P, Weber D, Wang M, Jones R, Matthes S, Champlin R, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: A new preparative regimen for autologous hematopoietic stem cell transplantation for multiple myeloma. Blood (2006 ASH Annual Meeting) 106(11):338a, (abstr 1159), 2006. e-Pub 2006.
Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Alexanian R, Yu Z, Zeldis J, Olesnyckyj, Weber D. Lenalidomide in combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma. Blood (2006 ASH Annual Meeting) 108, 2006. e-Pub 2006.
Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Yu Z, Zeldis J, Olesnyckyj, Weber DM. Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received thalidomide in relapsed or refractory multiple myeloma (MM). 2006 ASCO Annual Meeting 24(185):7522, 2006. e-Pub 2006.
Wang M, Delasalle K, Giralt S, Alexanian A. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood (2005 ASH Annual Meeting 106(11):231a (abstr 784), 2005. e-Pub 2005.
Donato M, Ana A, Weber D, Wang M, Qazilbash M, Davis M, Roden L, Mendoza F, Champlin R, Giralt S. Transplant outcomes after topotecan-melphalan-cyclophosphamide (TMC) conditioning for autologous stem cell transplantation for multiple myeloma. Blood (2005 ASH Annual Meeting 106(11):344a, (abstr 1177), 2005. e-Pub 2005.
Romaguera JE, Fayad L, Wang M, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez A, Younes A, Neelapu S, Goy A, Beasley V, Kwak L. High (95%) response rates in relapsed/refractory mantle cell lymphoma after R-HCVAD alternating wtih R-methotrexate/cytarabine (R-M-A). Blood (2005 ASH Annual Meeting) 106(11):688a, (abstr 2446), 2005. e-Pub 2005.
Wang M, Talpaz M, Jagannath S, Alban Chanan-Khan A, Alexanian R, Weber D, Gavino M, Estrov Z, Harris P, Picker D, Schlossman R, Tassone P, Anderson K, Munshi N. A phase I, multi-center, dose escalation study of atiprimod in patients with refractory or relapsed multiple myeloma (MM). Blood (2005 ASH Annual Meeting 106(11):36a (abstr 111), 2005. e-Pub 2005.
Fayad L, Pro B, Liu Q, Hess M, Hagemeister F, Romaguera J, Samaniego F, Cabanillas F, Rodriguez M, Younes A Wang M, McLaughlin P. Time to Treatment Failure (TTF) and FLIPI correlate well with survival and are independent variables in Stage IV indolent follicular lymphoma (IFL). Blood (2005 ASH Annual Meeting) 106(11):274, (abstr 933), 2005. e-Pub 2005.
Romaguera J, Fayad L, Hagemeister F, McLaughlin P, Rodriguez A, Cabanillas F, Younes A, Neelapu S, Goy A, Kantarjian H, Beasley V, Kwak L, Wang M. Relapsed and refractory aggressive mantle cell lymphoma: Preliminary results of salvage therapy with rituximab plus Hyper-CVAD alternating with rituximab plus methotrexate/cytarabine. 2005 ASCO Annual Meeting 23:7013-7023, 2005. e-Pub 2005.
McLaughlin P, Liu N, Poindexter N, Grimm E, Fayad L, Hagemeister F, Nunez R, Romaguera JE, Goy A, Samaniego F, Wang M, Ayala A, Lee B, Reuben J, Kwak L, Rodriguez MA. Rituximab plus GM-CSF (Leukine) for indolent lymphoma. Proceedings of the 9th International Conference on Malignant lymphomas 16(S5):68 (abstr 104), 2005. e-Pub 2005.
Wang M, Alexanian R, Delasalle KB, Weber DM. Confirmation of the Prognostic Value of the International Staging System (ISS) for Multiple Myeloma (MM) Proposed by the International Myeloma Working Group (IMWG) and Southwest Oncology group (SWOG) Staging System with Similar Results Using B2Microglobulin (B2M) Alone. 10th International Myeloma Workshop, Sydney, Australia, 2005. e-Pub 2005.
Weber D, Wang M, Delasalle K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine (2-CdA) and cyclophosphamide (Cy) alone or in combination with rituximab (Rit) for previously untreated Waldenstrom’s macroglobulinemia (WM). Blood (2004 ASH Annual Meeting) 104:11 (abstract 1476), 2004. e-Pub 2004.
Giralt S, Aleman A, Lei X, Davis M, Mickler K, Weber D, Wang M, Champlin R. Results of bortezomib (BTZ) therapy for myeloma (MM) patients relapsing after an allogeneic transplant: Preliminary results show efficacy without induction of GVHD. Blood (2004 ASH Annual Meeting) 104:1651, 2004. e-Pub 2004.
Alexanian R, Wang M, Weber D, Delasalle K. VTD (Velcade, Thalidomide, Dexamethasone) as primary therapy for newly diagnosed multiple myeloma. Blood (2004 ASH Annual Meeting) 104, 2004. e-Pub 2004.
Yao KC, Hentschel SJ, Fourney DR, Wang M, Rhines LD, Burton AW, Mendel E. Percutaneous vertebroplasty and kyphoplasty for painful vertebral compression fractures in patients with multiple myeloma. American Association of Neurological Surgeons (AANS) Annual Meeting, Orlando, FL, 2004. e-Pub 2004.
Weber DM, Wang LM, Delasalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. International Multiple Myeloma Conference:71-72, 2004. e-Pub 2004.
Alexanian R, Weber D, Wang M, Delasalle K. Thalidomide-Dexamethasone as primary treatment for multiple myeloma and role of added Bortezomib. International Multiple Myeloma Conference:164-5, 2004. e-Pub 2004.
Alexanian R, Weber D, Delasalle K, Wang M, Giralt S, Champlin R. Progressively Reduced Sensitivity of Multiple Myeloma to Serial Intensive Therapies. Blood (2003 ASH Annual Meeting) 102:11 (abst 3654), 2003. e-Pub 2003.
Goy A, Hart S, Pro B, McLaughlin P, Younes A, Dang N, Fayad L, Romaguera J, Cabanillas F, Hagemeister F, Samaniego F, Wang M, Mesina O, Gilles F, Trehu E, Shenkein D. Report of a phase II study of the proteasome inhibitor bortezomib in patients with relapsed or refractory indolent or aggressive lymphomas. 45th Annual Meeting of the American Society of Hematology 4(52):5-6, 2003. e-Pub 2003.
Wang M, Alexanian R, Delasalle K, Mathai V, Weber D. Abnormal MRI of the spine is a major risk factor for early progression of asymptomatic multiple myeloma. Blood (2003 ASH Annual Meeting) 102:11 (abstr 2546), 2003. e-Pub 2003.
Wang M, Roifman C, Harris D, Grunberger T, Demin P, Van Q, Rodriguez MA, Talpaz M, Estrov Z. CR4, a novel protein kinase inhibitor inhibits Stat 3 phosphorylation, suppresses proliferation and induces apoptosis in diffuse large B cell lymphoma cells. 2003 ASCO Annual Meeting 22:593 (abstr 2383), 2003. e-Pub 2003.
Wang M, Weber D, Alexanian R, Delasalle K, Rankin K, Gavino M. Thalidomide-dexamethasone vs HyperCVAD as primary therapy for multiple myeloma of high tumor mass. IX International Workshop on Multiple Myeloma 2003 4(S1):352, 2003. e-Pub 2003.
Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide alone or with dexamethasone for resistant or relapsing multiple Myeloma. Hem Jrnl, IX International Workshop on Multiple Myeloma, Salamanca , Spain 4(S1):S2, 2003. e-Pub 2003.
Sawyer TK, Jensen RT, Moran TH, Wang LH, Coy DH, Staples DG, DeVaux AE, Bradford VS. Structure activity relationships of cholecytokinin: Tyr[SO3H]: Substitutions Peptides. The Eleventh American Peptide Symposium:143-5, 1990. e-Pub 1990.

Book Chapters

Sullivan, TJ, Whitehead, K, Williamson, R, Grimes, D, Schlect, D, Brown, I, Dickie, G, Bhatia, S, Paulino, AC, Buatti, JM, Mayr, NA, Wen, BC, Pinnix, CC, Dabaja, BS, Milgrom, SA, Smith, GL, Abou, Z, Nastoupil, L, Romaguera, JE, Turturro, F, Fowler, N, Fayad, LE, Westin, JR, Neelapu, SS, Fanale, MA, Rodriguez, MA, Hagemeister, FB, Lee, HJ, Oki, Y, Wang, L, Samaniego, F, Chi, L, Esmaeli, B. Orbital adnexal lymphoma. In: Foundational Papers in Oculoplastics. Springer, 375-388, 2022.
Avery TP, Shah ND, Fu W, Weber DM, Lu G, Lin P, Qazilbash M, Wang M. Multiple Myeloma and other plasma cell dyscrasias (2nd edition). In: MD Anderson Manual of Medical Oncology 2nd Edition. McGraw-Hill Companies, 245-282, 2011.
Thomas S, Wang M, Weber D. Abnormal serum protein electrophoresis. In: Decision Making in Medicine, An Algorithmic Approach. Mosby; 3rd edition (November 10, 2009), 264-267, 2009.
Zhou Y, Alexanian R, Wang M. Targeted Therapy in Multiple Myeloma. In: Targeted Therapy in Cancer. Springer Science+Business Media, 213-236, 2007.
Seymour G, Wang M, Weber D. Multiple myeloma and other plasma-cell dyscrasias (1st edition). In: MD Anderson Manual of Medical Oncology. McGraw-Hill Companies, 175-195, 2006.
Jensen, RT, Wang, LH, Lin, JT, Benya, RV, Mroziski, JE, Jr, Coy, DH. Peptide-neuromedin B (NMB) receptor interactions: Comparison with gastrin-releasing peptide (GRP): GRP receptor interactions. In: Growth Factors, Peptides and Receptors. Plenum Publishing Co, 225-37, 1990.

Letters to the Editor

Jiang, C, Lee, W, Zhang, T, Jordan, A, Yan, F, Cai, Q, McIntosh, J, Vargas, J, Liu, Y, Wang, L. The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma. Biomarker Research 12: 62, 2024.
Le Gouill S, Dlugosz-Danecka M, Rule S, Zinzani PL, Goy A, Smith SD, Doorduijn JK, Panizo C, Shah BD, Davies AJ, Eek R, Jacobsen E, Kater AP, Robak T, Jain P, Calvo R, Tao L, Wang M. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica 109: 343-350, 2024.
Che Y, Liu Y, Li Y, McIntosh J, Jordan A, Yan F, Wang W, Nie L, Lee HH, Jin J, Yao Y, Zhao Z, Jiang VC, Wang ML. Dual targeting of CDK4/6 and Bcl-2 exhibits a potent anti-tumor effect on mantle cell lymphoma. Blood Adv 7: 3361-3365, 2023.
Liu Y, Yan F, Jiang VC, Li Y, Che Y, McIntosh J, Jordan A, Hou I, Nie L, Jin J, Wang W, Lee HH, Yao Y, Wang M. Pirtobrutinib and venetoclax combination overcomes resistance to targeted and CAR T cell therapy in aggressive mantle cell lymphoma. Haematologica 108: 1412-1416, 2023.
Wang ML, Le Gouill S, Dreyling M. Treatment of Mantle-Cell Lymphoma. Reply. N Engl J Med 387: 1148, 2022.
Dreyling M, Goy A, Hess G, Kahl BS, JÁ H, Schuier N, Qi K, Deshpande S, Zhu A, Parisi L, Wang ML. Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up. Hemasphere 6: e712, 2022.
Jiang VC, Liu Y, Jordan A, Leeming A, McIntosh J, Huang S, Zhang R, Cai Q, Chen Z, Li Y, Che Y, Nie L, Karlsson I, Mårtensson L, Kovacek M, Teige I, Frendéus B, Wang M. Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma. J Hematol Oncol 15: 42, 2022.
Zhou K, Zou D, Zhou J, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Zhou D, Tam CS, Simpson D, Wang M, Phillips TJ, Opat S, Huang Z, Lu H, Song Y, Song Y. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. J Hematol Oncol 14: 167, 2021.
Jiang VC, Liu Y, Jordan A, McIntosh J, Li Y, Che Y, Jessen KA, Lannutti BJ, Wang M. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol 14: 132, 2021.
Lee HC, Feng L, Oriabure O, Graham V, Chen W, Badillo M, Lu R, Lee HJ, Jain P, Manasanch EE, Orlowski RZ, Wang ML. A phase 1 trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol 96: E243-E246, 2021.
Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol 96: E137-E140, 2021.
Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Nastoupil LJ, Fowler NH. Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma. Blood 137: 1124-1129, 2021.
Manasanch EE, Jain P, Chen W, Oriabure O, Badillo M, Feng L, Berkova Z, Orlowski RZ, Wang M. Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma. Am J Hematol 95: E232-E235, 2020.
Lee HC, Shah JJ, Feng L, Morphey A, Johnson RJ, Wesson ET, Wang ML, Alexanian R, Thomas SK, Orlowski RZ, Weber DM. A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol 94: E319-E322, 2019.
Wang Y, Yang F, Wang ML. Immune Thrombocytopenia-A Neglected Adverse Event of PD-1 and PD-L1 Inhibitors in Clinical Trials-In Reply. JAMA Oncol 5: 1641-1642, 2019.
Wang J, Wang J, Lopez E, Guo H, Zhang H, Liu Y, Chen Z, Huang S, Zhou S, Leeming A, Zhang RJ, Jung D, Shi H, Grundman H, Doakes D, Cui K, Jiang C, Ahmed M, Nomie K, Fang B, Wang M, Yao Y, Zhang L. Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma. Blood Cancer J 9: 95, 2019.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Jain P, Frigault MM, Izumi R, Nguyen D, Patel P, Yin M, Dlugosz-Danecka M. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 33: 2762-2766, 2019.
Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol 94: E150-E153, 2019.
Lee HJ, Chihara D, Wang M, Mouhayar E, Kim P. Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. Leuk Lymphoma 57: 1-3, 2016.
Vij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DS. Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Leuk Lymphoma 56: 2959-61, 2015.
Axelrod M, Ou Z, Brett LK, Zhang L, Lopez ER, Tamayo AT, Gordon V, Ford RJ, Williams ME, Pham LV, Weber MJ, Wang ML. Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia 28: 407-10, 2014.
Wang M. Commentary on "Bisphosphonates May Potentiate Effects of Thalidomide-Dexamethasone Combination in Advanced Multiple Myeloma". American Journal of Hematology 5: 382-388, 2006.
Wang M. Commentary on "Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait". Clin Adv Hem & Onc 3: 3, 2005.

Patents

Molecular Signature for Selecting Lymphoma Patients for Treatment with Ibrutinib or IACS-010759. Patent Number: 62/819,937.

Less

CV information above last modified February 24, 2026

Luhua (Michael) Wang, MD

About Dr. Wang

In the News

ASH: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax

How BTK inhibitors treat mantle cell lymphoma

MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting

Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients

What to know about mantle cell lymphoma

Majority of patients responded in CAR T-cell trial for mantle cell lymphoma

CAR T-cell therapy effective for relapsed mantle cell lymphoma patients

Novel combination provides more effective treatment option for mantle cell lymphoma

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Clinical Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patents

Patient Reviews

Photo Gallery

Request an Appointment

Related Links

Non-Hodgkin Lymphoma

Lymphoma & Myeloma Center

CAR T-Cell Therapy

Clinical Trials

Lymphoma & Myeloma Department

Cancer Medicine Division

Wang Laboratory

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop MD Anderson